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Abstract
As we move towards an era of personalised medicine, the identification of lead
compounds requires years of research and considerable financial backing, in the
development of targeted therapies for cancer. We use molecular modelling and
simulation to screen a library of active compounds, and understand the ligand-
protein interaction at the molecular level in appropriate protein targets, in a bid
to identify the most active lead drug candidates.
In recent times, good progress has been made in accurately predicting binding
affinities for drug candidates. Advances in high-performance computation (HPC),
mean it is now possible to run a larger number of calculations in parallel, paving
the way for multiple replica simulations from which binding affinities are obtained.
This, then, allows for a tighter control of errors and in turn, a higher confidence in
the binding affinity predictions.
Here, we present ESMACS (Enhanced Sampling of Molecular dynamics with Ap-
proximation of Continuum Solvent) and TIES (Thermodynamic Integration with
Enhanced Sampling); a new framework from which binding affinities are calculated.
ESMACS performs 25 replica simulations of the same ligand-receptor system with
the only difference being the initial momentum of each atom. From this ensemble
of trajectories, an extended MMPBSA (Molecular Mechanics Poisson-Boltzmann
Surface Area) free energy method is employed. The TIES protocol constitutes 5
replicas simulations per lambda state followed by the integration of the potential
derivatives of each lambda state, generating a relative binding affinity. This is all
tied together using the BAC (Binding Affinity Calculator) which automates the
ESMACS and TIES workflow.
ESMACS and TIES, given suitable access to HPC resources, can compute binding
affinities in a matter of hours on a supercomputer; the size of such machines there-
fore means that we can reach the industrial scale of demand necessary to impact
drug discovery programmes.
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Chapter 1
A brief introduction to
biomolecular simulation and
applications in drug discovery
A great deal can be learned about biomolecules, such as proteins, through experi-
ment. Let us consider a vial, which is filled with a solution containing a protein and
a chemical compound which interacts and binds to this protein (a drug candidate).
The solution contains approximately 1024 molecules which are interacting with one
another. Any measurement that is taken with respect to this sample, returns a
macroscopic understanding of the interactions between protein and chemical com-
pound. For instance, if we determine the binding free energy of this sample, this
is the average binding free energy of all 1024 molecules in the sample. In this
context, an experiment is performed using a macroscopic sample that contains an
extremely large number of atoms or molecules that sample an enormous number
of conformations. It is from this macroscopic ensemble that we are able to gain a
physical understanding of drug binding.
However, such experiments tell us almost nothing at the microscopic level. For
example, we may be able to determine strength of binding of our hypothetical
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drug candidate to the protein through a series of experimental measurements, but
we do not know the mechanism of binding on the atomistic level. In other words,
how do the atoms of the respective entities interact which subsequently define its
binding strength? Detecting this atomic interaction on short timescales in which
they occur is virtually impossible using experimental approaches.
X-ray crystallography is an experimental technique within the structural biology
domain, that can give us a detailed description of proteins with an atomic resolu-
tion. As a result, we know with good confidence, the structure of different types
of proteins, from which we can predict the behaviour, such as protein folding and
conformational changes. However, large biomolecules are highly dynamic and their
motions are critical in all biological processes. In short, it is not entirely possible
to infer the dynamics of a protein from a static crystal structure. This can be
compared to a photograph of a football match; we can gain exceedingly limited in-
formation from this snapshot: to gain a true understanding of the football match,
we need to see a video recording [1].
1.1 Simulating biomolecules
This refreshingly simple statement from Richard Feynman [2], neatly summarises
the concept of biomolecular simulation: “Everything that living things do can be
understood in terms of the jigglings and wigglings of atoms”. The central goal is
to take static crystal structures, and ‘bring them to life’ through the use of sophis-
ticated computational techniques to allow us to understanding biological processes
on the atomic level. Simulations based on fundamental principles of physics gives
us the opportunity to bridge the gap between the structural understanding of pro-
teins, obtained from crystal structures, and the dynamic behaviour of proteins
responsible for biological activity.
The increasing power, and parallelism, of computer hardware, coupled with more
sophisticated approaches toward simulation and consequent techniques to analyse
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simulation trajectories, has meant that biomolecular simulations now play an im-
portant part in our understanding of biology [1]. Macroscopic experiments are
often accompanied with some sort of atomistic simulation. In fact, rational drug
design is a discipline where simulations are used to test hypothesis and interpret
experimental data [3]. A good example of this is quantitative structure-activity
relationship (QSAR) approaches, where experimental data associated with drug
binding is rationalised and interpreted by atomistic biomolecular simulation, and
often used to drive forward drug design projects. Artificial Intelligence (AI) and
machine learning (ML) approaches are also used to assist chemists in screening
large chemical databases. AI and ML technology is self-learning and thus has an
ability to learn and improve upon compound database searches on its own. QSAR
methods require explicit parameters that are inputted by chemists.
Interactions between proteins and small molecules, such as our hypothetical drug
candidate at the beginning of this chapter, are integral in a vast number of bio-
logical processes. We turn our attention to the importance of drug binding in the
treatment of disease, and hence the use of small molecules as therapeutic drugs.
The strength of binding, or binding affinity, of a drug to its protein target, is a phys-
ical quantity that is most often computed when designing drugs. Computing this
quantity in a rapid and reliable manner has piqued the interest of pharmaceutical
companies. Biomolecular simulation and subsequent binding affinity computation,
has shown promise in the drug discovery domain as a tool to lower costs and ex-
pedite drug design programmes.
1.2 Drug discovery in the pharmaceutical indus-
try
Pharmaceutical companies are being put under increasing pressure, from stake
holders and governments alike, to discover and develop cost effective drugs within
sustainable financial means. Add to this the increased regulatory hurdles that
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need to be cleared, and the impending patent cliff that awaits every new drug,
the productivity within the drug discovery and development branch, feels a strong
headwind [4, 5].
1.2.1 Growing costs of drug discovery pipelines
Fig. 1.1 displays a simplified representation, of the drug discovery and development
pipeline: from a library of millions of compounds, to a final drug being launched
into the market [4]. However, achieving this requires a vast amount of time and huge
financial backing. DiMasi and colleagues have estimated research and development
(R & D) costs since the turn of the century [6]. This was compared to prior studies
within a similar time frame [7, 8, 9]. They found that in the last 15 years, the cost
per new drug is estimated to be approximately $2.6 billion (Fig. 1.2, [6]). This is
nearly a 3-fold increase in cost compared to the ‘1990s - mid 2000s’ time window.
In fact it has been growing steadily since the 1970s; the cost increased by a factor
of 2.31 from the first to the second time window, and 2.53 times from the second
to the third time window. This is a clear indication of the rising costs of drug
Figure 1.1: The simplified schematic represents the various stages through the
drug discovery and development pipeline. The stages coloured in or-
ange are loosely termed as ‘drug discovery’ stages, where the blue
stages are termed ‘development’ phases. Drug discovery stages are
often described as programmes that involve the synthesis and identifi-
cation of pharmaceutically active compounds which are subsequently
tested in animal models. This leads to the clinical development phases
where human testing is introduced in three stages. This schematic
does not show the true complexity of this process, as many of the
stages in this pipeline often overlap. In additional, pharmaceutical
companies will submit investigational drugs that run in parallel with
lead active compounds.
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discovery and development costs in pharma.
Both hit-to-lead and lead optimisation stages could benefit from more efficient
approaches and a reduction in costs. Hit-to-lead research, in particular, accounts
for 6% of the total cost throughout the pipeline, which equates to $166 million, and
usually takes 1.5 years, per new molecular entity (NME [4]). In the pharmaceutical
industry, $414 million, and 2 years are spent, per NME, to take a drug to launch
– financially, that accounts for 17% of the entire process.
Another interesting conclusion is that the success rate of drugs has decreased by
10% since the last study [6], there are several possible reasons for this. Firstly,
regulatory authorities, in recent times, have become more stringent, so lead candi-
dates that may have been approved previously are now rejected. Secondly, there
has been a shift in focus towards drug discovery in areas of unmet medical need
[5], where scientific knowledge is comparatively underdeveloped, or the science is
Figure 1.2: Trends in costs for the discovery and development phases in the phar-
maceutical pipeline, and the combined amount, over a period of circa
45 years. A steady increase in costs for both sectors of the pipelines
is witnessed.
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difficult, leading to high percentage of failing drug candidates. Lastly, the influence
of molecular biology and subsequently genomic sciences, has led to the detection of
increasing number of drug targets. Although this is a vital development in the field
of drug discovery, there are cases where some drug targets have been poorly vali-
dated leading to the more drug candidates being developed, with little knowledge
of its success rates [10, 11].
1.2.2 Reliability of research
Needless to say, in an industry where the health of patients is in question, method-
ologies need to be reliable and reproducible. This would seem obvious, but recent
publications [12, 13] have shown that scientific research has frequently produced
unreliable, and irreproducible results, leading to false claims. The consequence of
this is that subsequent research efforts that aim to build upon these irreproducible
results, are also worthless. This has direct financial implications to pharmaceu-
tical companies – not withstanding the pursuit of scientific integrity – because
potentially millions of dollars could be invested, based on scientific results that, at
the time, seemed plausible, but turn out to be false. In fact, one of the leading
biopharmaceutical companies reviewed 53 “landmark” publications and of these,
only 6 (11%) of the results were successfully reproduced [12]. A similar case was
reported which involved another major pharmaceutical company, where only 25%
of publications could be validated [14]. This level of unreliability in methodologies
is unacceptable, especially in an industry where reliable and reproducible results
are of utmost importance.
1.2.3 Applications in early stage drug discovery
Hit-to-lead is a period during early stage drug discovery where small molecules,
which exhibit biochemical activity in a particular biological target (known as a
hit), are evaluated, to identify a lead compound which then undergoes further drug
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development [15]. Quantifying this biochemical association between a molecule and
biological target, known as the binding affinity, is essential in the pharmaceutical
industry, in the pursuit of identifying lead drug candidates. The hit-to-lead stage
usually means reducing hundreds of active compounds down to a handful of the
most promising drug candidates. The distinction between the best performing drug
candidates and the remainder is usually achieved by experimentally calculating the
binding affinity.
Lead optimization proceeds hit-to-lead, where the lead candidates from the latter
stage, are tested to ascertain their pharmacokinetic (PK) – absorption, distribu-
tion, metabolism and excretion) – and pharmacodynamic (PD) or drug-receptor
interactions profile. At this stage, the chemical structure of the lead candidate is
confirmed, however to improve upon already comparatively good PK/PD profiles,
small deviations are made to the structures, to induce, for instance, selectivity to
a particular receptor, or a better metabolism profile.
However, on an industrial scale, experimental techniques tend to be either labouri-
ous, imprecise or costly (or all). In additional to this, medicinal chemists spend a
vast amount of time and resources on synthesising, purifying and validating drug
candidates.
1.2.4 Personalised medicine
The personalised medicine domain will also benefit from improved drug design
methods. A clinician will have an array of medicines, which can then be used as
bespoke treatments for individual patients, based on their genetic profile. Predici-
tive tools to assist clinicians would make clinical decision-making more efficient by
administering the right therapy for each individual patient. The use of molecular
dynamics (MD) smulations from which drug binding affinities are estimated has
already shown promise in several different biological systems [16, 17, 18, 19].
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1.2.5 High-performance and cloud computing resources
Computational drug discovery, along with concurrent developments in structural
biology and genomics, has grown rapidly not least in part to the advancements
in high-performance computers (HPCs) and cloud computing. HPCs offer the
capabilities of parallelism, which allow computational scientists to run a number
of simulations concurrently across a large number of processors. Alternatively,
cloud computing allows users to run computational drug discovery applications
‘on-demand’ using remote resources. Section 3.4 describes in more detail the costs
and related issues associated with HPC facilities and the use of cloud computing.
1.2.6 Concluding remarks
Over approximately the last four decades, biomolecular simulation has changed
from picosecond simulations of crude macromolecular models, in vacuo, to mil-
lisecond simulations of complex and heterogeneous biological systems consisting
of millions of atoms. The development over this time has been hugely promis-
ing. However, it is only now that such approaches are being integrated into the
pharmaceutical industry.
The pharmaceutical industry faces huge financial challenges due to rising costs and
increased regulatory hurdles. Additionally, there is room for improvement in terms
of productivity: in the last 15 years, there has been an increase in failed new drug
applications compared to the previous 15 years [6]. A closer inspection of the hit-
to-lead and lead optimiziation stage of the drug discovery pipeline has shown that
much of the efforts are exerted here, both financially and temporally. There are
many failures in clinical trials too: these ‘late’ failures are particularly expensive
and need to be avoided. In tandem with more efficient drug discovery strategies,
reproducible results are essential, bringing reliability and confidence to the research
results obtained.
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Hence, there is unmet need in the pharmaceutical industry for financially viable
methods that can achieve reliable results, time and again. Computational develop-
ments that allow for predictive modelling of biomolecular systems, together with
emergence of multi peta-scale computational resources, have opened up an oppor-
tunity to drive such costs down. Computer-aided rational drug design is a division
within drug discovery which could directly benefit from such advances. Molecular
modelling techniques and the correct free energy calculation method can be incor-
porated to expedite this process of identifying a lead, or leads. The introduction
of molecular modelling tools within this space has the potential to assist in the
current experimental techniques, and as such, reduce the time and cost.
Computational Biomedicine (CompBioMed) is a Centre of Excellence in Computa-
tional Biomedicine that aims to advance the role of computional based modelling
and simulation within biomedicine [20]. This will be achieved through the use of
international HPC resources, and development of software tools which are capable
of delivering high fidelity modelling and simulation of the human body. The in-
novative modelling and simulation techniques will be of key interest to industrial
researchers, HPC manufactures and scientific software developers.
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Chapter 2
Theory
This chapter will outline the fundamental theoretical concepts that embody the
topic of binding affinity predictions. This begins with a kinetic and thermody-
namic definition of the processes involved in the binding of a drug to its target
protein. The ability to predict binding affinities using computational means re-
quires understanding of molecular simulation, which links the macroscopic scale of
experiment to the microscopic scale of simulation. A description of this connection,
through the use of statistical mechanics is also presented here. Finally, theoretical
and computational techniques used to quantify the binding affinity are explained.
2.1 What is a binding affinity?
In pharmacology, a ligand is a therapeutic drug that inhibits the biological responce
of its target which is usually a protein. This type of ligand is often termed an
antagonist. This is achieved through the process of binding, where the ligand will
attach onto the protein at either the active (orthosteric) site, or elsewhere on the
protein (allosteric site) [21]. The strength of this binding, through the various
interactions made between the ligand and protein determine the binding affinity
of the drug to the protein. The affinity alone does not give us a measure of the
performance of the drug [21]. A drug may have a very high binding affinity, but low
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efficacy. Thus, efficacy is the measure used to describe the action of the drug once
it is bound to the protein. Binding affinity and efficacy determine the effectiveness
of a therapeutic drug to inhibit the biological response of a protein – this term is
called the potency [21]. The following sections give a theoretical explanation of the
binding affinity, namely the kinetic and thermodynamic considerations involved in
the protein-ligand binding process. A more detailed description of these topics can
be found in the following sources [21, 22, 23].
2.1.1 Protein-ligand binding kinetics
A ligand binds to a protein to form a complex. This process can be reversible,
where the interactions between ligand and protein are non-covalent, or it can be
irreversible, where the interactions are covalent. In reversible binding, a protein and
ligand are also able to dissociate and a ligand is subsequently free to associate with
a different protein molecule. Drugs, in most cases, are designed to bind reversibly,
and so are attention will be directed to this mechanism of binding.
Protein-ligand kinetics describes the association between the two entities, and the
rate at which they bind to each other. For example, when a protein and ligand are
mixed in solution, with fixed concentrations, the rate of association between the
two can be described as such:
P +L
k1

k−1
PL (2.1)
where P is the protein, L is the ligand, and PL is the protein-ligand complex. The
rate constants, k1 (M−1 · s−1) and k−1 (s−1), are the kinetic rate constants that
represent the forward reaction of ligand binding or association, and the reverse
reaction of the ligand unbinding from the protein, termed dissociation. At equi-
librium, the rate of the forward reaction of ligand binding (P +L→ PL), and the
reverse reaction of unbinding (PL→ P +L), are equal. This can be represented
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like so:
k1[P ][L] = k−1[PL] (2.2)
where the terms in square brackets, [· · · ], corresponds to the concentration of each
entity, at equilibrium.
At equilibrium, then, the association constant, Ka (M−1), is equal to the reciprocal
of the dissociation constant, kd (M). In other words, a fast k1 and a slow k−1 yield
a high association, and low dissociation constant, which results in a high binding
affinity:
Ka =
k1
k−1
= [PL][P ][L] =
1
Kd
(2.3a)
[PL]
[P ] =Ka[L] (2.3b)
Rearranging Eqn. 2.3a to Eqn. 2.3b, shows that increasing the ligand concentra-
tion, gives rise to a large number of protein-ligand complexes. Further, a higher
concentration of complexes, means a larger Ka value.
2.1.2 A thermodynamic representation
Alternatively, one can understand protein-ligand binding by employing a thermo-
dynamic representation. The driving forces that characterise the binding of ligand
to a protein, in solution, is explained through the energy exchange between the
three components (P , L and PL). These driving forces can be quantified as the
Gibbs free energy (G).
The Gibbs free energy, G, is a thermodynamic potential that measures the maxi-
mum reversible work that can be performed by a thermodynamic system at con-
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stant pressure and temperature (isobaric-isothermal or NPT system). The change
in Gibbs free energy (∆G) can give us information about the spontaneous process
of protein-ligand binding. That is, the thermodynamic system, protein and ligand
in solution, needs to have a negative ∆G for protein-ligand association to occur.
In other words, the difference in G between the reactants and products requires a
negative value. This process will occur until the reaction reaches equilibrium, and
thus ∆G becomes zero:
∆G=G(PL)−G(P )−G(L) (2.4)
The relationship between Ka and the standard binding free energy (∆G◦) can be
described according to Eqn. 2.5:
∆G◦ =−RTlnKa (2.5)
where the free energy is obtained under standard conditions: 1 atm of pressure,
temperature of 298 K and 1 M concentrations of protein and ligand. The gas
constant, R, is 1.987 cal ·K−1mol−1, and T is the temperature. We see here
that as the Ka value increases, ∆G◦ becomes more negative, resulting in a higher
binding affinity. Hence, the kinetic rate constants, k1 and k−1 are connected to the
thermodynamic property, ∆G◦.
∆G= ∆G◦+RTlnQ (2.6)
It was mentioned earlier that when a spontaneous thermodynamic reaction in
isobaric-isothermal conditions reaches equilibrium, ∆G becomes zero. This is seen
in Eqn. 2.6 which describes the binding free energy, ∆G, during protein-ligand
binding, not limited to standard conditions. The reaction quotient, Q, is the ra-
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tio of the concentration of the protein-ligand complex ([PL]), and the product of
the concentration of the free protein and ligand ([P ][L]). When a reaction is in
equilibrium, Ka =Q and ∆G is zero.
Eqn. 2.7a describes ∆G as enthalpic and entropic contributions to binding:
∆G= ∆H−T∆S (2.7a)
∆G= (∆U +p∆V )−T∆S (2.7b)
where ∆H is the change in enthalpy, and T∆S is the change in entropy as a function
of temperature, in Kelvin. Enthalpy is the total energy of the thermodynamic
system. This includes the internal energies of the protein and ligand (U), and the
energy needed to displace the surroundings, which is a product of the volume (V )
and pressure (p) of the system (Eqn. 2.7b). Protein-ligand binding is an exothermic
process, where the non-covalent bonds that are formed are energetically favourable.
Thus, the change in enthalpy (∆H) is the change in the energies between the
reactants and products, where a spontaneous binding process yields a negative
∆H value.
Entropy is the overall disorder of the atoms within a system. The process of ligand-
binding sees two molecules, the free ligand and protein, form one protein-ligand
complex, and by definition, the entropy is higher when the components are free,
than when the components are complexed. Therefore T∆S is a positive value in
spontaneous protein-ligand binding, and acts as an entropic cost to the ∆G value.
∆S = ∆Ssolv + ∆Sconf + ∆Sr/t (2.8)
The total entropy change can be segmented into three terms, seen in Eqn. 2.8.
∆Ssolv is the entropy change due to solvation. Although the formation of a cavity
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in a solution is entropically unfavourable, as the system becomes more ordered,
the entry of the protein-ligand complex into this cavity is entropically favourable.
The net value of T∆S is positive. The change in conformational entropy ∆Sconf
between free ligand and protein, and protein-ligand complex can be either positive
or negative, and depends on the protein and ligand in question. Finally, ∆Sr/t
is the change in entropy of the rotational and translation degrees of freedom as a
result of ligand binding. This contributes unfavourably to entropy there is a loss
in rotational and translation freedom in the protein and ligand, in the complex
formed.
2.1.3 Kinetics of enzyme action
The function of an enzyme is to increase the rate of a reaction, without any change
to the enzyme concentration itself. The rate of reaction is determined by the
activation energy: this is the highest energy state that needs to be overcome by
the reactants to form the product. Enzymes lower the activation energy, and so
the rate of reaction increases. This can be illustrated using the Michaelis-Menten
equation [24] which relates the reaction rate to substrate concentration.
The activation energy is equivalent to the binding free energy between the enzyme
and the enzyme-substrate complex. Enzyme kinetics can be described like so:
E+S
k1

k−1
ES
k2→ E+P (2.9)
where k1 and k−1 are the association and dissociation constants for the enzyme and
substrate, and k2 is the rate constant for the catalysed reaction. Here we assume,
for simplicity, that the catalysed reaction is irreversible. This is because it is highly
unlikely, due to the thermodynamic stability of the enzyme and product, that it
will follow the reverse reaction to give the enzyme-substrate complex. The rate of
reaction (V ) is the rate at which product is formed is:
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Figure 2.1: A schematic of the course of a reaction for processes that are catal-
ysed (orange) and uncatalysed (blue). A catalysed reaction is repre-
sented by a smaller free energy barrier (∆GC) and so the reaction
can proceed at a faster rate. An uncatalysed reaction has a higher
free energy barrier (∆GU ). In the catalysed reaction, several tran-
sition states are formed, which eventually results in the formation
of product. The change in free energy of the reaction (∆GR) is the
difference in free energy between the reactants and products.
V = d[P ]
dt
= k2[ES] (2.10)
where [· · · ] indicates the concentration of the product or enzyme-substrate complex.
The rate at which the concentration of the enzyme-substrate complex changes is
equivalent to the rate of its association, minus the rate of its dissociation as shown
in Eqn. 2.11:
d[ES]
dt
= k1[E][S]− (k−1 +k2)[ES] (2.11)
Here, we introduce the idea that the total number of enzyme available ([E]T ), is
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equal to the free enzyme plus the enzyme-substrate complex, which can be formu-
lated as [E]T = [E] + [ES]. Taking this into account we get the Eqn. 2.12a, which
is further simplified by making two assumptions. The steady-state assumption
says that the rate of enzyme-substrate complex formation is equal to the rate of
formation of the product and the dissociation back to free substrate and enzyme
(Eqn. 2.12b). The second assumption, shown in Eqn 2.12c, also holds true, as the
concentration of the enzyme-substrate complex is much larger than the term on
the left side, for the majority of the reaction time.
d[ES]
dt
k1[S] +k−1 +k2
+ [ES] = k1[E]T [S]
k1[S] +k−1 +k2
(2.12a)
d[ES]
dt
= 0 (2.12b)
d[ES]
dt
k1[S] +k−1 +k2
 [ES] (2.12c)
Thus, the Michaelis-Menten equation is derived from Eqn. 2.11 and 2.12a. The
Michaelis constant Km is substituted, for k−1+k2k1 under the equilibrium approxi-
mation, kd kcat:
V = k2[ES] =
k2[E]T [S]
[S] +Km
(2.13)
where Vmax is the maximum rate of reaction when all enzyme molecules are fully
occupied by the substrate. When the rate of reaction is at the maximum speed,
in other words when V0 = Vmax, then the total enzymatic concentration, [E]T , is
the same as the concentration of the enzyme-substrate, since all the enzymes are
occupied with substrate ([E]T = [ES]). Substituting this into Eqn. 2.13 gives the
simplified Michael-Menten equation:
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V = Vmax[S][S] +Km
(2.14)
But what is the importance of Km? Consider that Km equals the substrate con-
centration, [S]. Then, substituting this into the Michaelis-Menten equation, we see
that Km is the substrate concentration where the rate of product formation is half
of the maximum reaction rate, Vmax.
V = 12Vmax (2.15)
So the lower the Km, the better an enzyme can function when substrate concen-
trations are limited.
2.1.4 Enzyme inhibition
Reversible inhibitors fall in to three categories: competitive, uncompetitive and
non-competitive inhibitors. Competitive inhibitors bind to the free enzyme and
slow down the rate of enzyme-substrate formation. Thus, such inhibitors compete
with the substrate at the binding side. Uncompetitive inhibitors, conversely, bind
to the enzyme-substrate complex and do not directly compete for the binding site
of the substrate. Intuitively, uncompetitive inhibitors binding elsewhere on the
enzyme to inhibit the formation of product. Non-competitive inhibitors are also
known as “mixed” inhibitors, because they can bind to the free enzyme or the
enzyme-substrate complex, to inhibit the rate of product formation.
Properties associated with enzyme inhibition can be described effectively using
Lineweaver-Burk plots [25], which can be derived by taking the inverse of both
sides of the Michaelis-Menten equation (Eqn. 2.14):
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Figure 2.2: Lineweaver-Burke plots illustrating the effects of increasing inhibitor
concentration ([I]), on maximum reaction rate (Vmax) and the bind-
ing affinity of the substrate to the enzyme Km. The blue and grey
lines are low and high [I], respectively. The plots are conceptual and
are not an accurate representation.
1
V
= Km
Vmax
· 1[S] +
1
Vmax
(2.16)
where 1/V is the dependent variable, Km/Vmax represents the slope of the line
function, 1/[S] is the dependent variable, and 1/Vmax represents the y-axis inter-
cept. Using this, we can determine the activity of each type of inhibitor, with
respect to Km and Vmax
As the concentration of competitive inhibitor is increased, the slope of the lines
increases too, but the y-intercept is the same. This means that an increased con-
centration of competitive inhibitor will increase the Km, resulting higher inhibi-
tion at low substrate concentrations. However, the Vmax stays unchanged (same
y-intercept), and so competitive inhibitors do not effect the maximum reaction rate
of the enzyme. In other words, at high concentrations of substrate, the inhibitor
loses effect.
An increase in uncompetitive inhibitors sees a decrease in Vmax, because the y-
intercept (1/Vmax) is increasing, and no change in Km. So at low concentrations of
substrate, an increase in uncompetitive inhibitor does not effect the enzyme activ-
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ity, but at high substrate concentrations, uncompetitive inhibitors remain effective.
Finally, increasing the concentration of non-competitive inhibitors, we see no
change in Km, and a decrease in Vmax. So these inhibitors are still effective at
high concentrations of substrate, but the enzyme activity is unchanged at low con-
centrations.
As in Eqn. 2.9, we are able to depict competitive binding in a similar fashion:
E+S+ I
k1

k−1
ES
k2→ E+P + I (2.17a)
E+S+ I
k3

k−3
EI+S (2.17b)
where the notation is consistent with equation 2.9, but includes the inhibitor, I,
and the rate constants for for the association k3 and dissociation k−3 of the enzyme-
inhibitor complex. Following the same derivation of the Michaelis-Menten equation
(Eqn. 2.14) we obtain:
V = Vmax[S]
Km(1 + [I]Ki ) + [S]
(2.18a)
Ki =
k−2
k2
(2.18b)
where inhibition constant, Ki, is the equal to the disassociation constant (Eqn.
2.18b). The introduction of Ki is important, because now we can quantify the
binding affinity of an inhibitor to an enzyme. A low Ki value, corresponds to a
high rate of enzyme-inhibitor formation (k3) and thus a higher binding affinity.
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2.2 Experimental binding affinities
Testing the interaction between two molecules, is one of the most common ex-
periments in biochemistry and molecular biology. For this reason, there are a vast
amount of different techniques used to measure these interactions [26]. Our interest
is focused on the interaction of a ligand with a protein, and in this domain, there
are several techniques that are preferred. Binding affinity experiments fall into two
categories. Direct methods, which measure the actual concentrations within the
sample, and indirect methods, which measures a signal from an external source,
and is subsequently converted into a binding affinity value. The most common
methods are described below.
2.2.1 Isothermal titration calorimetry
The gold standard of experimental binding affinity measurements is isothermal
titatration calorimetry (ITC, [27]). This quantitative thermodynamic approach
is the only protocol that can directly measure physical properties, like ∆G, ∆H
and ∆S, in addition to the Ka constant. In addition, when ITC experiments are
conducted on the same protein-ligand system, with variations in temperature, the
heat capacity (∆Cp) can also be measured.
First, the ligand of interest is injected, in small aliquots, into a solution containing
the protein. The aliquots are precisely titrated into the sample cell which trig-
gers a change in temperature relative to a reference cell. Then, the cell heater
responds by heating or cooling, depending on whether the reaction is exothermic
or endothermic, to return the sample cell to base temperature. The power applied
by the cell heater to the sample cell after each titration of ligand, can be converted
into the heat produced by the cell.
qi = v∆H∆[L]i (2.19)
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The energy required decreases as the titration proceeds, as there is less protein on
to which the ligand can bind. Finally, the change in heat over the entire reaction
time can be used to calculate ∆H directly, using Eqn. 2.19, where v is the volume
of the cell, qi is the heat generated for each aliqout of ligand titrated into the
sample, and [L]i is the concentration of ligand for each aliquot. The Ka can also
be calculated from the total amount of heat produced which can, in turn, be used
to calculate ∆G and and ∆S via Eqns. 2.5 and 2.7a.
2.2.2 Fluorescence spectroscopy techniques
This group of techniques measure the rate of product formation, or the rate at which
the substrate is associating with the enzyme, through the use of fluorescence.
The general idea of fluorescence-based experiments is to label either the ligand or
substrate with a marker that has fluorescent properties. A fluorometer detects the
strength of this signal. The reaction between the competing ligand and substrate
is initiated, resulting in a change of strength in fluorescence signal. For example, a
protein and substrate are allowed to interact where initially, there is no fluorescent
signal. Upon the addition of a known concentration of a competitive inhibitor,
which has been labelled with a fluorescent marker, the strength of the fluorescent
signal indicates the concentration of inhibitor occupying the binding site.
The two main techniques are fluorescence polarisation (FP, [28, 29]) and fluores-
cence resonance energy transfer (FRET, [30, 31]). FP uses the idea of polarised
fluorescence emission which becomes unpolarised faster in the bound state, than
the unbound state. Here the inhibitor is excited using polarisable light, and the
speed at which it becomes unpolarised indicates the amount of ligand bound to
the enzyme. FRET requires a double labelling of the enzyme and inhibitor. When
apart, the labels do not emit fluorescent light, but when the inhibitor binds to the
enzyme, the energy transfer between the two labelled molecules emits a fluorescent
signal. The strength of this signal corresponds to the amount of inhibit occupying
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the enzyme.
Ki =
IC50
1 + [S]
Km
(2.20)
The results of these techniques are usually reported as the concentration of inhibitor
required to reduce the enzyme activity by half (IC50). This value can be related
to the Ki due to the reasoning that at low values of [S], the Ki equals the IC50.
The Cheng-Prussoff equation [32], in Eqn 2.20, demonstrates this relationship.
2.2.3 Surface plasmon resonance
Surface plasmon resonance (SPR, [33]) is an optical based technique that measures
the change in refractive index due to ligand association and dissociation. Protein
molecules are immobilsed on a sensor surface and the analyte molecules, that is
the inhibitor, is injected onto the surface allowing for inhibitor association. This
association of inhibitor to the immobilised protein is accompanied by an increase
in refractive index, yielding the rate of ligand association, k1. After some time, a
solution that dissociates the ligand (usually the sample buffer) from the protein is
introduced, and the refractive index is measured, giving rise to the rate of ligand
dissociation (k−1). Using Eqn. 2.3, the association constant, Ka, can be deduced.
2.2.4 Experimental error
Experimental techniques are associated with errors due to a number of factors, and
the difficulty in controlling them. Here, potential sources of error [34, 35, 36, 37,
28, 38] will be outlined for the approaches that have been explained in section 2.2
.
Although ITC is highly sensitive, the detection of heat from protein-ligand asso-
ciation, for systems that report very low enthalpies, is difficult to measure accu-
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rately. Similarly, ITC is insensitive in cases where the kinetic rate of reaction is
very slow. In addition, the technique requires a large sample size, and so pro-
teins and inhibitors that are difficult to prepare, or expensive in large quantities,
are not suited for this method. The experiment itself is time-consuming and low-
throughput and for this reason is would not be well placed in a drug discovery
programme where a large amount of inhibitors need to be tested in a relatively
short space of time. Further, the laborious and intricate nature of ITC means that
replicates are rarely performed and so there is often a lack of error bars associated
with the measurement.
SPR has the benefit of real-time analysis of the refractive index and so a clear
understanding of the reaction kinetics is available. However, a large draw-back
of this method is the immobilisation of the protein, which constrains the protein
conformational, translation and rotation degrees of freedom. As a result, the ka
constant is not representative of the actual ligand binding process.
Fluoresence-based assays are commonly used as they are relatively inexpensive,
high-throughput, and require small sample sizes. For this reason, they are suited for
drug discovery programmes as the protocol can be automated. On the other hand,
factors such as light-scattering and auto-fluorescence can alter the true signal that
is detected. Further, labelling the ligands or enzymes alters the binding behaviour,
similarly to what is experienced in SPR.
2.3 Computational binding affinities
An alternative approach to measuring binding affinities is to predict them using
computational means. This is done by using a theoretical framework to define the
binding free energy, and the calculations associated with this are then executed
using computers. The benefits of this approach are numerous. Firstly, there is
no need for reagents, solvents, chemicals and large laboratory space to generate
binding affinities. It can all be completed in the comfort of one’s office desk.
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Additionally, the process of synthesising new and complex small molecules, is a
laborious and expensive process, and computational techniques can overcome this
problem. These methods also have the benefit of giving us information about the
atomistic properties of binding.
The basis of computational prediction of binding affinities is linking the microscopic
simulation that is performed on computers, with the macroscopic thermodynamic
description of an experiment. Statistical mechanics connects these two scales. The
following sections explain how statistical mechanics allows us to run a simulation
of a single protein-ligand complex, and achieve comparable binding affinities of an
experiment that contains 1024 molecules (like the one describes at the beginnig of
this thesis). A thorough explanation of the following topics, and more, can be found
by accessing the following textbooks. One of these sources provides an introductory
explanation of the theory behind a number of computational chemistry approaches
[39]. The other focusses more on the principles and applications within molecular
modelling [40].
2.3.1 Statistical mechanics
The macroscopic and microscopic system are connected through statistical me-
chanics, and a key component of understanding this link, is the partition function.
At temperature of absolute zero (0K), all molecules are in their ground energetic
state. However, at any other temperature, there is a probability associated with a
molecule being in any particular energy state (relative to the ground state energy).
This is described by the Boltzmann factor:
P ∝ e/kT (2.21)
where P is the relative probability,  is the energy state of the molecule, T is the
temperature, and k is the Boltzmann constant. Eqn. 2.21 demonstrates that,
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although there are many more states with high energy than low energy, the prob-
ability of finding a molecule with low energy is minimal. A Boltzmann energy
distribution plot shows the probability of a molecular being in a particular energy
state.
q =
∞∑
statesi
ei/kT (2.22a)
P (i) =
ei/kT
q
(2.22b)
The partition function (q), then, is the sum of all possible microstates of a single
molecule (Eqn. 2.22a), and can also be viewed as a weighted probability of the
molecule being in any particular energy state (Eqn. 2.22b). The partition function
q, describes a single molecule that has no interactions (i.e. behaves like an ideal
gas), however, a protein and ligand in solution is a system that contains many
molecules, which are all interacting with one another. Therefore, a partition func-
tion, Q, is calculated by summing over all energy states for the entire system (Eqn.
2.23a) and can also be presented as weighted probability of the system being in a
particular energy state (Eqn. 2.23b):
Q=
∞∑
i
eEi/kT (2.23a)
P (Ei) =
eEi/kT
Q
(2.23b)
The discrete sum of the energies, can also be replaced by an integral of the co-
ordinates (r) and momenta (p) of a system, where p is the product of velocity
and mass, and this known as phase space. This equation becomes important when
considering molecular simulation, which will be explained later:
27
2.3. COMPUTATIONAL BINDING AFFINITIES
Q=
∫
eE(r,p)/kTdrdp (2.24)
The importance of the partition function is that it allows us to calculate thermo-
dynamic properties, such as internal energy (U), Helmholtz free energy (H) and
Gibbs free energy (G). Note, that U and G is related to Q via a derivative, where
A is directly linked to Q:
U = kT 2
(
∂ lnQ
∂T
)
V
(2.25a)
A=−kT lnQ (2.25b)
G=H−TS = kTV
(
∂ lnQ
∂V
)
T
−kT lnQ (2.25c)
For small, di- or tri-atomic systems, it is possible to calculate the partition function,
q, directly. However, for condensed phases, like a protein-ligand solution, it is not
possible to calculate Q by summing over all energy states, or integrating the whole
of phase space as the amount of configurations possible is too large. It is possible,
though, to estimate Q by generating a representation of the system, where only a
portion of phase space is sampled.
2.3.2 Time and ensemble averages
Thermodynamic properties are dependent on the position (r) and momenta (p) of
N particles, that make up a system. From a time-dependent MD trajectory, then,
a value of a particular thermodynamic property (i.e. G) is defined by the position
and moment of N particles at time t. As t tends to zero, G changes as the system
changes, and a time average of Gibbs free energy, G¯, is obtained like so:
G¯= lim
t→∞
1
t
∫ t
0
G(rN (t),pN (t))dt (2.26)
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where rN (t) and pN (t) are the position and momenta of N particles of a system at
time t. Eqn. 2.26 shows that as the time of the simulation approaches infinity, the
integral approaches the ‘true’ value of G. To obtain the true value of G¯, a molecular
simulation must record configurations infinitely, which is clearly not plausible.
〈G〉=
∫∫
G(rN ,pN )ρ(rN ,pN )drNdpN (2.27)
Ensemble averages (Eqn. 2,27) treat each snapshot in time of an evolving system
as an individual ‘microstate’, rather than a ‘macrostate’, meaning that position
and momenta of N particles for each time t are considered independently and
simultaneously. Where 〈G〉 is the ensemble average of Gibbs free energy, and
ρ(rNpN ) is the probability density of the ensemble. This was previously shown in
Eqn. 2.24, where the energy state (E) can be replaced with the continuous phase
space formulation, ρ(rNpN ). The connection between time and ensemble averages
is made by applying the ergodic hypothesis, 〈G〉= G¯.
2.3.3 Statistical uncertainty of binding affinity predictions
We noted that thermodynamic properties, such as U and G are related to the
partition function, Q, through a derivative, and conversely, A is directly related to
Q. This is also demonstrated by deriving formal expressions for U and A, from
the idea that ∂ lnQ/∂T =Q−1∂Q/∂T , and then rewriting as an integral using the
continuous phase space notation:
U =
∫
E(rN ,pN )P (rN ,pN )drNdpN (2.28a)
A= kT ln
∫
eE(r
N ,pN )/kTP (rN ,pN )drNdpN (2.28b)
Here, U is a sum of the weighted probabilities of the system being in a particular
energy state, and thus has a linear relationship with E(rN ,pN ) (Eqn. 2.28a).
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The areas of phase space with a low probability of being sampled, that is high
energy configurations, contribute little to the final U value, and so U converges
quickly. On the hand, the exponential connection of A with E(rN ,pN ) (Eqn.
2.28b), which is synonymous with G, states that the infrequently visited, high
energy configurations, contribute significantly to the final thermodynamic value,
and so these values do not converge quickly.
Calculating G is challenging, because of the statistical uncertainty surrounding the
sampling of a sufficient number of configurations. The statistical uncertainty is
proportional to the inverse square root of the number of configurations sampled:
σ(X)∝ 1√
M
(2.29)
where σ is the statistical uncertainty, and M is the number of configurations sam-
pled. Alternatively stated, if the sample size is increased, then statistical error
decreases. However, we have learned that there are limits to simply increasing the
sample size, and one must generate a representative sample. Obtaining a represen-
tative sample that visits a small area of phase space, frequently, will yield a result
that has low statistical error, but high systematic error. In other words, the value
will be precise, but inaccurate. Calculating U and other energy properties do not
have this problem, as results converge quickly at low-energy regions, but entropic
properties, like G are reliant on the whole of phase space, and so obtaining the ab-
solute value of G is impossible. The alternative, though, is to calculate differences
in G, which gives rise to a relative change in G.
2.3.4 Ensemble simulations
The most common approach to calculating thermodynamic properties, like the
binding free energy of a ligand to a receptor, is by running a ‘long’ simulation,
traversing a part of the energy landscape, and then, using the ergodic hypothe-
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sis, claiming that this represents the macroscopic thermodynamic properties of a
system [41]. The error with this approach is that the ergodic theorem requires
all states to be passed which is beyond our computational capabilities due to the
enormity of the number of states available for a biomolecular system.
An alternative approach is to execute more independent simulations of the same
ligand-receptor complex. This approach stays true to the theory of statistical
mechanics by calculating average values of thermodynamic properties from n repli-
cations of ensemble averages. Calculating binding free energies from ensemble
simulations recognises that systems in an equilibrium state exhibit dynamics that
are chaotic. As a result, binding free energies computed from independent trajec-
tories are described by Gaussian random processes. Thus, it is a stochastic process
from which the binding free energy can be obtained statistically conforming to a
Gaussian distribution (Fig. 2.3). Ensemble simulations, then, allow us to exploit
stochastic calculus by reintepreting many equations, to determine binding free en-
ergies. With respect to phase space, ensemble simulations explore a larger area
compared with a single trajectory [41]. In addition, the use of replicas allows for
reproducible results with error bars, which are scientifically much more valuable.
The studies detailed in later chapters embrace ensemble-based approaches, and
have been shown to produce rapid, reliable and precise binding affinity predictions
for the reasons described above [42, 16, 43, 18, 19].
Some groups have reported accurate approaches to predicting binding free energies
[44, 45, 46], but there is no defined automated, ensemble-based workflow that also
takes reproducibility and speed into account.
2.4 Generating a trajectory of configurations
Sampling the entirety of phase space, for quite large systems such as protein-ligand
complexes in solution, is not possible. Computer simulation techniques, allow us to
explore a small but representative section of the energy landscape, from which we
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Figure 2.3: Normalized frequency distributions of binding affinities obtained by
ESMACS for 5 different receptor-ligand systems, which are specified
in the top left corner of each graph: a) is the distributions for the
MMGBSA and b) using the MMPBSA method. Each data point cor-
responds to one frame from which binding affinities were generated.
The chaotic dynamics of receptor-ligand systems allow us to com-
pute, from Gaussian distributions, reliable probabilistic binding free
energies.
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are able to obtain accurate and/or precise thermodynamic properties. Ensemble
averaging, through the application of the ergodic hypothesis, connects the macro-
scopic scale of experiment, to simulation, which is executed on the microscopic
scale.
Obtaining thermodynamic properties, via ensemble averaging, is achieved by molec-
ular simulation, which explores the energy landscape of the system of study. A
variety of molecular simulation algorithms have been developed, but the two most
common methods in biomolecular modelling are Monte Carlo (MC) and molecu-
lar dynamics (MD). A brief explanation of MC simulations will be provided, but
much of this section will focus on MD, as this is generally the preferred choice in
biomolecular modelling, and is a major component of the methodology applied in
this thesis.
2.4.1 Monte Carlo
The basis of MC is random exploration of configurations of a system, where the
sample state M is only dependent on the preceding state, and has no bearing on
the succeeding state. Thus, an MC simulation is a stochastic and time-independent
sampling approach, and cannot give information of the evolution of a dynamical
system.
MC simulations generate random configurations using a set of criteria that either
accepts, or rejects, the succeeding configuration. If the move is accepted, than the
simulation proceeds, but if a move is rejected, then another iteration is performed
where a different configuration is chosen at random. The probability of the suc-
ceeding configuration being selected is equal to the Boltzmann factor, e−V(rN )/kT ,
where V(rN ) is the potential energy of a system. The accepted configurations
are then used to calculate an ensemble average of the thermodynamic property in
question, by averaging over the total sample states (M):
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〈G〉= 1
M
M∑
i=1
G(rN ) (2.30)
When a new random configuration is chosen, the potential energy is computed
(V(rN )). If the succeeding move is accepted, then V(rN ) of the succeeding state is
lower than the energy of current configuration. If V(rN ) is higher in the succeeding
state, the the following occurs. The Boltzmann factor of the difference between
the old and new move are calculated:
e−(Vnew(r
N )−Vold(rN )/kT (2.31)
where Vnew and Vold is the potential energy of the new and old configuration,
respectively. A random number, between 1 and 0 is also generated. If the random
number is lower than the value obtained from Eqn. 2.31, then the move is accepted,
otherwise, the move is rejected. The most common used MC algorithm is the
Metropolis algorithm [47].
MC simulations are preferred for simulations of gases or other lower density sys-
tems. This is because the large energy barriers in such molecules (e.g. torsional
rotations) are easier to overcome because of the ability to make random moves.
MC can also be used in simulations which vary in the number of particles (Grand
Canonical MC), by adding moves for the creation or annihilation of particles [48].
MC would not be suitable for simulating condensed phase systems, like ligand-
receptor complexes, because there is a large probability that the random move
would result in the overlap of molecules. This means that a large number of moves
will be rejected which will decrease the sampling efficiency. MC is also not suitable
for studying phenomena that are dependent on time, like transport properties.
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2.4.2 Molecular dynamics
The relative mass of nuclei, compared to electrons, is used as a reasonable approxi-
mation where atoms can be modeled as classical particles, and classical Newtonian
mechanics can be applied. MD applies this theory to give a time-dependent sam-
pling algorithm, with a temporal relation between configurations.
Newton’s laws of motion
MD generates configurations by integrating Newton’s second law of motion, Fi =
miai, where Fi is the force felt by an atom, and m and r are the mass and accel-
eration of that atom. The differential form is:
− ∂V
∂ri
=mi
d2ri
dt2
(2.32)
where V is the potential energy of the atom at position r, and d2ri/dt2 is the second
derivative of the position (r) of an atom, with respect to time, t, which equates
to the acceleration of the atom, ai. Eqn. 2.32 also demonstrates the important
relationship between force, F, and the potential energy, V : the force felt by an
atom, is equivalent to the negative gradient of the potential energy, with respect
to the position of that atom, −∂V/∂ri.
Updating atomic coordinates
Finite difference methods are used to integrate Newton’s second law, and thus
obtain a time-dependent trajectory of configurations. The MD integral is solved
numerically, by breaking the integral into small frames, from which positions, ve-
locities and accelerations of all atoms in a configuration are recorded. The fixed
time period between the frames is known as the time step, δt. The integration
process can be broken down like so:
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• the force of each atom in a configuration is calculated at time t
• the accelerations of all atoms are determined at time t
• from this, the positions (r) and velocities (v) are calculated, also at time t
• r(t) and v(t) are then used to calculate the r(t+ δt) and v(t+ δt)
• the forces of each atom at time t+ δt are computed
which is iterated for a given time period. There are many finite difference algo-
rithms [49, 50, 51] used to generate trajectories, and all are approximated as a
Taylor series expansion. Here, we will describe the velocity Verlet algorithm [52]
(Eqn. 2.33) which is thought to be the best MD algorithm, as it is precise, and
generates r, v and a in the same time step.
r(t+ δt) = r(t) +v(t)δt+ 12a(t)δt
2 (2.33a)
v(t+ δt) = v(t) + 12[a(t) +a(t+ δt)]δt (2.33b)
Eqn. 2.33b states that the acceleration must be known at time t, and t+ δt, and
so the velocity Verlet algorithm is performed in three steps.
v(t+ 12δt) = v(t) +
1
2δta(t) (2.34a)
v(t+ δt) = v(t+ 12δt) +
1
2δta(t+ δt) (2.34b)
First, the positions of all atoms, at time t+ δt are determined using Eqn. 2.33a,
using the velocities at accelerations at time t. Secondly, velocities at time t+ 12δt
are calculated (Eqn. 2.34a). The forces can be calculated from the current time
step, to give the acceleration of the atoms at time t+ δt, and finally the velocities
at t+ δt are determined using Eqn. 2.34b.
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MD at constant temperature and pressure
A standard MD simulations is performed using an NV E ensemble, where the num-
ber of atoms (N), the volume (V ) and energy (E) remain constant, but the tem-
perature and pressure are allowed to change. In the context of the protein-ligand
binding process, the experimental environment should be replicated, and here the
temperature (T ) and pressure (P ) are constant, and the energy fluctuates. This
introduces the NPT , or isothermal-isobaric ensemble, where the atomic positions
of a simulation are updated on the basis of constant temperature and pressure. In
MD simulations, the average temperature and pressure of configurations are kept
constant using thermostats and barostats, respectively.
The total energy of a system is the sum of the kinetic and potential energies, which
can be calculated from the positions and velocities of all atoms:
Etot =
N∑
i=1
miv2i +V(ri) (2.35)
where the temperature of a system is proportional to the average kinetic energy,
〈Ekin〉 = 3kT/2. Here, 〈Ekin〉 is the average kinetic energy. Since, in NPT en-
sembles, the average energy of the system is kept constant (Eqn. 2.35), and the
the potential energy is dependent on the positions of the atoms, the kinetic energy,
and thus the temperature, will fluctuate considerably to compensate.
The Berendsen thermostat [53] is a way of maintaining the average temperature of
a system, where the simulation unit cell is coupled to a heat bath. The velocities
of the atoms are scaled so that the change in temperature of the system is equal to
the difference in temperature between the simulation unit cell and the heat bath:
dT (t)
dt
= 1
τT
(Tbath = Tactual(t)) (2.36)
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where τT is the coupling parameter that determines the magnitude of the coupling
between unit cell and heat bath, Tbath is the temperature of the heat bath, and
Tactual(t) is the temperature of the unit cell at the current time step.
λ2T = 1 +
dt
τT
(
Tbath
Tactual(t)
−1
)
(2.37)
The scaling factor, shown in Eqn. 2.37, is λ2T . When τT is large then the scaling
factor is weak, and vice versa.
Scaling the velocities does not overcome the phenomenon of “hot solvent, cold
solute” where the thermal energy is not distributed evenly throughout the system,
resulting in different temperatures for the solvent and solute. Langevin dynamics,
explained later in the next section, resolves this problem.
Maintaining constant average pressure of a system is tackled in a similar way to
a Berendsen thermostat. The Berendsen barostat [53] scales the volume of the
system, by adjusting the coordinates of the atoms. This has the same form as the
thermostat where the change in pressure of the system is equal to the difference in
pressure between the simulation unit cell and the ‘pressure bath’.
dP (t)
dt
= 1
τP
(Pbath = Pactual(t)) (2.38)
Here, τP is the coupling constant and Pbath and Pactual are the pressures of the
‘bath’ and unit cell, respectively.
λP = 1−κ dt
τP
(Pbath−Pactual(t)) (2.39a)
r′i = λ
1/3
P r
′
i (2.39b)
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The volume of the system is scaled by λP (Eqn. 2.39a), and the compressibility
factor κ equals −1/V (dV/dP )T . The updated atomic positions are given by Eqn.
2.39b.
Langevin dynamics
The benefit of Langevin dynamics (LD) is that primary focus can be turned away
from the solvent, and onto the solute. LD allows to incorporate the effects of
solvent without the requirement of explicit solvent molecules to be present. Thus
a simulation using LD means that solvent effects can be taken into account, which
also influences the dynamics of the solute. This happens through random collisions
and a frictional drag force places on the solute, as it moves through the solvent.
As cited earlier, LD can be used to overcome “hot solvent, cold solute” effects. By
introducing a Langevin thermostat [54, 55], thermal energy from the heat bath, can
be transferred to the unit cell through collisions between the atoms in the heath
bath, and that of the unit cell. LD, shown in Eqn. 2.40, has three components that
contribute to the force exerted on an atom. The first component on the right side
of Eqn. 2.40, is the force exerted by other atoms, and is described by the potential
energy. The second, is the force of an atom moving through solvent, which is
modeled by a frictional drag due to the solvent, where ζ is the friction coefficient.
The last term is the force is due to random fluctuations in the interactions with
solvent.
m
d2ri
dt2
= Fi(ri(t))− ζidri(t)
dt
mi+Ri(t) (2.40)
The random force adds thermal energy into the system, and is thus associated with
temperature, and the frictional force removes thermal energy from the system.
There are some assumptions made in the LD model. First, it is assumed that
the frictional coefficient, ζ, has no bearing on the time and position of the atoms.
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Second, the random force is independent of the velocities of the particles and is
taken to have a Gaussian distribution with zero mean. Due to the random force
component, implementing a Langevin thermostat in an MD algorithm, means that
the simulation is no longer deterministic.
Periodic boundary conditions
In simulations methods, an appropriate definition of a boundary enables the correct
determination of macroscopic properties with the use of a relatively small number
atoms. Periodic boundary conditions [40, 39] makes this possible in such a way that
the forces exerted on the atoms are the same as if they were in bulk fluid. Without
this condition, a significantly larger number (technically an infinite number) of
atoms would be required to achieve a solution to macroscopic properties.
The basic principle of periodic boundary conditions is that if a solvent molecules
leaves the simulation unit cell, which is most commonly cubic in shape, from one
side, it will re-enter from the opposing side. The purpose of this is that the system
should not feel the effects of the boundaries. This is achieved by replicating the
cubic box of the simulation unit cell, in all directions. The coordinate of the
atoms in the imaginary unit squares can be calculated by adding or subtracting
the integral multiples of the simulation box length. The box size needs to be large
enough so that the protein atoms in the simulation unit cell, do not feel an effect
from the protein atom of any periodic image. A key consideration in periodic
systems is the treatment of long and short range forces, which will be described
next.
Non-bonded cut-offs
The potential energy of a system is the sum of the bonded and non-bonded inter-
actions (Vtotal = Vbonded +Vnon−bonded). The number of bonded interactions that
need to be calculated are proportional to the number of atoms (3N −6), whereas
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non-bonded terms increase in the order of N2. Therefore, the most laborious term
to calculate is the non-bonded contributions to the potential energy. In theory,
non-bonded interactions should be generated for all pairs of atoms, but this is not
always required. A way to truncate the potential is by: (a) introducing a non-
bonded cut-off where the potential is set to zero for any interaction past the cut-off
distance, and (b) apply the minimum image convention, where each atom interacts
with only one image of itself, within the cut-off distance (this is repeated infinitely
using periodic boundary conditions).
Cut-offs alone do not improve the efficiency of computing the potentials, because
this would still require the distances between each pair of atoms to be determined.
In liquid phase simulation, the atoms within a cut-off do not fluctuate much over 10-
20 time steps, meaning that distances between atoms are calculated less frequently,
and thus improving the compute efficiency. The non-bonded neighbour list stores
the information of all atoms within the cut-off distance, and additional atoms that
are slightly over the cut-off.
An important consideration is the frequency at which the neighbour list is updated.
If it is updated too frequently, then this compromises the efficiency, and if the
neighbour list is not updated enough, then incorrect energies will be calculated.
Further, setting the potential to zero so suddenly, introduces a discontinuous energy
potential. This can be overcome by using a switch function [56] which gradually
tapers off the potential energy close to the cut-off distance.
The long-range electrostatic term requires the most compute time as the r−1 term
decays slowly with respect to distance. Further, when periodic boundary conditions
are applied, cut-offs cannot be so large that an atom interacts with its own image,
and so this limits cut-offs to less than half of the simulation unit cell. Slow decay
of electrostatic interactions mean that considerable contributions are made to the
potential at distances greater than half of the unit box length.
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The Ewald summation [57] exploits the periodicity of the simulation unit cell, and
splits the potential into near- and far-field contributions. The near-field contri-
bution is obtained by taking a Gaussian function centered at each atom, with an
opposing point charge. This has a screening effect on the atomic charges allowing
for rapid convergence of near-field contributions. To reinstate the original point
charge interaction, the screening potentials are subtracted again. This compensat-
ing term is an interaction between Gaussian distributions, and is thus a far-field
interaction. This can be efficiently evaluated as the sum of the Fourier transforms of
the potential and charge density. The Ewald Summation reduces the scaling from
N2 to N3/2. A related approach, the Particle Mesh Ewald method [58] further
improves scaling to N ln(N).
Constrained dynamics
The limitation, in terms of time step selection, is the speed of the fastest processes
in a simulation: bond vibrations. A time step of 1 femtosecond (10−6 s) is required
to capture the bond vibrations in a simulation. Recording atomic information at
this frequency, is computationally inefficient and would require a vast amount of
time steps to gain accurate representations of biological phenomena.
The stretching vibration of hydrogen atoms bonded to heavy atoms are the fastest
of the degrees of freedom, but has a relatively small influence on the energy outputs.
By treating the bonds between heavy and hydrogen atoms rigid, the time step can
be increased to 2 or 3 femtoseconds. Although this seems a small change, over the
course of a simulation this contributes considerably and enables longer, or more
simulation replicates, to be performed at the same computational expense.
The SHAKE [59, 60] and RATTLE [59] algorithm are common constraint methods
incorporated into MD algorithms. Here, the positions of all atoms are determined
using Newton’s equation of motion, with no constraints. The atomic positions
are then corrected by the method of Lagrange determined multipliers. Another
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method, SETTLE [61], has specifically been developed to constrain bonds in solvent
molecules.
2.5 Molecular mechanics force fields
An MD algorithm computes the force experienced by each atom. To compute
the force, it is required to know the potential energy of each atom. A molecular
mechanics force field is a potential energy function that defines the intramolecular
forces using classical mechanics. The following is a breakdown of a force field into
its component parts.
2.5.1 A force field model
A force field can be segmented as follows:
Vtotal = Vbonded+Vnon−bonded (2.41a)
Vbonded = Vstretch+Vangle+Vdihedral (2.41b)
Vnon−bonded = VvdW +Velec (2.41c)
where the total potential energy Vtotal is the sum of the bonded (Vbonded) and
non-bonded (Vnon−bonded) intramolecular forces. The bonded forces can be broken
down even further into bond stretching (Vstretch), bending (Vangle) and torsional
(Vdihedral) terms. The bonded terms are represented as a deviation of the bond
length (r), angle (θ) or dihedral (γ) from an equilibrium value.
Vstretch =
∑
stretch
Kr(r− req)2 (2.42a)
Vangle =
∑
angles
Kθ(θ− θeq)2 (2.42b)
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Vdihedral =
∑
dihedral
Vn
2 [1 + cos(nφ−γ)] (2.42c)
The Vstretch term is modeled by the harmonic potential, that is Hooke’s law for-
mula, where req is the equilibrium bond length, and Kr is the stretching constant.
Another expression that derives realistic energy profiles is the Morse potential,
however this is used in systems where bond distances deviate significantly from
the equilibrium values, which is not often seen in biological systems, therefore,
Hooke’s law usually suffices. Vangle describes the deviations of bond angles from
their reference values, and is also commonly described by Hooke’s law, where θeq
is the equilibrium bond angle, and Kθ is the bending constant. It requires much
more energy to stretch bonds, than it does to bend them, so force constants will
be much larger in the first term. Vdihedral expresses the torsional angles, that is,
the rotation around the B−C bond of a molecule, A−B−C−D. Torsional or
dihedral potentials are usually defined using a cosine series expansion, where φ is
the dihedral angle, n is the multiplicity which defines the number minimum points
when the bond is rotated 360°, γ shows where the dihedral angle passes through a
minima, and Vn is the barrier height.
Similarly, the non-bonded interactions can be broken down in to a short-range van
der Waals term (VvdW ), and a long-range electrostatic (Velec) term:
VvdW =
∑
i<j
[
Aij
r12ij
− Bij
r6ij
]
(2.43a)
Velec =
∑
i<j
qiqj
rij
(2.43b)
The van der Waals force is described by the 12-6 Lennard-Jones equation which
models the attractive and repulsive interactions depending on the inter-atomic
separation, rij . As rij decreases from infinity, the negative 1/r6 term dominates
the interaction and so the atoms feel an attractive force as the energy becomes
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more negative. As rij continues to decrease, and tends towards zero, the 1/r12
dominates and leads to an increase in energy, and thus repulsion between the two
atoms. Coloumb’s law is most commonly used to describe electrostatic interactions
in macromolecular systems, where qi and qj are the atomic charges,  is the relative
permittivity of space and rij is the interatomic distance. A more detailed account
on the implications of non-bonded interactions in molecular simulations, can be
found in the section 2.4.2 under “Non-bonded cut-offs”.
In addition to the functional form that is selected to model respective interactions,
parameters are also included which describe geometric and energetic properties of
the interaction [62]. These can be derived either using computational means (i.e.
quantum mechanical calculations) or empirically. The combination of a functional
form, and a set of parameters is a force field.
There are several molecular mechanics force fields that have been developed; all
of these are based on a similar functional form to describe molecular interactions.
The most widely used force fields are AMBER [63], CHARMM [64], GROMOS
[65] and OPLS [66]. There are subtle differences between these force fields. For
example, in the case of defining the energy of improper dihedral angles, OPLS and
AMBER incorporate the improper dihedral term within the dihedral term seen in
Eqn. 2.42c. CHARMM and GROMOS have an additional functional term that
defines this molecular property.
Choosing a potential energy function for a protein is relatively simple compared
with that of small drug-like molecules. The function for a protein is limited to
the 20 amino acids that are commonly found in proteins, and the atom type and
intramolecular forces that define them. These have been described and tested
extensively, and so a realistic simulation of protein dynamics is available. Small
molecules, however, have many more permutations with respect to atom types and
degrees of freedom, and so careful parameterisation is required.
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All of the aforementioned force field packages have a extensive range of defined atom
types that are commonly seen in drug-like molecules. AMBER has the benefit,
for end-users, that it is able to generate a force field model automatically and is
compatible with the AMBER protein force field, whereas OPLS requires manual
selection of atom type selection. Transferrability of parameters across a wide range
of small molecules has been achieved and general force fields have been developed,
such as General Amber Force Field (GAFF, [67]) and CHARMM General Force
Field (CGenFF, [68]) which aim to incorporate the parmaterised small molecule
within the respective protein force field. OPLS 2.1 is a force field, which has been
applied to several biological systems [45] that relate to calculating binding free
energies.
Applying accurate force field parameters to a biological system is crucial when
preparing a MD simulation. The difference between the above force fields is subtle,
however one has to pick carefully which force field is best suited dependent on the
type of simulation.
2.5.2 Sources of error
The number of configurations sampled, then, is irrelevant if the model describing
the intra and intermolecular force is not an accurate representation. This applies to
both the protein and small-molecule that is simulated. Perhaps, a greater challenge
is determining the correct parameters for small molecules that exhibit unconven-
tional stereochemistry, or contain chemical groups, that are not extensively studied.
Thus, the quality of the simulation is directly dependent on the accuracy of the
molecular mechanics force field.
2.6 Free energy methods
As was described in section 2.3.3, it is challenging to determine entropic thermody-
namic properties, such as the change in Gibbs free energy, ∆G, but it is possible to
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calculate the difference of such properties. Hence, in the context of protein-ligand
binding, we can calculate the change in ∆G which gives ∆∆G. This is a relative
binding affinity, as it is the calculation of the relative change in ∆G, between two
systems. Techniques which employ this strategy, namely Thermodynamic Integra-
tion (TI, [69, 70]) and Free Energy Perturbation (FEP, [71]), are commonly known
as ‘exact’ methods, and are computationally rigourous. An alternative, and compu-
tationally more efficient strategy, is to compute the absolute binding affinity (∆G)
through the application of a less accurate physical model, and empirically derived
parameters. The most widely used of these approaches is Molecular Mechanics and
the Poisson-Boltzmann Surface Area Approximation (MMPBSA, [72]). This yields
binding affinities that are ‘approximate’, but exhibit precision. This section will
detail the key ‘exact’ and ‘approximate’ free energy methods that are commonly
applied in protein-ligand binding.
2.6.1 Exact methods
TI and FEP are related methods inasmuch that they both compute the relative
binding affinity between two states, through a series of alchemical transformations
each defined by a coupling parameter, λ. λ = 0 is the initial state and λ = 1 is the
final state. The transformations are termed ‘alchemical’ because the intermediate
states are unphysical, and would not be seen in experiment. However, asG is a state
function, the path taken between the first and last λ state is irrelevant. Through the
use of a thermodynamic cycle, relative changes in ∆G can be determined (∆∆G).
Both methods require MD simulations for each λ window which is the reason for the
high computational cost. They also require small increments of the intermediate λ
state, because in FEP, an overlap in phase space is needed; and in TI, this allows
for accurate numerical integration.
A property of a state function, such as G, is that regardless of the path taken from
initial to final state, the sum of all paths required to close a thermodynamic cycle,
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Figure 2.4: A representation of the the thermodynamic cycle used in the compu-
tation of relative binding affinities (∆∆Gbind) using exact methods,
namely TI and FEP.
will always equal to zero. Exact methods employ the thermodynamic cycle in Fig.
2.4, to calculate ∆∆Gbind. A logical approach is to compute the difference of the
processes that represent ∆GA and ∆GB:
∆∆Gbind = ∆GB−∆GA (2.44)
where ∆GB and ∆GA are the processes of ligand A and ligand B, binding to a
protein. Simulating this process is cumbersome because the path involves large
conformational rearrangements of the ligand binding to the protein, plus the con-
formational changes of the protein associated with the binding process. Modeling
this process would require an extremely long simulation to obtain converged ∆G
values.
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A counter-intuitive approach is to simulate the alchemical transformation of ligand
A, to ligand B, bound to the protein, ∆Gboundalch , and the transformation of the two
entities dissociated in aqueous solvent, ∆Gaqalch. Since the ∆G value of the protein
will not change considerably, as it is the same in the initial and final state, only a
simulation of the alchemical transformation of the ligand is required. This requires
the transformations of chemically related ligands, so that conformation changes are
small, and converged ∆G values are obtained.
∆∆Gbind = ∆Gaqalch−∆Gboundalch (2.45)
As such, using the thermodynamic cycle, we can calculate the relative binding
affinity, of two chemically similar ligands, using alchemical free energies. This is
formulated in the above equation.
2.6.1.1 Free energy perturbation
FEP computes ∆∆G by averaging over finite differences of λ in the potential energy
function. The difference in free energy between two states is defined like so:
∆G= ∆GA−∆GB =−kT ln〈e−(VB−VA)/kT 〉M (2.46)
Since the alchemical transformation from final to end state is broken down into λ
states, the potential energy is computed by summing the change in each λ window:
V (λ,r) = (1−λ)VA(λ,r) +λVB(λ,r) (2.47)
where the potential energy of ligand A and B is defined as VA(λ,r) and VB(λ,r),
and V (λ,r) is the potential energy of the intermediate state.
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Recently, there has been an advance in FEP-based methods that has led to con-
siderable interest [45]. FEP+ uses FEP and replica exchange solute tempering
(REST, [46]), where the hamiltonian between different λ windows are exchanged
to enhance the sampling of the simulation, particularly in the region of ligand bind-
ing. However the predictions that are made are based on a single simulation for
each ligand transformation. Further, the error is calculated by averaging the error
around a thermodynamic cycle, involving numerous perturbations. This method
spreads error evenly of a number of perturbations, and yields an unrepresentative
error for a particular FEP calculation.
2.6.1.2 Thermodynamic integration
TI calculates the relative binding affinity by averaging over a differentiated energy
function, with respect to the intermediate λ states.
To generate the free energy changes of an alchemical transformation, the derivative
of the total potential energy with respect to λ is computed, and then integrated
numerically for all lambda states (Eqn. 2.48). This is done for both the ligand in
aqueous solution, ∆Gaqalch, and the ligand-protein complex, ∆Gboundalch :
∆Galch =
∫ 1
0
〈
∂V (λ,r)
∂λ
〉
dλ (2.48)
Then, the thermodynamic cycle is used (Fig. 2.4) to determine the relative binding
affinity, ∆∆Gbind, between ligand A and B, which is equal to the the difference in
∆G between the free (∆Gaqalch), and bound ∆Gboundalch ligand (Eqn. 2.45).
A recently published method, “Thermodynamic Integration with Enhanced Sam-
pling” (TIES, [42]), runs replica simulations for each λ window of each ligand
transformation, which allows for tighter control over standard errors and thus pro-
duces more reliable results. Running replica simulations means that the error is
representative of the perturbation in question.
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2.6.1.3 Absolute binding affinity predictions
It is also possible to create a thermodynamic cycle that enables the determination
of absolute binding affinities. Following a similar approach described in Fig. 2.4,
calculating absolute binding affinities requires only two simulations, that is the
disappearance of a ligand in aqueous solution and the disappearance of a ligand
within a complex. The initial and final λ states would then be the ligand, and
absence of ligand, respectively.
Historically, absolute binding affinities have not been shown the same levels of inter-
est as relative binding affinity predictions, but a recent study conducted by Aldeghi
and colleagues [44] performed FEP-based absolute binding free energy calculations
on a diverse range of ligands. Good correlation were reported with experimental
binding affinities. However, this approach was tested on a rigid drug target system,
resulting in fast converging properties. Tight error bars were reported, albeit from
a single simulation, which is due to the rigidity of the protein target. Recently,
an ensemble-based method to determine absolute binding affinities has also been
developed [73].
2.6.2 Approximate methods
The computational cost of executing the so-called ‘exact’ methods has led to alter-
native, more computationally efficient approaches, involving empirical parameters,
and some general assumptions. In the context of drug discovery programmes, the
requirement to predict binding affinities for a large library of drugs has led to the
development of ‘approximate’ methods, which is thought to be a good balance be-
tween computational cost and accuracy. However, there is an inverse relationship
between computational efficiency, and accuracy which needs to be considered. The
following ‘approximate’ methods that are explored, are presented in the order of
increasing computational cost, and thus increasing accuracy.
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2.6.2.1 Molecular docking and scoring functions
The purpose of molecular docking and subsequent free energy scoring functions, are
to predict the binding affinity of large libraries of compounds to a protein target
[74]. This is more commonly known as virtual screening and has been employed
in drug discovery as a strategy to rapidly assess binding affinities. Binding affin-
ity assessment on this scale brings two main problems. The ‘docking problem’ is
where realistic generation and evaluation of structures is difficult without enhanced
sampling methods. Secondly, generating a realistic scoring function requires the
evaluation of many energy terms, but this is not possible in virtual screening due
to the large computational time required to calculate all energy terms. For these
reasons, virtual screening techniques are highly approximate, and are, at best, suit-
able as a first approximation of binding affinities before more rigorous techniques
are used [75].
To achieve efficient computation, docking algorithms usually employ a rigid protein
structure and allow the ligand to explore conformations. The obvious issue here
is that proteins often experience significant conformational changes upon ligand
binding, which is ignored. With regard to scoring functions, the computational
requirements in calculating all energy terms involved in binding means only some
energetic terms are considered. For example, the internal bonded interactions
described by molecular mechanics is often used, but the non-bonded terms are
usually predicted by linear dependence to polar and non-polar regions.
There are a number of molecular docking and scoring functions available with
varying performance [76, 77, 78, 79, 80, 81].
2.6.2.2 Linear activation energy
The linear interaction energy (LIE, [82]), also know as the linear response (LR)
method is a semi-empirical approach that requires sampling of only two states: the
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protein-ligand complex in solvent, and the free ligand in solvent. LIE takes into
account only the electrostatic and van der Waals potential interactions between
the solute and solvent.
∆GLIEbind = α∆〈Velec〉+β∆〈VvdW 〉+γ (2.49)
The free energy is obtained by linearly fitting the the difference in Velec and VvdW
between the ligand and its environment, either protein or solvent. The parameters
α, β and γ are empirically derived, depending on the protein and ligand that is
under study. The reliance of experimentally derived parameters for new ligands
means that this method is a poor strategy for drug discovery purposes.
2.6.2.3 Molecular Mechanics and the Poisson-Boltzmann Surface
Area approximation
Molecular Mechanics and the Poisson-Boltzmann Surface Area approximation
(MMPBSA) is the most computationally rigorous of the approximate methods
described. MMPBSA has been a popular strategy for predicting absolute bind-
ing affinities for protein-ligand systems. This is due to the relatively inexpensive
computational requirements, and good comparisons in binding affinities between
different ligands bound to the same protein. A minimum requirement of MMPBSA
is a single simulation of the protein-ligand complex, compared with TI and FEP,
which require simulations for each λ state.
MMPBSA computes the average binding free energies of the end-states in a protein-
ligand system. These being the initial state, the ligand and protein unbound in
aqueous solvent; and final state, the bound protein-ligand complex. These free
energies are then used to determine the ∆G value:
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∆Gbind = 〈Gcomplex〉−〈Gprotein〉−〈Gligand〉 (2.50)
where 〈· · · 〉 denotes ensemble averages of the three entities, from a representative
sample of configurations obtained from an MD simulation.
The purpose of the MMPBSA approach is to compute the free energy of the as-
sociation of a ligand and protein, in aqueous solution, ∆Gaqbind. The problem that
arises here, is that the majority of the energetic contributions will come from the
solvent-solvent interactions, giving rise to large fluctuations in ∆Gaqbind. To achieve
converged results, an inordinate number of configurations need to be sampled.
To overcome this, a thermodynamic cycle (Fig. 2.5) can be designed to circumvent
the simulation of the ∆Gaqbind process. Instead, the binding free energy in vacuo,
∆Gvacbind, is computed, in addition to the free energies of solvation of the complex
(∆Gsolcom), protein (∆Gsolrec) and ligand (∆Gsollig ).
Figure 2.5: A representation of the the thermodynamic cycle used in the compu-
tation of absolute binding affinities (∆Gbind) using the approximate
method, MMPBSA.
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As a result, using the thermodynamic cycle in Fig. 2.5, ∆Gaqbind can be calculated
like so:
∆Gaqbind = ∆G
vac
bind+
(
∆Gsolcom−∆Gsolrec−∆Gsollig
)
= ∆Gvacbind+ ∆Gsol (2.51)
The binding free energy in vacuo is the summation of the electrostatic, (∆GMMelec ),
van der Waals (∆GMMvdW ) and intramolecular interactions (∆GMMint ):
∆Gvacbind = ∆GMMint + ∆GMMvdW + ∆GMMelec (2.52)
and is calculated using the molecular mechanics force field described in section 2.5.
∆Gsol = ∆Gsolnon−pol+ ∆Gsolpol (2.53)
The free energy of solvation term, ∆Gsol, is the free energy of transferring the
protein, ligand or complex, from a vacuum, into an aqueous solvent. This term
can be broken down even further to a polar (electrostatic) and non-polar (van der
Waals) contributions (Eqn. 2.53). The polar contribution is calculated by treating
the solute as a continuous region of low dielectric constant, and the solvent is
represented as a constant high dielectric continuum, enabling numerical solution
of the linear Poisson-Boltzmann equation. The non-polar term is calculated from
empirical parameters related to the solvent accessible surface area.
Linear Poisson-Boltzmann equation
The Poisson-Boltzmann (PB, [72]) equation is used to determine ∆Gsolpol, by com-
bining the Poisson equation, which relates charge density, ρ, to the electrostatic
potential of a changing dielectric medium, and the Boltzmann distribution for mo-
bile ions.
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The electrostatic potential, in a medium of changing dielectric value with respect
to position, can be related to the charge density:
∇· [(r)∇φ(r)] =−4piρ(r) (2.54)
The above Poisson equation (Eqn. 2.54) describes the local electrostatic potential,
φ(r), generated by the charge density at that localised region, ρ(r), where the
charge density, ρ, is the distribution of charge across the system. In biomolecular
systems, the variation in dielectric constant (r) will be between the solute, which
is generally between 1 and 4, and the solvent, usually set at approximately 80.
The Poisson equation requires modification to incorporate the ionic distribution
in solution, as a response to the electrostatic potential. Thus, negative ions will
accumulate where the potential is positive, and vice versa. Over accumulation
of ions is compensated due to natural thermal motion which is represented as a
Boltzmann distribution:
ρ± =±qce−qφ/kT (2.55)
where ρ± is the charge density, ±q is the ionic charge and c is the concentration.
Combining Eqn 2.54 and 2.55, gives the Poisson-Boltzmann equation:
∇· [(r)∇φ(r)]−κ′2sinh[φ(r)] = 4piρ(r) (2.56a)
κ2 = κ
′2

= 8piNAe
2I
1000kT (2.56b)
where κ′2 is related to the Debye-Hu¨ckel equation, which takes into account the
interaction energy of ions: e is the electronic charge, I is the ionic strength of
the solution, and NA is Avogadro’s number. This equation can be linearised by
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expanding the sine function as a Taylor series expansion (Eqn. 2.56), and selecting
only the first term:
∇· [(r)∇φ(r)]−κ′2φ(r)
[
1 + φ(r)
2
6 +
φ(r)4
120 + · · ·
]
= 4piρ(r) (2.57a)
∇· [(r)∇φ(r)]−κ′2φ(r) = 4piρ(r) (2.57b)
consequently, leading to the linearised Poisson-Boltzmann equation.
The derivatives in Eqn. 2.57b are determined by solving a partial differential
equation for the potential, φ(r). A cubic lattice is superimposed on the solute
and solvent, and values for the dielectric constant, charge density, electrostatic
potential, and ionic strength are assigned to each grid point (i.e. the centre of
each grid cube). The atomic charge does not always fall on a grid point, and so
the charge is distributed to 8 surrounding grid points. As the atomic charge nears
a grid point, a greater proportion of the total charge of that grid is assigned to
that atomic charge. The boundary between solute and solute are defined as the
molecular surface, and solvent accessible surface. Grid points that fall within the
solute are assigned a dielectric constant representative of the solute, and grid points
that fall outside this are assigned a high dielectric constant, representative of water.
The ∆Gsolpol term is calculating by performing two calculations, using the same grid
points and solute dielectric, but different exterior dielectric constants; water and
vacuum:
∆Gsolpol =
1
2
∑
i
qi
(
φwati −φvaci
)
(2.58)
where qi is the charge assigned to each point on the cubic grid, and φwati and
φvaci are the electrostatic potentials in water and vacuum respectively, at the same
point. This calculation is performed for all three entities in the protein-ligand
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binding process, that is the protein, ligand and complex.
Generalised Born equation
The Born equation is an alternative way of calculating the electrostatic contribution
to the free energy of solvation using continuous dielectric media:
∆Gelec(q) =−
(
1− 1

)
q2
2a (2.59)
where q is the net charge and a is the radius of the cavity. The Born equation treats
positive and negative ions the same which is not representative of biomolecular
solutes in solvent, but a variation of Eqn. 2.59, where partial atomic charges are
incorporated leads to the generalised Born (GB, [83]) equation:
Gelec(qi, qj) =−
(
1− 1

)
qiqj
fij
(2.60a)
fij =
√
r2ij +a2ije−D (2.60b)
a2ij = aiaj (2.60c)
D =
r2ij
4a2ij
(2.60d)
where the Coulombic interaction between to atomic partial charges, is combined
with the Born equation, by a function fij which depends on the atomic charge
distance, rij , and the Born radii for both atoms, ai and aj . Similarly to non-
bonded neighbour lists, the ai and aj values do not have to be updated so often,
as the the dependence on other atoms is relatively weak.
The Poisson-Boltzmann equation can be replaced with the generalised Born equa-
tion to give another method termed, Molecular Mechanics and the Generalised
Born Surface Area approximation (MMGBSA).
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Solvent accessible surface area
The non-polar contribution to the free energy of solvation, ∆Gsolnon−pol, is comprised
of the the van der Waals interactions involved in the solvation process, ∆GvdWnon−pol,
and the free energy required to form a cavity for the protein-ligand complex, in
the aqueous solution, ∆Gcavnon−pol. Forming a cavity in the solvent is an energet-
ically unfavourable process and so ∆Gcavnon−pol will be positive. The ∆GvdWnon−pol is
favourable, and will thus have a negative value. The ∆Gsolnon−pol is determined like
so:
∆Gsolnon−pol = ∆Gcavnon−pol+ ∆GvdWnon−pol = γA+β (2.61)
where A is the total surface accessible surface area (SASA), and γ and β are con-
stants derived empirically. The linear relationship between SASA and ∆Gsolnon−pol is
explained using two assumptions. First, it is assumed the solvent molecules most ef-
fected by the formation of a cavity and redistribution around the molecular surface
is the first solvation shell, and thus the non-polar interactions are proportional to
the SASA. Secondly, due to the rapid decay of the van der Waals potential energy,
the solute-solvent van der Waals interaction are, again, assumed to be proportional
to the SASA.
Calculating configurational entropy
Although some consideration has been given to entropic penalties, namely the
entropic penalty of creating a cavity in solvent, for the solute, there has been no
discussion about the configurational entropy. This describes the changes in the
configurational degrees of freedom, of the ligand and protein, once the two solutes
are associated. There is an entropic cost to ligand-protein association, because
once bound, both entities are restricted in the number of conformations available
to them. This can be incorporated into the free energy estimate, obtained via the
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MMPBSA method:
∆Gbind = ∆GMMPBSAbind −T∆Sconf (2.62)
where ∆GMMPBSAbind is the binding free energy estimate achieved using MMPBSA,
and T∆Sconf is the configurational entropy as a function of temperature, T . To
determine ∆Sconf then, the entropy S, needs to be determined for each species,
and is subsequently calculated as seen in Eqn. 2.63a.
SXconf = Svibconf +Srotconf +Stransconf (2.63a)
∆Sconf = ∆Scomconf −∆Srecconf −∆Sligconf (2.63b)
The configurational entropy is the sum of the vibrational, rotational and transla-
tional degrees of freedom (Eqn. 2.63b), where SXconf is the configurational entropy
for any of the three components. The entropic components on the right side can
be determined using statistical mechanics expressions.
A common approach in calculating configuration entropies is via normal mode anal-
ysis (NMA, [84]), which achieves relatively converged entropy values. The idea is
that the terms on the right side of Eqn. 2.63b are estimated using the frequencies
from NMA. Conventionally, NMA is performed by removing all explicit solvent
molecules, and truncating the protein to a region around the ligand binding site.
This is because of the high computational demands, and difficulty in obtaining con-
verged entropies, when a fully explicit system is used. This truncated configuration
is minimised and harmonic frequencies are calculated.
There are a number of limitations with using NMA to predict entropies. First, is
the computational demands associated with performing these estimations. Second,
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is that estimates are calculated from minimised structures in the absence of solvent,
which is not representative of the hydrated simulation. Finally, NMA estimates
frequencies from a single minimum, which again is not representative of an energy
landscape which contains many minima. Other quasi-harmonic approaches [85]
have been applied, with unconvincing results.
A SASA-based method for the estimation of configurational entropy has been de-
veloped [86]. This approach has the benefits that it estimates entropy contributions
based of actual snapshots, inclusive of water, and does not require minimisation or
truncation of the system. Further, it can be completed on conventional desktops.
A theoretical description of this approach can be found in section 5.1.2.
Multi-trajectory methods and adaptation energy
Binding free energies, using the MMPBSA method, can be calculated using either
single or multiple simulations. Usually, free energies for complex, protein and ligand
are extracted from a single simulation of the complex, termed 1-trajectory (Eqn.
2.64a). This approach has the advantage that the energies which are not involved
in ligand binding, namely the internal bonded interactions, ∆GMMint , cancel out
exactly, and so have lower computational requirements.
Alternatively, one may calculated ∆Gbind from independent simulations of the com-
plex and receptor, where the free energy of the ligand is obtained from the complex
simulation. This is termed the 2-trajectory approach (Eqn. 2.64b). Lastly, free
energies can also be obtained from three separate simulations of each component,
and is called the 3-trajectory method (Eqn. 2.64c).
∆G1−trajbind =G
com
com−Gcomrec −Gcomlig (2.64a)
∆G2−trajbind =G
com
com−Grecrec−Gcomlig (2.64b)
∆G3−trajbind =G
com
com−Grecrec−Gliglig (2.64c)
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In the 1-trajectory approach the free energy estimate of the ligand will be limited to
the conformations that are sampled by the protein within the complex trajectory.
But in practice, a ligand can cause conformational changes in the protein, and vice
versa, known as the adaptation energy.
Adaptation energies allow one to understand the energetics involved in ligand bind-
ing. For example, a small adaptation energies for both the receptor and ligands
would suggest a ‘lock-and-key’ method of binding, where large changes in adapta-
tion energy for receptor, and negligible difference for the ligand, would follow the
‘induced-fit’ mechanism.
If one averages theGrec value obtained from the 1-trajectory method, for all ligands,
then the difference between the original Grec value and the averaged value is an
estimated adaptation energy of the receptor. Similarly, evaluating Glig from free
ligand MD trajectories, allows one to compare the ligand adaptation energy. This is
the difference between the Glig obtained from conformations bound to the protein,
and the Glig from the free ligand simulation.
2.7 Ensemble-based binding affinity predictions
The basis of all studies in this thesis, is the use of ensemble-based binding affinity
predictions, which was briefly explained in section 2.3.4. In the following sections,
a more detailed explanation will be presented of two ensemble-based approaches,
namely Enhanced Sampling of Molecular Dynamics with Approximation of Con-
tinuum Solvent (ESMACS, [16]), and Thermodynamic Integration with Enhanced
Sampling (TIES, [42]).
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2.7.1 Enhanced Sampling of Molecular Dynamics with Ap-
proximation of Continuum Solvent
ESMACS computes 25 identical simulations, of a specific ligand and receptor com-
plex, with the only difference being the initial velocities assigned to the atoms after
minimisation, according to a Maxwell-Boltzmann distribution at constant temper-
ature. This group of 25 simulations is termed an ensemble and the individual
simulations themselves are replicas.
Figure 2.6: A schematic representation of ensemble simulation, performed in ES-
MACS, and single simulations. Running multiple replicas allows for
tight control of errors, and so we obtain reliable and reproducible
binding affinity predictions. Single simulations do not have error
bars, and thus yield unreproducible results.
Upon completion of the ensemble simulations, MD trajectories are used to compute
the free energies are calculated based on the extended MMPBSA and MMGBSA
method described in section 2.6.2.3, for each replica. We have witnessed that the
frequency distribution of these set of values lie essentially on a Gaussian curve
(Fig. 2.3). A number of statistical techniques are applied to produce a mean final
∆G value, and the standard deviation associated with it. This will be described in
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the next section.
Structuring the MD simulations and free energy calculations in such a way, allows
for reproducible results, and thus makes it reliable. The strength of this approach
is that it allows for precise ranking of drugs to a protein target.
(a) CDK2-L1Q ; MMGBSA (b) CDK2-L1Q ; MMPBSA
(c) TYK2-L02 ; MMGBSA (d) TYK2-L02 ; MMPBSA
Figure 2.7: Plot of the variation of the bootstrapped statistics as a function of
replica number and simulation length: (a) and (b) show the variation
and normalised frequency of the error as a function of replica num-
ber for the CDK2-L1Q complex using the MMGBSA and MMPBSA
method, respectively; (c) and (d) show the varation of the bootstrapped
error as a function of simulation length for the TYK2-L02 complex,
using the MMGBSA and MMPBSA, respectively. The above bench-
marking tests justify the replica number and simulation length selec-
tion in ESMACS.
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Two factors determining the sampling of phase space, in ESMACS, are the number
of replicas in an ensemble simulation, and the simulation length. Both need to be
gauged to ensure that a sufficient amount of phase space is sampled, but equally the
wall clock time remains reasonably low. Benchmarking tests have shown that 25
replicas and an equilibration length of 2 ns, followed by 4 ns of MD simulation [43],
achieves statistically converged binding affinities. Fig. 2.7 presents the quantifies
the variation of error as a function of replica number and simulation length for two
receptor-ligand complexes that are investigated in chapter 4.
2.7.2 Thermodynamic Integration with Enhanced Sam-
pling
In TIES, 5 replicas of 13 lambda states are generated, for which ∆V/∆λ are cal-
culated, that is 65 simulations in total. This was justified through benchmarking
tests, which showed that this number of replicas, and λ windows gave the best
compromise between accuracy and reproducibility in ∆∆G values, and computa-
tional expense [42]. Potential derivatives for each replica are the average potential
energy derivative over the entire trajectory. ∆V/∆λ, for each lambda, is calcu-
lated by averaging the 5 potential derivative values obtained. Then the integral in
Eqn. 2.48 is solved numerically, using the trapezoidal rule, to achieve ∆Gaqalch and
∆Gboundalch for the free ligand and complex, respectively.
It should be noted that TIES is not limited to these parameters. If one wishes to
increase phase space sampling, then system-specific modifications to the replicas
size, simulation length or number of λ values can be made. Error quantification
analysis was performed by Bhati et al. [42] to justify the selection of 5 replicas per
λ window and simulation length of 4 ns, reporting similar results to what is seen
in Fig. 2.7.
Binding free energies obtained by TIES is a stochastic variable described by a
Gaussian random process, which means that the integral in Eqn. 2.48, is itself a
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stochastic variable (described in 2.3.4). Therefore, statistical mechanics permits us
to interpret Eqn. 2.48 in terms of stochastic calculus. In short, the integral that
is computed for each λ window is for the average of 5 replicas, which consist of
MD trajectories that also display random Gaussian distributions. This allows for
a more reproducible calculation of each λ integral and effectively ‘smoothes’ the
integral that is computed. The conventional approach would be to run a single
replicas for all λ windows, and subsequently compute the integral for all λ. This
is then repeated n times and then an average is taken. The difference here is that
single potential derivative value can lie anywhere within, what would be, large
error bars. As a result, n set of integrands with a ‘jagged curve’ from which an
inaccurate, and unrepeatable ∆Galch is generated.
Figure 2.8: A representation of ensemble-based free energy methods, compared
with single simulations. TIES averages ∆V/∆λ from all replicas,
with respect to λ; which gives a close control over. This is depicted
by reproducible blue line, with small red error bars. The integral is
then numerically calculated from the resultant averages. Conversely,
evaluations of ∆V/∆λ from single simulations lead to largely varied
results which change with each new simulation. This is represented
with an orange line, and an absence of error bars.
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In the same way, we are able to use to stochastic calculus to generate standard
errors. The error for each λ window is the bootstrapped standard error of the
mean for all potential derivative, of all replicas. The variance of ∆Gaqalch, ∆Gboundalch
and the final relative binding affinity are as follows:
σ2aq/bound =
∑
σ2λ(∆λ)2 (2.65a)
σ2 = σ2bound+σ2aq (2.65b)
Hysterisis, the sum of ∆∆Gbind associated with the closing of a thermodynamic
cycle, in theory, is zero. Due to the finite integration of the potential derivative,
uncertainties are inevitable, and so hysteresis in practice is never zero. Thus, as the
calculated hysteresis tends to zero the accuracy of the predictions improves. The-
oretically, the difference of the integral of the forward and reserve transformation
is also zero. Through the use of stochastic calculus (section 2.3.4) in the aforesaid
fashion, in conjunction with replica simulations per lambda window, TIES keep
hysteresis to a minimum. This is achieved through sufficient sampling of phase
space and the correct approaches taken towards error propogation. Recent meth-
ods [46, 45] have reported low hysterisis by averaging total hysteresis over a full
cycle closure, generating unrepresentative errors. The same method reports rel-
ative binding free energies from single replica simulations, and with no standard
error assigned to the calculated ∆∆G.
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Chapter 3
Methods
In this chapter, a detailed account of the ESMACS and TIES methodology is
presented. Then, it is described how the methods are automated and coupled with
high-performance and cloud computing, through the application of the Binding
Affinity Calculator (BAC, [87]).
3.1 Enhanced Sampling of Molecular Dynamics
with Approximation of Continuum Solvent
We begin with ESMACS, the approach based on ensemble MD simulations that
estimates binding affinities using end-point free energy methods. The theoretical
background behind this protocol is found in section 2.7.1.
3.1.1 Model preparation
Geometry optimisation of the ligands was completed using Gaussian03 [88], and
the restrained electrostatic potential (RESP, [89]) method was used to generate
partial atomic charges. Ligand parameters were created using the general AMBER
force field (GAFF, [67]). GAFF is used as it can generate a force field model
automatically and is compatible with the AMBER protein force field. With regards
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to the protein parameters, ff14SB [90] were loaded, along with the parameters for
phosphorolated threonine (T2P, [91]) and phosphorylated serine residus (S2P, [91]).
The Leap module in AMBER14 [89] was used to electrically neutralise the complex,
using counter ions, and solvated in a cubic box with a 14 A˚ buffer, using atomistic
TIP3P water [92]. Topology and coordinate files were subsequently created.
3.1.2 Simulation set-up
Equilibration and subsequent MD production runs were performed by the MD pack-
age NAMD2.9 [93] using an isobaric-isothermal (NPT) ensemble. NAMD2.9 uses
the velocity Verlet integration method to advance positions and velocities through
time. The SHAKE algorithm [60] was included for all atoms covalently bonded
to hydrogen, allowing for an integration time step of 2 fs. Periodic boundary con-
ditions were used through equilibration and simulation stages. The particle mesh
Ewald summation method (PME, [58]) was used to handle long-range Coulombic
interactions, with a cut-off distance of 12 A˚. Each equilibration and production
stage was performed in replicates of 25.
Minimisation was conducted using the conjugate gradient and line search methods
for 2000 iterations whilst achieving a gradient tolerance of 10. The system was
then annealed from 50 K to 300 K, over a period of 50 ps, where it was maintained
at 300 K, and 1 bar using the Langevin thermostat and the Berendsen barostat,
respectively. Equilibration phase was 200 ps while maintaining a 4 kcal/mol A˚2
force constant on both ligand and receptor, to ensure solvation of the complex. This
was followed by step-wise force constant relaxation for both the ligand and receptor.
Firstly, the ligand force constants were reduced, in increments of 1 kcal/mol A˚2,
from 4 to 0 kcal/mol A˚2 over a period of 200 ps. The receptor force constants were
similarly reduced from 4 to 1 kcal/mol A˚2 for 150 ps. Finally, all constraints were
removed and the system was equilibrated, unrestrained, for 200 ps.
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MD simulation were performed over a period of 4 ns and coordinates were recorded
every 1 ps. The simulation length was decided based on previous studies which
showed sufficiently converged free energy values at this time length [16, 43].
3.1.3 Free energy calculation
The binding affnities were achieved using the MMPBSA and MMGBSA method
via the AMBERTools15 [90] package. MMPBSA.py.MPI [94] module was used for
the calculations. The module employs SANDER to calculate the bonded and non-
bonded molecular mechanics terms Ebnd, Eelec and Evdw with no cut-off assigned
for non-bonded energies.
The Gpol is described by the PB or GB equation (see section 2.6.2.3). Both methods
assign an internal and external dielectric constant of 1 and 80, respectively. For PB
[72], the linear PB equation was solved on a cubic lattice with 0.5 A˚ grid spacing.
The GB model is described by Onufriev et al. [83]. In the case of MMPBSA
Gnonpol term, γ = 0.0052 kcal/mol A˚ and β = 0.92 kcal/mol, and for MMGBSA,
γ and β were set to 0.0072 kcal/mol A˚ and 0.92 kcal/mol, respectively.
Both ∆G (via PB and GB methods) and ∆TS were calculated using 48 snapshots,
out of a possible 400, from the 4 ns simulation trajectory. The snapshots were ex-
tracted evenly i.e. every 8th snapshot. ESMACS calculates the binding free energy
obtained from the PB/GB method alone, and with the inclusion of configurational
entropy and free energy of association. For each method, free energies are averaged
over 48 snapshots to get a free energy per replica. To obtain the final binding free
energy for a ligand-protein system, an average is taken of all 25 replicas.
3.1.4 Statistical analysis
To calculate mean ∆Gbind we use all 1200 binding free energies generated from the
48 frames of 25 replicas. The mean ∆Gbind is evaluated by statistical bootstrapping
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techniques, the data is re-sampled with replacement, 100,000 times. This means
that there is a possibility that a data point can represented more than once, and
others may never be sampled. Standard errors are the standard deviations of the
mean ∆Gbind. The 3-trajectory method generated free energy values of the com-
plex, receptor and ligand from individual MD simulations, and so the bootstrapping
protocol described above performed for each trajectory.
3.2 Thermodynamic Intergration with Enhanced
Sampling
The TIES protocol also adopts ensemble simulations and calculates the relative
binding affinity, or free energy difference, between two ligands. A theoretical de-
scription of this method is presented in section 2.7.2.
3.2.1 Model preparation
TIES follows an identical process as ESMACS for geometry optimisation and pa-
rameterisation of the individual ligands. However, the dual topology method [95]
employed by TIES means that hybrid PDB structures, parameters and topologies
need to be created specifically for each alchemical ligand transformation.
Firstly, the coordinates from the ligand PDB structure are overlapped for ligands
at λ = 0 and λ = 1 (that is the initial and final ligand) for the common region
found in both states. To qualify as the ‘common region’, the atom charge must not
be greater than 0.1 e between the equivalent atoms on each ligand. This criterion,
however, can be modified for highly charged, or polar ligands. The partial charges
for each atom in the common region is the average partial charge of the equivalent
atom in each ligand. Following this, the partial atomic charges and parameters
were generated for the hybrid ligand, using the same approach seen in ESMACS.
Protein parameters were achieved in the same way as ESMACS.
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With regard to model preparation, the only difference here between TIES and
ESMACS is that TIES contains the hybrid ligand PDB structure bound to thes
receptor and not the individual ligands. From this point, Tleap, as in ESMACS, is
employed to build the topologies and solvate the complex.
3.2.2 Simulation set-up
Equilibration and simulation stages are identical in the duration, ensemble selec-
tion (NPT), and conditions at which simulations were conducted, as ESMACS.
Although almost all simulation parameters are shared between the two methods,
TIES requires some additional selections because of the dual topology method that
has been employed.
A bounded (soft-core) van der Waals (vdW) potential [96, 97] was used (default co-
efficient of 5) to ensure the vdW potential is finite across the whole perturbed space,
and avoids overlapping of atoms at low λ values (so-called “end-point catastro-
phes”). Alchemical decoupling was turned on so that only non-bonded interactions
were scaled and the interactions within the perturbed region was preserved. Elec-
trostatic and vdW interactions were scaled separately. For the created atoms, the
electrostatic interactions were fully coupled at λ = 1 and fully decoupled between
λ = 0 and λ = 0.45. Between λ = 0.45 and λ = 1, the electrostatic interactions
were linearly coupled. Conversely, for the annihilated atoms, the electrostatic in-
teractions were fully coupled at λ = 0 and fully decoupled between λ = 0.55 and λ
= 1. Between λ = 0 and λ = 0.55 the annihilated atoms were decoupled linearly.
Van der Waals interactions were linearly decoupled from λ = 0 to λ = 1 for created
atoms, and vice versa for annihilated atoms.
13 λ windows were implemented in TIES. This is composed as follows: λ = 0.0,
0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 0.95, 1.0. Simulations were performed,
in replicates of 5 per λ window. Coordinates were recorded every 10 ps, and ∆V/∆λ
every 2 ps.
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3.2.3 Statistical analysis
The error analysis in TIES is performed similarly to ESMACS. The bootstrapping
technique described in section 3.1.4 is performed for each λ window, that is 10000
∆V/∆λ recordings corresponding to 2000 recordings for every replica. This data
set is re-sampled with replacement, 10,000 times for each λ window from which
mean and standard deviations are calculated.
3.3 Binding Affinity Calculator
A distinguishing feature of the TIES and ESMACS methodology compared to
other binding affinity methods [45, 46, 44, 98], is the high level of automation.
TIES and ESMACS are facilitated by the Binding Affinity Calculator (BAC, [87])
through an automated workflow. BAC is an e-infrastructure tool that comprises
a selection of software programmes and services. It automatically completes the
model building stage of both protocols, this is followed by submitting large numbers
of replica simulations to high performance computers (HPCs) or in the cloud, and
subsequently collecting and analysing the data to evaluate free binding energies,
and errors that are associated with this. BAC eradicates a vast amount of manual
overhead, which naturally leads to removal of human error.
FabSim [99], a toolkit integrated within BAC, completes a range of computational
tasks. It is responsible for creating a uniform directory structure, which makes it
easy for users to navigate through input and output files, and transport the data
across different machines. FabSim also submits replica jobs to HPCs or clouds of
choice. Within this, input files are automatically copied to the remote machine
and, upon completion of calculations, the subsequent files are transferred back to
the user’s local machine.
Completing complex workflows, like TIES and ESMACS, requires a user to have a
high technical ability. The development of a user-friendly BAC (uf-BAC, [42, 100])
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will allow for non-technical users to calculate binding affinities. This is targeted at
medicinal chemists and biochemists who would like to support their experimental
results with calculated values.
3.4 High-performance and cloud computing
Ensemble-based free energy predictions, like ESMACS and TIES, are not possible
without utilising industrial strength computers, namely HPC and cloud services.
Table 2.1 demonstrates the vast computational resources required to perform ES-
MACS and TIES calculations for one ligand-protein complex, or a single alchemical
transformation, respectively.
Consequently, the two ensemble-based approaches have been used on an unprece-
dented scale, when over 50 protein-ligand complex and perturbations were studied,
resulting in considerable news coverage [101, 102]. To achieve this level of scientific
output, approximately 250,000 cores were required, for an uninterrupted duration
of 36 hours. Thus, very significant resources, and wall clock time, are required to
generate binding affinity predictions on industrially relevant timescales.
HPC services have their drawbacks. The process to acquire computing time in-
volves time-consuming proposals, where compute time is allocated in yearly cycles,
or longer time frames. This means users are constantly tied to the allocated compu-
tational resources, and must carefully plan projects well in advance. In the phar-
maceutical environment, this framework would not be conducive to fast moving
drug discovery programmes that require, on occasions, spontaneous use of com-
pute time. Outsourcing to HPC services is often associated with queuing times for
calculations to begin, which can sometimes last for several days. This too would
not be acceptable in an industrial setting.
As a consequence performing ‘on demand’ calculations has become an attractive
alternative, and cloud computing offers this service. Cloud computing is an al-
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Table 3.1: HPC requirements for ESMACS and TIES. The core counts and sub-
sequent wall clock times are obtained from runs on the LRZ SuperMUC
Phase 1 and Phase 2 machines. ESMACS/TIES calculations can be
run in parallel making largely scalable dependent on the user’s needs.
An increase in core count is directly proportional with a speed-up in
wall time. The bottle neck is normal mode analysis which is largely
variable in time. Total core hour allocation for for ESMACS is calcu-
lated using an average 17 hour normal mode analysis calculation.
Method ESMACS TIES
Replicas per complex 25 65
Equilibration
Location HPC HPC
Cores 4,608 12,480
Time (hrs) 1.41 2.15
Production
Location HPC HPC
Cores 4,608 12,480
Time (hrs) 2.81 4.27
Free Energy Calc. (Normal Mode)
Location HPC -
Cores 1,200 -
Time (hrs) 0.1 (9-24) -
Statistical Analysis
Location desktop desktop
Time (hrs) 0.5 0.1
Total Core Hours (approx) 40,000 80,000
ternative framework which allows users to run applications from remote resources.
Access to computer time is provided in return for monetary payment. There are two
modules used in cloud computing. First, there is the ‘Infrastructure as a Service’
(IaaS) model, which provides access to computing time, memory and storage, but
the user is required to run their own applications. The other model is ‘Software as
Service’ (SaaS), which provides software that users are able to exploit. Currently,
BAC is being implemented into the SaaS model, through DNANexus, Microsoft
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Azure and Amazon Web Services (AWS) cloud platforms.
Historically, central processing units (CPUs) have been used as the workhorse to
perform programming tasks, however relatively recent developments in the graph-
ics processing unit (GPU), has seen it gain traction. The use of GPUs has shown
increased performance compared to CPUs, when completing MD molecular simu-
lations, however, most GPU codes are yet to scale beyond a single node. A recent
paper reports fast, accurate GPU-accelerated binding affinities, via TI calculations
[98]. The method also acknowledges the requirement for ensemble simulations, and
implements this approach to generate reproducible binding affinities.
3.4.1 Specification of HPC resources
The binding affinity values reported in this thesis are made possible through ac-
cess to several HPCs in the UK, and Europe. Below is a description of the HPC
resources that have been used, and some detail about each.
The Hartree Centre, an institution run by the the Science & Technology Facilities
Council (STFC), boasts an iDataPlex and Xeon Phi, and NextScale Cluster, com-
prising 2,016 and 8,640 cores, respectively [103]. Both machines have infiniband
interconnect. Of the 84 nodes in the iDataPlex machine, 42 nodes have acceler-
ators. The de-commissioned BlueGene/Q (98,304 cores) and BlueGene/Q BGAS
(40,960 cores) machines were also used.
ARCHER, the UK National Supercomputing Service, is based around a Cray XC30
supercomputer which contains 4,920 nodes (9,840 cores) [104]. ARCHER has com-
pute nodes that have 64 GB memory shared between two cores, and a small number
of high-memory nodes (128 GB). ARCHER uses the Cray Aries interconnect to link
all nodes.
SuperMUC Petascale System is the name of the HPC at the Leibniz-Rechenzentrum
(Liebniz Supercomputing Centre, LRZ) near Munich, Germany [105]. SuperMUC
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has more than 241,000 cores at its disposal. The phase 1 installation is made up
of three clusters: BladeCenter HX5 (8,200 cores), and two iDataPlex dx360M4
machines (147,456 and 3,840 cores, respectively). The phase 2 installation is a
NeXtScale nx360M5 WCT with 86,016 cores.
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Chapter 4
Application of ESMACS and
TIES in the context of a drug
discovery programme
4.1 Introduction
Recently, there have been promising advancements in MD-based free energy pro-
tocols aimed at achieving results on an industrially relevant timescale. Wang and
colleagues [46, 45] – researchers at Schro¨dinger – reported good relative binding
affinity predictions, using their FEP+ methodology. A strong correlation was seen
with experimental results, for 8 different biological systems, and anti-correlated
binding affinities were obtained using the MMGBSA free energy method. Simi-
larly, Aldeghi and colleagues [44] performed FEP-based absolute binding free en-
ergy calculations on a diverse range of ligands. Good correlation with experimental
binding affinities, and tight error bars were reported, however, this approach is so
far limited to rigid drug targets only.
Coveney and colleagues have developed two ensemble-based approaches, utilising
both alchemical and end-point methods in each case. Running ensemble simulations
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in parallel on high-performance computers (HPCs), and in the cloud, give rise to
rapid, accurate and precise binding affinity predictions. These are termed “Ther-
modynamic Integration with Enhanced Sampling” (TIES, [42]) and “Enhanced
Sampling of Molecular dynamics with Approximation of Continuum Solvent” (ES-
MACS, [16]). The frameworks, and the associated theory that underpins these
approaches, are described in detail in chapter 2 and 3.
These two approaches have been used to estimate binding affinities for a selection of
ligands, across 5 different receptor targets, which have been adopted from Wang et
al. [46, 45]. In this chapter, we will compare and contrast the TIES and ESMACS
approach with that of Wang et al [45]. TIES results for this work have recently
been published [42] and so the first half of this chapter will report results obtained
using the ESMACS method. We have obtained binding affinities for 100 ligands
across five drug targets.
The latter part, will address the TIES results where 61 ligand transformations
where analysed. Although TIES is able to yield more accurate results, the compu-
tational resources required are vast compared to ESMACS. It would be beneficial,
then, to be able to run TIES calculations using a smaller number of λ windows.
Here we investigate if this is at all possible. The overarching motivation of this
chapter is to gain knowledge about how TIES and ESMACS perform across these
5 systems, and if one approach could be used over the other, in each case.
4.1.1 Biological activity and role in disease
The systems that are studied in this chapter have been selected for three reasons.
Firstly, this chapter compares TIES and ESMACS with another methodology [46,
45] that determines ligand binding affinities. For this reason, we maintained the
same systems that were used in that study, achieving a direct comparison in this
respect. The receptor and ligand structures have been extracted from previous
publications which are outlined in Fig. 4.1 and Table 4.1.
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Secondly, the systems studied cover a number of different protein families (i.e.
kinase, phosphotase, protease) which vary in size, mechanism of binding and bio-
logical function. The ligands for which binding affinities are calculated also vary
in size, charge and flexibility. Investigating ESMACS and TIES across a diverse
range of proteins and ligands will give a good indication of the robustness of these
methodologies. Ultimately, such methods are being developed for the application
in the drug discovery setting, and therefore need to produce reliable binding affini-
ties regardless of the system of study. Lastly, these proteins play an important role
in a number of disease areas which are current areas of interest. The biological
activity and role in disease are described below.
Cyclin-dependent kinase 2
Cyclin-dependent kinases (CDKs) are a member of a family of enzymes that reg-
ulate cell proliferation in the eukaryotic cell cycle. The cell cycle is the process in
which a cell is divided and duplicated to produce two replica daughter cells. CDK2
regulates the initiation of the DNA synthesis during interphase [106].
CDK2 activity has been described by Russo et al. [107]. CDK2 is fully activated
by a two-stage process: firstly, it binds to regulatory sub-units called cyclin A,
which induces low level catalytic activity [107]. CDK2, now complexed to cyclin
A, is phosphorylated by a CDK2-activating kinase (CAK) at a conserved threonine
residue located on the CDK2 regulatory T-loop. CAK is constitutively active and
so phosphorylated CDK2 concentrations are regulated by the presence of cyclin
A. The loss of CDK2 activity can result in loss of G1 check-point control and
subsequently gives rise to unregulated cell growth [108]. CDK2 has been a popular
drug target because they are directly involved in the regulation of cell proliferation.
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Figure 4.1: Structures of the 5 receptors used in this chapter shown as a teal
ribbon representation: (a) cyclin-dependent kinase 2 (CDK2); PDB
code: 1H1Q, (b) protein tyrosine phosphotase 1B (PTP1B); PDB
code: 2QBS, (c) induced myeloid leukemia cell differentiation pro-
tein 1 (MCL1); PDB code: 4HW3, (d) non-receptor tyrosine-protein
kinase 2 (TYK2); PDB code: 4GIH, (e) thrombin; PDB code: 2ZFF.
Each receptor is shown with a ligand (blue stick representation)
present in the binding pocket. Additional physical and structural
properties are presented in Table 4.1.
Non-receptor tyrosine-protein kinase 2
Non-receptor tyrosine-protein kinase 2 (TYK2) is one of four Janus kinases (JAKs)
– the others being JAK1, JAK2 and JAK3 – and is associated with cytokines and
growth factor proteins in mediating inflammation [109]. JAKs interact with a
specific set of receptors, which ultimately results in the creation of docking sites on
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signal transducers and activators of transcription (STAT) proteins. STAT proteins
are phosphorylated by JAKs and mediate gene transcription.
TYK2 interacts with the IL-12/IL-23 pathway [110, 111] which are associated with
the T helper type 1 (Th1, [112]) and T helper type 17 immune responses (Th17,
[113]). TYK2 phosphorylates the STAT proteins which then transolacates into the
nucleus and mediates gene expression. The pathogenesis of psoriasis and inflamma-
tory bowel disease (IBD) is linked to abherrent function of the Th1/Th17 immune
responses and IL-12/IL-23 pathways, resulting in inflammation of the skin and gut,
respectively [114, 115].
Induced myeloid leukemia cell differentiation protein 1
Normal, non-cancerous cells that exhibit aberrant growth are subject to pro-
grammed cell death [116, 117]. A dysfunctional induced myeloid leukemia cell
differentiation protein (MCL1), has been found to circumvent programmed cell
death of cancer cells [118]. It has also been found that aberrant function of MCL1
is one of the most common traits found in human cancer [119, 120]. Studies that
silenced the MCL1 gene show to significantly decline particular non-small-cell lung
cancer (NSCLC, [121]), suggesting that MCL1 is has potential to be an effective
drug target.
Thrombin
Thrombin is a serine protease that cataylses the formation of fibrin by cleaving the
peptide bond in fibrinogen. This increased concentration of fibrin activates fibrin
stabilising factor 13 (Factor XIII) and results in platelet aggregation and forma-
tion of thrombus [122]. Although this function is extremely important – without
this our blood would not be able to clot – it is the cause of dangerous intravas-
cular clot formation, which results in several cardiovascular diseases (myocardial
infarction, deep vein thrombosis and ischemic stroke, to name a few). Historically,
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anticoagulants like heparin and warfarin were administered subcutaneously which
for obvious reasons is undesirable, and so thrombin has long been a desired drug
target which offered the benefit of oral administration.
Protein tyrosine phosphatase 1B
Protein tyrosine phosphatase 1B (PTP1B) is an attractive target for type 2 diabetes
and obesity, as it is a negative regulator of the insulin and leptin pathways [123,
124]. Phosphotases have the opposite function of kinases (such as TYK2 and
CDK2) and are responsible for dephosphorylation. That is, PTP1B has found to
supress generation and subsequent secretion of insulin and leptin, resulting in high
blood sugar levels. Studies have shown that mice without PTP1B have displayed
higher sensitivity to insulin, more efficient glycemic control and resistance to obesity
as a result of high fat diets [125, 126].
4.2 Methods
All models in this study were extracted from the references available in Table 4.1.
Model preparation and simulation set-up were performed using the Binding Affinity
Calculator (BAC) which is described in chapter 3.
All binding affinities generated in this chapter have been performed used the ES-
MACS and TIES methodology which is also described in chapter 3.
4.3 Results
We will critically assess the performance of ESMACS and TIES, across 5 systems
of study: CDK2, TYK2, PTP1B, MCL1 and thrombin. Knowledge gained within
this section will allow us to understand how these ensemble-based methods can be
applied in the context of a drug discovery programme. A thorough description of
TIES and its performance across the systems in this chapter, has recently been
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published by Bhati et al. [42].
Table 4.1: An overview of the systems explored in this chapter, and the predic-
tive performance of the ESMACS protocol for all trajectory meth-
ods. GB and PB are the generalised Born, and Poisson-Boltzmann
free energy methods used to obtain binding affinities.
CDK2 TYK2 MCL1 PTP1B Thrombin
No. of ligands 16 16 42 15 10
PDB code 1H1Q 4GIH 4HW3 2QBS 2ZFF
Structure resolution method XRD XRD XRD XRD XRD
Structure resolution (A˚) 2.5 2.0 2.4 2.1 1.47
Reference [108] [127, 128] [129] [130] [131]
∆Gexp method IC50 Ki Ki Ki ITC
∆Gexp range (kcal/mol) 4.21 4.28 4.18 5.13 1.7
Receptor size (residues) 297 288 150 298 231
Charged ligands No No Yes Yes Yes
GB PB GB PB GB PB GB PB GB PB
Pearson, rp
1-traj 0.49 0.61 0.70 0.73 0.75 0.80 -0.41 -0.40 0.85 0.92
2-traj -0.55 -0.56 0.56 0.71 0.62 0.64 -0.20 0.02 0.31 0.07
3-traj -0.56 -0.56 0.41 0.47 0.64 0.66 -0.25 -0.04 0.23 -0.01
Spearman, rs
1-traj 0.24 0.38 0.49 0.53 0.56 0.64 0.16 0.16 0.72 0.84
2-traj 0.31 0.29 0.31 0.51 0.39 0.41 0.04 0.00 0.09 0.00
3-traj 0.31 0.29 0.17 0.22 0.41 0.44 0.06 0.00 0.05 0.00
σaverage (kcal/mol)1 0.30 0.18 0.34 0.48 0.21
1 σaverage is the averaged standard error of all ligands within a system. σaverage is reported for only the
best performing ESMACS trajectory approach.
We will begin with a critique of ESMACS. Following this, a more detailed descrip-
tion of the systems will be presented, highlighting specific considerations that are
required when completing binding affinity calculations. The subsequent segment of
this chapter will compare ESMACS and TIES, working towards and understanding
when each respective approach could be applied in a drug discovery setting. We
close the chapter with a TIES study that explores what the lowest number of λ
states is required to gain reliable results, but save on compute time.
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4.3.1 An assessment of the ESMACS protocol across 5 bi-
ological systems
Table 4.1 displays a detailed description of the systems, including the predictive
performance and reproduciblilty of the results. The most significant trend observed
across all systems, bar PTP1B, is that the 1-trajectory method results in superior
rp and rs values, in comparison with the 2 and 3-trajectory approaches. In fact,
in the case of CDK2, we report anti-correlated results for 2- and 3-trajectory ES-
MACS binding affinities. The electrostatic contribution to the binding affinity is
responsible for the anti-correlation seen PTP1B. This will be assessed more closely
in section 4.3.3. Additionally, the PB approach is superior to GB in all systems.
This is perhaps expected, as the PB approach is a more theoretically rigourous free
energy method.
In all scientific work, reproducibility is of key importance in drug discovery ap-
proaches. MD trajectories diverge rapidly from differences in initial starting veloc-
ities [41, 87, 43], and as such, generating binding affinity predictions from a single
trajectory gives rise to unreproducible binding affinities. ESMACS, through the
use of ensembles, and the subsequent statistical bootstrapping approach, reduces
uncertainty of the calculated binding affinities. Calculating standard errors has
been described previously (section 3.1.4). The average of all standard error values
obtained in each ligand set (σaverage) gives us an idea of the reproducibility of
ESMACS binding affinities.
The TYK2 system, followed by CDK2, report the lowest σaverage value. The stan-
dard error for any ligand in the CDK2 system is no more than 0.55 kcal/mol, and
0.21 kcal/mol in TYK2. The systems with the two lowest σaverage values corre-
spond with ligand sets that do not contain charged ligands. This therefore suggests
that ESMACS loses some reliability when ligands with formal charges are assessed.
The highest σaverage value comes from the PTP1B system. All compounds in this
set have two formal charges, and thus giving rise to further uncertainty when the
86
4.3. RESULTS
electrostatic contribution is evaluated. In general, ESMACS has shown a tight
control over errors when binding affinities obtained from complex simulations only
i.e. 1-trajectory ESMACS [41, 87, 43]. We have shown here that when ligands do
not possess formal charges, ESMACS generates a low σaverage value and thus gives
rise to reproducible binding affinities.
4.3.2 CDK2 system: challenges involving sulphonamide
parameterisation and ligand conformer selection
Closer visual inspection of ligand structures containing a sulphonamide group led to
the discovery of unnatural dihedral angles. Th atoms involved in the diheral bond
are C-C-S-N and a O-S-N for the bond anglel. The pre-simulation parameterised
ligand structure showed a dihedral and bond angle of 89.8° and 105.6°, respectively,
however, post-simulations the same angles were 53.8° and 87°, respectively. Upon
assessing the force field parameters, we noticed that indeed, the General Amber
Force Field (GAFF) parameters did not account for the sulphonamide group.
It is likely that the poor parameterisation is due to the partial atomic charges
assigned for the N and S atoms in the sulphonamide group. This was confirmed
after assessing the other three ligands that contain the sulphonamide group. Three
inhibitors have an unmethylated nitrogen atom (L1S, LIU and L32), whereas one
of them is dimethylated at the nitrogen (L29). The difference lies with the partial
atomic charges. The partial charges assigned to N and S atoms in inhibitor L29
are -0.22 e and 0.92 e, respectively. In the remaining structures the partial charges
for the same atoms are -0.94 e and 1.22 e, respectively. The difference in partial
atomic charge between the N and S atoms is large in the unmethylated inhibitors,
compared to inhibitor L29 and this difference causes the O-S-N bond angle to
become acute, disrupting the conformation of the sulphonamide group, including
the dihedral angle. Inhibitor L29, does not experience these changes, and this is
supported with an expected bond angle of 107.28°, and dihedral angle of 96.75°.
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Atom
GAFF
CGenFF
L29 L1S
C1 0.01 -0.23 0.24
S 0.92 1.22 0.61
O1 -0.53 -0.57 -0.42
O2 -0.53 -0.57 -0.42
N -0.22 -0.93 -0.77
H1 – 0.41 0.38
H2 – 0.41 0.38
C2 -0.19 – –
C3 -0.19 – –
Figure 4.2: The partial atomic charges generated by GAFF for the ligands L29
(top) and L1S (bottom) are reported. For comparison, the charges
assigned by CGenFF are also included in the table. The structures
on the left show the sulphonamide group. L29 contains two methyl
groups substituted on the nitrogen atom where L1S contains only hy-
drogen atoms. The aromatic group belonging to atom C1 has been
included, and the remainder of the ligand has been omitted.
The unusual partial charge assignment was investigated further by comparing these
values with another force field, namely CGenFF [68], developed by CHARMM. It
was noticed that the partial charges, particularly on the N and S atoms are more
representative of what was generated for L29 (Fig. 4.2). More specifically, when
comparing L1S partial charges generated by GAFF, and CGenFF, the S atom is
less positive, and the N atom less negative in the latter. It was also observed that
the aromatic carbon C1 possess a negative charge, which is uncharacteristic for this
atom type. A slightly positive charge on the C1 atom was achieved when using
CGenFF, which is what is expected for this atom type.
Based on this, it was decided to complete an ESMACS run on a sulphonamide-
containing ligand with CHARMM partial atomic charges. If the binding affinities
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obtained from this model complement the successfully parameterised ligands, then
it is very likely that the wayward results due to the sulphonamide-containing ligands
is due to incorrect partial atomic charge assignment. This was done by constraining
the partial charges for the sulphonamide group atoms (shown in Fig. 4.2), and
generating an electrostatic potential, as completed previously. These new partial
atomic charges were used and the ESMACS workflow was completed as before.
Indeed, Fig. 4.3 shows that the sulphonamide-containing ligands, with CHARMM
partial charges, has integrated well with the remaining ligands. There has been a
considerable improvement in ranking and correlation across all free energy meth-
ods, with a decent coefficient observed for the PB method. This highlights the
importance of correctly parameterising ligands prior to MD simulations. Small
changes in initial assignments plays a very sensitive role in the final outcome.
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Figure 4.3: Correlation plots for calculated and experimental ∆G values for
16 ligands complexed with CDK2, using the 1-trajectory ESMACS
method.
In this study, multiple rotamers are available for some of the ligands. It is impor-
tant to find a method of selecting the correct rotamer conformation, rather than
choosing the ligand that fits the correlation the best.
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In some cases, the selection process is redundant: if a crystal structure is avail-
able than this can be used. In the CDK2 case, the starting crystal structure is
ligand L1Q, which is essentially the sub-structure for all of the remaining ligands.
Substitutions in the para position are allowed as this protrudes towards the bulk sol-
vent and the chemical group has room for manouvre. Additionally, any movement
around the rotable bond of the aromatic group will not change the arrangement in
space. However, substitutions of chemical groups in the meta position mean that
the aromatic group will rotate around the bond to find an energetically favourable
arrangement.
The lowest energy ligand rotamer is selected by summing the free energy of the
ligand and the calculated binding affinity (Glig + ∆Gcalc). This not only takes
into the account the lowest free energy of the rotamer, but also the interactions
attributed to binding with the receptor, that is, the calculated binding affinity
(∆Gcalc). Alternatively, the free energy of the complex (Gcomplex) can be assessed
but this would introduce too much noise from all other interactions within the
receptor and deem it unreliable.
We see that selecting rotamers based on the above criterion does not make any
significant improvement in correlation. Equally, selection of the original data set (in
other words, excluding the rotamer ligands), there is no improvement in correlation.
4.3.3 PTP1B system: aberrant electrostatic energy calcu-
lations result in a loss of correlation
The PTP1B system reports a negative correlation (Table 4.1). A closer look at
the energetic terms that contribute to the binding affinity showed a very positive
ranking and correlation for the non-polar terms (∆Gvdw and ∆Gsurf , and an op-
posite trend for the electrostatic terms (∆Gelec and ∆G
PB/GB
solv ). Figure 4.4 shows
the correlations of the above terms with experimental values.
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Figure 4.4: Correlation plots of: (a) the van der Waals (∆Gvdw) energy con-
tributes to the binding affinity versus the experimental binding affin-
ity (∆Gexp), (b) the electrostatic contribution (∆Gelec) to the bind-
ing affinity against ∆Gelec, and (c) the final binding affinity (∆Gcalc)
versus ∆Gexp. All values reported are obtained via the PB free energy
method.
There are two probable reasons for this. We have already elucidated that the
ligands in the PTP1B set all contain two formal charges (both are deprotonated
carboxylic acid groups). Formal partial charges have generally received mixed
ranking correlations [132], using the MMPBSA and MMGBSA approach. This is
likely the case here. The second issue is that the binding pose of this data set is
such that two crystal water molecules are trapped within the pocket. Using the
implicit solvent models, the electrostatic contribution associated with presence of
these two crystal water molecules are disregarded.
Table 4.2: A table describing summarising the ligand transformations, along with
the corresponding relative free energies. All free energy values are
reported in kcal/mol.
Transformation Initial Ligand Final Ligand ∆∆Gexp ∆∆∆GTIES ∆∆Gvdw
T01 L73 L68 -0.64 -0.14 -6.01
T02 L66 L74 1.26 1.19 9.77
T03 L74 L72 -0.50 0.04 -2.88
T04 L74 L77 1.01 0.80 3.75
T05 L78 L77 1.04 1.54 5.00
T06 L75 L76 0.69 0.68 4.34
T07 L80 L79 0.42 -0.61 -0.84
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As a result of the aforesaid, the σaverage for the electrostatic contribution is ap-
proximately 10 kcal/mol. This is the main reason for the high σaverage seen in
Table. 4.1. On the other hand, the σaverage for the non-polar van der Waals con-
tribution is around 2 kcal/mol. We also see a good correlation and ranking for
the van der Waals contribution, shown in Fig. 4.4a. In the PTP1B case, only the
non-polar contributions are required to generate strong correlations, and this could
be the case for other ligand sets with high formal charges.
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Figure 4.5: A correlation plot of: (a) relative binding affinities between 7 ligand
pairs, obtained using the TIES protocol (∆∆GTIEScalc ), and (b) relative
van der Waals energy of the TIES ligand pairs, obtained using the
1-trajectory ESMACS approach (∆G DeltaGESMACSvdw ). We see a
better ranking and correlation when considering ∆∆GESMACSvdw , but
∆∆GTIEScalc produces more accurate results. Table 4.2 explains the
ligand pairs used in this analysis.
Taking the impressive correlations from the van der Waals term further, we com-
pared this with TIES results. Fig. 4.5 shows the ranking ∆∆GTIEScalc value obtained
for some TIES transformations, and the change in ∆∆Gvdw between corresponding
ligands that was obtained using ESMACS. We report that the latter, ∆∆GESMACSvdw
reports better rankings and correlation than the original TIES results. With this
said, TIES still generates accurate binding affinities, where ESMACS results are
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precise, and thus generate only good rankings.
4.3.4 ESMACS distinguishes between TYK2 ligand chem-
ical groups
ESMACS binding affinities for the TYK2 system, using only the MMPBSA and
MMGBSA free energy method (as opposed to including configurational entropy
contributions using normal mode analysis), shows no ranking and minimal lin-
ear correlation (Fig. 4.6a). However, the inclusion of configurational entropy al-
lows us to distinguish between chemical signatures within the ligand set, shown
in Fig. 4.6b. The TYK2 ligand set comprises two sub-sets, that is ligands that
contained aromatic and aliphatic variable groups. The total rp and rs is 0.17 and
0.03 respectively, but if we split the data set into the respective ligand sub-sets,
we see that the aromatic and aliphatic sub-set perform considerably better when
treated separately. We see rankings and correlations of 0.86 and 0.74, respectively.
In this instance we report a promising result using normal mode analysis (NMA)
to obtain the configurational entropy term which contributes to the total binding
affinity. However, NMA has traditionally received mixed results and its use is
greeted with skepticism, due to the large compute requirements, and approximate
nature of generating entropy estimates. This is depicted in the case of CDK2
where we also applied NMA, and as a result, we see a degradation in ranking and
correlation.
4.3.5 Thrombin and MCL1 systems give rise to good cor-
relation and ranking metrics
ESMACS generated good binding affinities for the thrombin and MCL1 systems,
all reporting ranking and correlation coefficients above 0.60 and 0.80 respectively.
Thrombin performed particularly well, generating an rp of 0.92 and rs of 0.84 for
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Figure 4.6: A correlation plot of: (a) the binding affinities of 16 TYK2 lig-
ands using the MMPBSA method, and (b) the MMPBSA free energy
method is coupled with configurational entropy estimates, generated
by normal mode analysis (SNMA). The inclusion of the entropy term
considerably improves the ranking for two ligand sub-sets that display
specific chemical signatures, and thus allow us to distinguish between
different chemical groups within a data set.
PB approach.
We see that good binding affinity predictions are generated when studying smaller
systems of study. Both thrombin and MCL1 are the smallest systems here, and it
is likely that we obtain good results for this reason.
4.3.6 TIES as a tool in drug discovery
TIES results correlate very well with experimental binding affinities for the sys-
tems that have been selected in this chapter [42]. Two statistical measures were
used to determine accuracy, which are the root-mean-square error (RMSE) and
mean absolute error (MAE). Both are measure of the differences in values between
calculated and experimental free energies of binding. The only difference being
MAE does not take direction into account, as all values are absolute. Both RMSE
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Figure 4.7: Correlation plots using the ESMACS 1-trajectory approach with
MMPBSA. Fig. (a) reports 10 thrombin binding affinities where as
Fig. (b) shows binding affinties for 42 MCL1 ligands.
and MAE indicate very high levels of accuracy. With regard to rp and rs, this
too, performed well with coefficients values that represent very strong linear de-
pendence and ranking, respectively. Reproducibility is defined by the control of
errors. TIES has shown to keep a very tight control of errors, this is depicted in
Fig. 4.8. A more detailed description of TIES performance on these systems has
been published recently [42].
There were, however some difficulties with ligands that contained a sulphonamide
group (L1S, LIU and L32). Although L32 produced a satisfactory ∆∆Gcalc value,
L1S and LIU calculations were aberrant. Inclusion of these three binding affinities
drastically degrades the statistical measure that is employed. This is attributed to
challenges in parameterising the ligand which was also experienced in the ESMACS
study. We incorporated the same parameters (Fig. 4.2) in TIES, as was used in
ESMACS, but this did not fix this issue.
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4.3.7 Can we obtain equally good TIES results using fewer
λ windows?
TIES calculations, using the default settings, require a large amount of compute
resources. It would be of considerable interest if the core count could be decreased
without sacrificing accuracy and precision. Simulation length, and replica number
per λ window are set at the lower limit and so further decreases in these parameters
would most likely mean insufficient phase space sampling [42], per λ window. Se-
lecting which λ states to sample could allow for more compute efficient calculations.
We applied this to the systems described here.
We first tested the the role of sampling a selection of λ windows, ranging from 3
to 11 for all transformations, and subsequently generating ∆∆Gcalc values with
standard errors. Then we compile the performance metrics (RMSE, MAE, rp and
rs) used previously. We also included the original set which we used to compare
our results.
Intuitively, as the number of λ windows sampled increases, we generally see an
improvement in all metrics. Particularly, when increasing from 3 to 5 windows.
However, in the case of TYK2 and MCL1, there is not a significant deviation in
metrics between 5 windows and the original full set of 13 windows. This would
suggest that, at least initially for these systems, it would have sufficed to run 5
windows. This corresponds to nearly a 30% decrease in compute resources.
However, we also see a trend in all systems which is not entirely expected. In some
instances, when λ windows are increased, a degradation is reported in the perfor-
mance metrics. This was assessed further by performing λ ‘exclusions’ (Fig. 4.9).
∆∆Gcalc with standard errors were generated, but with the omission of selected λ
states. This was completed serially for each λ window. In other words, we obtained
13 sets of performance metrics, and in each, one λ window has been excluded. This
would give us some indication of how each λ window is performing, and why we
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Figure 4.8: A plot of correlation and prediction metrics for TIES relative bind-
ing affinities, extracted from a various λ window selections. Plots are
shown for each system of study, and each line represents a different
metric with its assignment shown in the key. The axis labelled ‘λ
window’ is the amount of λ within the selection. For example selec-
tion 1 has 3 λ windows. 13 λ windows is the original data set, with
relative binding affinities obtained from all λ windows.
see a worsening in metrics, when λ windows are increased.
The PTP1B system shows a large amount of fluctuation when different λ windows
are excluded. A likely reason for this is the formal charge that exists in the PTP1B
ligands. Although there is a large fluctuation in this system, the σavg value is stable
and low, suggesting that sufficient sampling has been completed. All other systems
shows significant fluctuations as each λ window is excluded. In all systems, we see
97
4.3. RESULTS
0.0
0
0.2
0
0.4
0
0.6
0
0.8
0
1.0
0
0.
00
0.
10
0.
20
0.
30
0.
40
0.
50
0.
60
0.
70
0.
80
0.
90
1.
00
λ window
(a) CDK2
0.0
00
.10
0.2
00
.30
0.4
00
.50
0.6
00
.70
0.8
00
.90
1.0
0
0.
00
0.
10
0.
20
0.
30
0.
40
0.
50
0.
60
0.
70
0.
80
0.
90
1.
00
λ window
(b) TYK2
0.0
00
.20
0.4
00
.60
0.8
01
.00
1.2
01
.40
1.6
01
.80
0.
00
0.
10
0.
20
0.
30
0.
40
0.
50
0.
60
0.
70
0.
80
0.
90
1.
00
λ window
(c) MCL1
0.0
00
.10
0.2
00
.30
0.4
00
.50
0.6
00
.70
0.8
00
.90
1.0
0
0.
00
0.
10
0.
20
0.
30
0.
40
0.
50
0.
60
0.
70
0.
80
0.
90
1.
00
λ window
(d) Thrombin
-0.
20
0.0
00
.20
0.4
00
.60
0.8
01
.00
1.2
01
.40
1.6
0
0.
00
0.
10
0.
20
0.
30
0.
40
0.
50
0.
60
0.
70
0.
80
0.
90
1.
00
λ window
(e) PTP1B
RMSE
MAE
r
rs
σavg
Figure 4.9: A plot of correlation and prediction metrics for TIES relative binding
affinities, extracted from a various λ window selections. Plots are
shown for each system of study, and each line represents a different
metric with its assignment shown in the key. The λ sets are selected
by excluding one λ window in serial fashion. Thus the x-axis label
‘λ window’ is the λ that has been excluded. For example λ window
0.00 means that this window has been excluded and all others have
been used to generate relative binding affinities.
a peak at λ= 0.50 (and surrounding λ windows) which corresponds to a worsening
of performance metrics. Similarly, we see peaks at the end points, between 0.00
and 0.10, and 0.90 and 1.00. This indicates that near the end points, a higher
resolution of λ windows is required. This applies also for the region between 0.40
and 0.60.
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4.4 Discussion
ESMACS generates good correlations for 5 systems of study, using the MMPBSA
free energy method. The MMGBSA method consistently performs worse compared
to MMPBSA. Additionally, the 1-trajectory approach is beneficial in all cases. The
σaverage for all systems is very low – no higher than 0.48 kcal/mol – indicating that
ESMACS is able to generate reproducible and precise binding affinities. We see
that in the case of CDK2, that the correct parameterisation of ligands is vital.
Here, the sulphonamide group had to be reparameterised manually, which gave
improved results. ESMACS, or TIES, does not take into account different ligand
conformations. This means one conformation has to be selected that is believed to
be correct, which is not a theoretically rigorous approach that can be used in drug
discovery programmes.
We see in the PTP1B system that the electrostatic contribution was incorrectly
generated resulting in a negative correlation when correlated with experimental
binding affinities. Conversely, the non-polar terms performed impressively, and
even produced a better ranking than TIES when correlated with relative binding
affinities. Care must be taken when completing ESMACS calculations with ligands
that contain high formal charges.
In the TYK2 system, we are able to distinguish between chemical signatures when
we include entropy calculations. ESMACS binding affinities with MMPBSA alone
showed modest correlation, but when entropy values were included, we see a good
correlation and ranking for two different chemical groups. Thus ESMACS, with
the use of entropy estimates, could allow us to distinguish between subsets of a
chemical data set, and subsequently generate good correlations. Both MCL1 and
thrombin perform well using the MMPBSA approach.
TIES results show good accuracy as portrayed by the RMSE and MAE metrics. As
a result it also generates good rankings and correlations [42]. Standard errors are
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extremely low, indicating reproducibility. Parameterisation was also an issue here,
for the CDK2 ligands that contained sulphonamide groups. However, the modified
parameters did not perform as expected in TIES, as it did in ESMACS.
Running TIES calculations requires a large amount of compute resources and so
reducing the CPU usage without compensating on performance would be desired.
In the TYK2 and MCL1 systems, running only 5 λ windows has shown similar
performance metrics to running all 13 windows. In CDK2 and thrombin, running 7
λ windows will generate comparable metrics to completing all windows. Therefore,
a decrease in λ windows is a plausible approach to save on compute resources and
still achieve acceptable results.
When excluding λ windows serially, we see that there is a large fluctuation in
performance metrics. This is particularly the case at end points, and at λ windows
surrounding 0.50. It is likely that further λ windows should be included to improve
TIES performance.
In conclusion, we have shown that the both ESMACS and TIES generate repro-
ducible binding affinities across 5 different proteins and 99 ligands varying in size,
flexibility, charge and biological function. The reproducibility is characterised by
tight control of error bars through the use of replica simulations. TIES binding
affinities are shown to be accurate whereas ESMACS generated precise free energy
values. The current limitations of ESMACS and TIES is that the user is required to
select the correct ligand conformation prior to simulation requiring a highly tech-
nical user and additional investigation of the correct ligand conformation. Both
protocols are limited by the parameterisation of the ligands. For example, ligands
containing the sulphonamide group required reparameterisation which resulted in
binding affinities with an improved correlation and ranking coefficient.
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Chapter 5
Towards improved solvent models
for the prediction of binding free
energy and configurational
entropy
5.1 Introduction
A major challenge in computational drug design is developing realistic solvent
models to be able to generate accurate binding affinities. Some approaches, such
as TI and FEP, are accurate and capture solvent effects as water molecules are
treated explicitly. These ‘exact’ free energy methods are computationally more
expensive than ‘approximate’ methods, namely MMPB/GBSA, and thus require a
large amount of CPU time to estimate the binding affinity of one receptor-ligand
complex. TI/FEP are often limited to smaller and chemically related data sets.
MMPB/GBSA is thought to be good balance between accuracy and compute re-
quirements when estimating binding affinities. Section 2.6.1 and 2.6.2.3 explains
how binding affinities are obtained from from TI/FEP and MMPBSA, respectively.
5.1. INTRODUCTION
In this chapter we will work towards improving the current models by understand-
ing the relationship between atomic partial charge assignment, and subsequent
calculation of electrostatic energy terms. This can be done by optimising current
implicit solvent models. We also employ a solvent accessible surface area-based
entropy method and assess its performance compared to normal mode analysis.
5.1.1 Estimating the free energy of binding
MMPB/GBSA method applies the approximation of a continuous medium for the
solvent that describes the internal and external dielectric constant of the protein
and water, respectively. This is known as a continuum or implicit solvent model.
Applying a continuous medium requires the polar contribution to the free energy
of solvation, ∆Gsolpol, to be solved using the Poisson-Boltzmann (PB) or Generalised
Born (GB) formula. Although implicit solvent models reduce compute cost and
minimise background solvent-solvent interactions, important solvent effects are of-
ten over-looked which would otherwise make significant contributions to the binding
free energy.
Much work has been done to improve the prediction of binding free energies by
improving the solvent models used. One alternative is to simply add a small number
of explicit water molecules (or even a single water molecule) that play a direct role
in ligand binding. Here, important solvent-solvent and solvent-solute interactions
are preserved whereas the remaining solvent is modelled implicitly. Inclusion of
a handful of water molecules that play an important role in ligand binding will
not result in excessively large fluctuations in energy. Studies in this domain have
generated mixed results. For instance, Greenidge et al. showed that the inclusion of
select explicit water molecules in fact slightly worsened the predictive performance
of MMGBSA on a large and diverse set of ligands [133]. Equally, Checa et al.
[134] have shown that the inclusion of explicit waters results in poor correlation
coefficients when studying trypsin inhibitors. On the contrary, Wanoefer et al. [135]
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and Wan et al. [100] show improved correlations when a single, and a network of,
crystal waters were included, respectively. Only one of these studies [100] executed
multiple MD simulations from which reproducible binding affinities were obtained.
Binding affinities obtained from single MD simulations are not reliable.
Alternative methods include adjusting the internal dielectric constant (int) before
free energy calculation as the int is more difficult to predict due to the polarity
of residues that occupy a binding pocket. Modifications of int have been shown
to be very sensitive, with varying degrees of change in correlation coefficients with
experimental values. Hou et al. [136, 137] have shown that int should be system
dependent; increasing the int for the α-thrombin system yields an improvement in
ranking, where the same increase in int produces a degradation in ranking of other
systems. Genheden and colleagues [138] have noticed that int values between 1
and 25 all show largely varying correlations. Genheden et al. [139] recognise the
importance of using an ensemble of short, independent MD simulations to pro-
duce statistically converged binding affinities using the MMGB/PBSA free energy
method.
Fundamentally, there have been mixed results on performance when incorporating
explicit water molecules into MMPB/GBSA calculations, and modifying the int
parameter, and there is yet to be a universally accepted method that assigns correct
explicit water molecules or int, respectively, to any given biological system, which
consequently achieves consistently improved binding affinity predictions.
The quality of binding affinity predictions are highly dependent on the type of
molecular mechanics force field that is selected. In the AMBER force field that is
implemented in ESMACS and TIES, the molecular mechanic partial charges is fit-
ted to reproduce the quantum mechanical electrostatic potential of small molecules
which is a good strategy to replicate multipole moments and electrostatic interac-
tions. The disadvantage is that this type of force field fails to take into account
polarisation by the varying dielectrics of the environment. The incorporation of a
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polarisable force field in ESMACS/TIES is a legitimate avenue of exploration. The
development of polarisable force fields is a fruitful area of research with a number
of models available. A recent review [140] highlights the development of robust
polarisable force fields (AMBER ff02, AMOEBA, Drude) that are compatible with
existing, popular models.
5.1.2 Estimating the configurational entropy of binding
The SXconf term in Eq. 2.63 is the configurational entropy associated with ligand-
receptor binding, and is the sum of the entropies of the vibrational, translation
and rotational degrees of freedom. This term is often estimated using normal
mode analysis (NMA), employing the rigid-rotor harmonic oscillator (RRHO) ap-
proximation.
NMA is a technique used to assess the vibrational degree of freedom of a harmonic
oscillating system, which is at, or very close to, its equilibrium [141]. Computa-
tionally, this requires minimisation of a simulation snapshot, building a Hessian
matrix, and subseqeuntly diagonalising the matrix to gain frequencies. Hessian di-
agonalisation scales as (3N)3 where N is the number of atoms in the system [142].
These calculations are computationally expensive, and require large-memory cores,
which are not always available. Due to compute and memory requirements, NMA is
usually performed in a vacuum and on a truncated system with approximately a 10
A˚ radius around the protein-ligand binding region. As a result of these changes to
the original simulation snapshot, values from the normal mode method are not an
accurate representation of the simulated system, and so the configurational entropy
is largely approximate.
As a result, a solvent accessible surface area-based method [86] was employed to
estimate configurational entropy term in Eq. 2.62. Note that Wang et al. refer
to the SXconf term as ‘conformational’ entropy, but here we use ‘configurational’
entropy. One of the main strengths of this method is that configurational entropy
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estimates can be generated on a commercial PC within minutes. In addition,
estimates are not based on a minimised structure as in NMA.
A macromolecule is made up of atoms that are exposed to solvent to different
extents. Interior atoms have more restricted movement and thus contribute less to
entropy, however, it is incorrect to assume that these atoms play no part in entropy
changes associated with ligand binding. In other words, atoms that are completely
buried play a non-negligible role in entropy and must be included.
SWSASA =
N∑
i=1
wi(SASAi+kBSASAi) (5.1)
In Eq. 5.1, wi is the weight of atom i; SASi and BSASAi are the solvent and and
buried solvent accessible surface areas of atom i, and N is the number of atoms in
the model system . The term BSASAi is estimated using Eq. 5.2 where rprob is the
probe radius which has been set to 0.8 A˚ .
BSASAi = 4pi(ri+ rprob)2−SASAi (5.2)
The term k is an adjustable parameters that allows the user to adjust the extent
to which the buried atoms (BSASA) contribute to S. Setting the k parameter to
0 means that the buried atoms do not contribute to the entropy, and conversely,
setting k to 1 means that the buried and solvent accessible atoms contribute equally
to the estimate of S. Estimating entropy using this approach is termed ‘WSASA’.
5.1.3 Role of PAK4, BACE1 and ROS1 in pathogenesis
Below is a brief explanation of how each system is implicated in disease, giving
context to the inclusion in this chapter.
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PAK4
P21 protein-activating kinases (PAKs) are orchestral in regulating the formation
and organisation of the actin cytoskeleton in mammalian cells, which induces
changes in cell growth, morphogenesis, adhesion and proliferation [143]. PAKs
fall into two categories: Group A PAKs, consisting of PAK1, 2 and 3. This group
of PAKs may not have a direct role in cytoskeletal organisation [144], and thus their
roles are not entirely understood. Group B PAKs, consisting of PAK4, 5 and 6.
PAK4 is expressed ubiquitously [145], where both PAK5 and 6 are predominantly
expressed in the brain, amongst other tissues [146, 147, 148].
Group B PAKs have highly conserved binding domain and kinase domain sequence
structures, which hold a 50 percent homology with group A PAKs. Outside of the
binding and kinase domain, Group B PAKs have no resemblance to each other, or
that of Group A PAKs [144].
PAK4 acts as an effector, a protein that selectively binds to its target and regu-
lates biological function, of the cell division control protein 42 homolog (CDC42)
protein [149, 150]. CDC42 is a GTPase, which is a large family of enzymes that
hydrolyse guanine triphosphate (GTP) into guanine diphosphate (GDP). CDC42 is
part of the Rho family of GTPases that have been linked with cytoskelton dynam-
ics and organelle development and other important cellular functions [145]. PAK4
interacts with the active conformation of CDC42, through the GTPase-binding
domain. Subsequently, the PAK4-CDC42 complex induces redistribution of PAK4
to the Golgi membrane which triggers actin formation necessary for cell growth
and proliferation. The formation and reorganisation of the actin cytoskeleton is
dependent on PAK4 activity and its interaction with CDC42. Over-expression
of PAK4 sees the genesis and profileration of highly-disorganised cancer cells in
various tissue types [151, 152].
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BACE1
Over the past 2 decades, the role of BACE1 [153, 154, 155, 156, 157] has been
linked with the development of Alzheimer’s Disease (AD). Therefore, developing
an BACE1 inihibitor is an ongoing area of research with the goal of treating AD.
Pathogenesis of AD, in part, is a result of the accumulation of plaques, or peptides,
in the brain, known as β-amyloid (Aβ). The formation of Aβ is a sequential cat-
alytic process beginning with the cleavage of the amyloid precursor protein (APP),
by β-secretase enzyme, into the N-terminus Aβ, and the C-terminal fragment C99.
Following this, the γ-secretase enzyme cleaves C99, which gives rise to additional
Aβ. The γ-secretase enzyme splices the C99 peptide in varying lengths and so
different isoforms of Aβ are present. It is the longer isoforms that are responsible
for the onset of AD.
Research has shown that there are over 200 mutations in the genes that code for
APP and γ-secretase enzyme [158], which are directly associated with familial AD
(FAD). In fact, the most widely known mutations (K670N and M671L) [159], are
found close to the catalytic side, of β- and γ-secretase, and hence support the
cleavage of APP. This causes a larger deposit of Aβ isoforms in cerebral tissue.
Conversely, the A673V mutation in APP results in less effective cleavage by β-
secretase, and so Aβ is decreased by 40% [160].
The β-secretase enzyme was identified as a key target for the treating FAD, and
was subsequently renamed ‘β-site APP cleaving enzyme’ (BACE1) [153]. BACE1
is an aspartic acid protease that is 501 residues long, with a signature sequence of
DTGS and DSGT that characterise the aspartic acid proteolytic site [161].
ROS1
ROS1 is a serine/threonine kinase that plays a role in oncogenesis. Little is known
about the function of wild-type ROS1. However, mutant forms of ROS1 create
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fusion proteins, in which the catalytic region of the kinase becomes constitutively
active [162]. As a result, this drives uncontrolled cellular proliferation. ROS1 fusion
proteins have most recently been linked non-small cell lung cancer (NSCLC, [163]).
5.1.4 Motivation
In this chapter, we take a PAK4 data set that shows little correlation with experi-
mental results, and attempt to improve the solvent model by: (a) including explicit
water molecules that may make a considerable contribution to the binding affinity
and (b) modifying the int which has shown to improve binding affinity predictions
in some systems. In the same system, we witness a degradation of correlation when
the configurational entropy calculated using NMA, is included. Thus, we employ
the WSASA entropy method and assess its performance. The above was extended
to other challenging systems: BACE1 and ROS1.
The PAK4 receptor and corresponding ligands were extracted from a publication by
Crawford et al. [164]. The rationale for selecting this system of study was primarily
due to the ligands in question; structurally there are two sub-sets which contain
an aliphatic and aromatic ring structure in the variable group. We were interest to
see how ESMACS performs across ligands with different ring structures, within the
same binding domain. A distinct difference in the performance of ESMACS was
seen in the TYK2 system described in chapter 4 and it is possible that a similar
trend could be witnessed here. BACE1 and ROS1 were subsequently included for
the same reasons. BACE 1 represents a ligand data set with a ring structure of
varying size. The ROS1 ligand data set, like PAK4 ligands, contain saturated and
unsaturated rings.
5.2 Methods
ESMACS, which includes the 1-, 2- and 3-trajectory variants, were employed for all
systems in the study. PAK4 binding affinities were generated using two different
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MD trajectories: one group of simulations included crystal water molecules whereas
the other group disregarded crystal waters. Preparation of these models are de-
scribed here. Binding affinity calculations involving changes in int, and inclusion
of explicit water molecules, are also described in more detail, here.
5.2.1 Model preparation
Complex models that have been used to complete MD simulations can be divided
into two sub-sets, each containing 14 identical ligand-receptor complexes. One
contains crystal waters present in the PDB file, where the other set has been
stripped of crystal water molecules, from this point, both complexes were then
solvated using tleap. The PDB code for the receptor without crystal waters is
5BMS [164], and with crystal waters is 2X4Z [165]. For the simulations with
retained crystal waters, all 142 molecules within the PDB file were kept.
Fourteen ligands (Fig. 5.3) were selected, which originate from an experimental
study [164]. Ligand L01 is a previous pre-clinical drug candidate which failed
on the grounds of poor oral bioavailability [165]. All remaining ligands were cre-
ated by extracting the skeletal structure from PDB codes 4ZY4, 4ZY5 [164], and
the variable moiety manually modified using Schro¨dinger’s Maestro Suite (free of
charge). Ligands L01 and L04 came directly from PDB codes 4ZY4 and 2X4Z,
respectively. These ligands were then docked into the respective PAK4 receptor
models described above.
With regard to the experimental binding affinity of L01, the binding affinity from
the initial study [165] was used, whilst the remaining values were extracted from
Crawford et al. [164]. Error bars are not available for any of the experimental
ligand binding affinities. A more thorough review on experimental binding affinities
is presented in section 2.5.3.
The initial model of BACE1 was based on PDB 3ZOV [166] with loops modelled
109
5.2. METHODS
by Janssen. Binding poses were provided for 21 diverse ligands as shown in the
Fig. A.7. BACE1 was assayed fluorometrically on Monaco Safas spektroflourometer
[167].
The initial model of ROS1 was based on an X-ray structure determined in-house
by Janssen. Missing sequence Lys2117–Gly2121 has been extracted from a non-
disclosed in-house ROS1 X-ray structure and merged in the structure. No local
minimization has been performed on the rebuilt structure. The provided dataset
contained 32 ligands (see Fig. A.6). The ligands have been manually aligned using
compound JNJ-54192398 from the X-ray structure as a reference. Alignment was
performed with the Template CoMFA flexible alignment tool.
5.2.2 Explicit water free energy calculations
The protocol applied here has been adapted from a previously published method
[168]. The same frames that were used for the implicit solvent calculations were also
used here. The closest water molecules within n A˚ of the ligand, were selected for
each frame using the closest flag within cpptraj package, developed by AMBER[89].
Seven sets of explicit water calculations were completed with varying amounts of
water molecules in the vicinity of the respective ligands. The values of n were 10
to 70, increasing in increments of 10. The water molecules were included as a part
of the receptor and the remaining solvent was removed. Binding free energies were
calculated using the MMPB/GBSA models based on same protocol as previously
described.
5.2.3 MMPB / GBSA calculations with varying internal
dielectric constants
The int parameter can be adjusted in the MMPBSA module, however a more
temporally efficient approach is to simply divide the electrostatic component of
the GMMelec , and the GXsol in Eq. 2.52 and 2.53, respectively, by the int value, after
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completing MMPBSA calculations with int = 1. This yields the same results as
completing the MMPBSA calculation with an adjusted int parameter, and has
been reported in a previous study [136]. The external dielectric constant, ext, has
been maintained at 80 throughout all calculations.
5.3 Results
The respective correlation and ranking metrics, Spearman (rs) and Pearson (rp)
coefficients, perform poorly for binding affinity predictions with and without crys-
tal water molecules, in the 1-, 2- and 3-trajectory approach. There is a slight
improvement when crystal waters are introduced but this is negligible. It is also
evident that there is no significant difference in correlation and ranking between
binding affinities, regardless of the inclusion of configurational entropy, in either
the GB or PB method.
Within these results, we obverse some interesting trends. Firstly, ligand L01 has
a much larger negative ∆Gbind value than expected. Additionally, the inclusion
of crystal water molecules in this model causes the largest change in ∆Gbind than
any other ligand. The binding affinity becomes more positive by approximately
7 kcal/mol in all free energy methods. The importance of crystal waters when
calculating binding affinities is seen here: it is evident that specific water molecules
contribute heavily to binding, and disregarding this results in aberrant calculated
free energies. Secondly, any semblance of correlation and ranking that has been
reported thus far, is responsible for the large negative ∆Gbind attributed to ligand
L01 (Table B.11). Removing this data point, however, results in the absence of a
correlation or ranking shown in Fig. 5.1. This lack of correlation was the motivation
for the study. Therefore, two investigations will take place: the first is to identify
the reason for the large fluctuation in ∆Gbind when crystal water molecules are
included in the PAK4-L01 complex; and second is to understand why the PAK4
complexes studied here seem to insensitive to ESMACS.
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Table 5.1: Binding free energies using the 1-trajectory ESMACS approach for
PAK4 ligands bound to the PAK4 receptor when crystal water
molecules were included. GB/PB is the free energy method using the
Generalised Born or Poisson Boltzmann approximation. GB/PBNM
is the above method with the inclusion of configurational entropy term.
All values are in kcal/mol.
1-trajectory
Ligand GB PB GBNM PBNM ∆Gexp
L01 -52.58 -39.17 -29.60 -16.18 -11.70
L03 -41.17 -31.89 -19.43 -10.15 -11.66
L04 -39.98 -32.18 -17.47 -9.69 -10.62
L18 -36.84 -30.37 -14.94 -8.47 -11.26
L19 -40.20 -29.91 -17.47 -7.24 -8.38
L20 -39.42 -31.53 -15.21 -7.31 -8.33
L22 -39.99 -32.15 -17.45 -9.61 -9.17
L23 -40.83 -33.22 -19.87 -12.27 -9.89
L24 -40.35 -31.39 -18.43 -9.47 -8.07
L25 -39.99 -32.35 -21.76 -14.13 -7.75
L27 -40.06 -33.56 -26.20 -19.70 -9.35
L29 -42.24 -32.81 -32.60 -23.17 -8.50
L30 -43.36 -32.28 -22.58 -11.51 -8.80
L31 -45.89 -33.71 -44.39 -32.21 -8.39
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5.3.1 Crystal waters within the binding pocket of L01 play
a critical role in binding affinity predictions
We begin with the investigation of L01 and the considerable contribution crystal
water molecules have to binding. To understand what causes this, the trajectories
of simulation states, with and without crystal water molecules, were analysed.
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Figure 5.1: Correlation plot for calculated and experimental ∆G values for 13 lig-
ands complexed to PAK4, using the 1-trajectory ESMACS method:
(a) using the MMPBSA free energy method and (b) MMPBSA in-
cluding the configurational entropy term (T∆S) generated using nor-
mal mode analysis. The dotted line shows the line of best fit. Error
bars are removed for clarity, but standard error was no great than ±
1.0 kcal/mol.
Both simulations states show the formation of a water pocket surrounding the
oxygen of ligand L01. A water bridge is formed between this oxygen and a neigh-
bouring serine or lysine residue. The small water pocket in Fig. 5.2a is occupied
by three water molecules that are trapped in this location, isolated from the bulk
solvent. Conversely, in Fig. 5.2b, where crystal waters were included from the start
of the simulation, a water tunnel is maintained which stretches through the binding
pocket and is therefore able to interact with the oxygen of L01. The removal of
key water molecules results in a change in ligand conformation to accommodate
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the absence of the water tunnel. In the simulation with no initial crystal waters, a
dihedral rotation is witnessed between the atoms beginning with the first carbon
on which the oxygen is substituted, and the first carbon of the benzene ring (C-N-
C-C), highlighted in Fig. 5.2c. This rotation causes the benzene and substituted
amide to block the small water pocket from being exposed to the bulk solvent.
This rotation is not witnessed when crystal waters are included in the simulation,
and so this ligand conformation allows for a deep water cavity to be formed.
Here we see that the exclusion of crystal water molecules results in critically in-
correct changes to the binding pocket and ligand conformation. Crystal waters are
required to maintain the structure of the water tunnel, which keeps the ligand in
the conformation favoured in reality. The absence of these waters causes the ligand
to adopt a different, and more stable conformation, resulting in a more energeti-
cally favourable complex. The inclusion of crystal waters correct this, maintaining
the expected ligand conformation. It is essential to understand fully the binding
pose of any ligand-receptor complex to be able to execute correct modelling.
Ligand L01 shares little structural relation to the remaining ligands whom all be-
long to a congeneric series. This also means that L01 adopts a slightly different
binding pose. Although both groups of ligands have the same pyrazolyl pyramidine
amine moiety, L01 extends from the pyrazolyl end to make key interactions with
lysine and asparagine residues. The congeneric series extends from the opposing
pyramidine flank, interacting with asparagine and aspartic acid. Due to the struc-
tural differences, L01 is redundant for our investigation to elucidate the reason
for a lack of correlation within the congeneric series (Fig. 5.1). The remainder of
this study will focus on the results obtained from simulations with crystal water
molecules.
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(a) (b)
(c)
Figure 5.2: The rotation of a dihedral angle results in the ligand tail regulating
the exposure of the water pocket (represented by a red wired frame)
to the bulk solvent; (a) simulations that excluded crystal waters show
that an isolated water pocket is formed due to a change in ligand con-
formation, (b) when crystal waters are included at the start of the
simulations, the water tunnel that characterises the binding pocket is
maintained, and the conformational integrity of the ligand is subse-
quently maintained, (c) the absence of a water pocket causes a change
in ligand conformation through a rotation of a bond; with crystal wa-
ters (blue line) this dihedral angle averages ca. 70° and without (red
line) it is ca. 140°.
5.3.2 Aliphatic cyclic moieties result in aberrant electro-
static free energies
Observing the chemical structures of the congeneric series, we see that the variable
group of ligands L03, L04 and L18 possess unsaturated rings, compared with the
remaining ligands which all have saturated, aromatic rings. The trends observed
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(a) L01 -10.49 kcal/mol (b) L03 -11.66 kcal/mol (c) L04 -10.62 kcal/mol
(d) L18 -11.26 kcal/mol (e) L19 -8.38 kcal/mol (f) L20 -8.33 kcal/mol
(g) L20 -8.33 kcal/mol (h) L23 -9.89 kcal/mol (i) L24 -8.07 kcal/mol
(j) L25 -7.75 kcal/mol (k) L27 -9.35 kcal/mol (l) L29 -8.50 kcal/mol
(m) L30 -8.80 kcal/mol (n) L31 -8.39 kcal/mol
Figure 5.3: Chemical structures and binding affinities of 14 PAK4 inhibitors.
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between the two ligand sub-sets were assessed more closely. Decomposed free en-
ergy terms were obtained to identify any differences between the two sub-sets and
thus allow us to make comparisons between the two sets. Indeed, the existence of
a sub-set of ligands was confirmed; the L03 L04 and L18 sub-set corresponds to
a less negative value for the electrostatic free energy contribution associated with
binding (Fig. 5.4b).
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Figure 5.4: Distribution of: (a) the absolute sum of the partial atomic charge,
and (b) the calculated electrostatic free energy associated with the
binding free energy, for 13 PAK4 ligands.
Electrostatic interactions are defined by the non-bonded interactions between par-
tially charged atoms in the ligand and surrounding residues, and so analysis of the
partial charges of the ligands were performed. To do this, the sum of the absolute
values of the partial charges of each atom of the ligand was calculated. If the sum
of the partial charges of a ligand is higher compared to other ligands, this means
that the partial charges on the atoms of the variable groups are, relative to the
other ligands, more highly charged. This means that ligands with a large absolute
sum will consequently contribute more to the electrostatic free energy term of the
binding free energy. Conversely, if the absolute sum is relatively low, the electro-
static free energy term will have a smaller contribution. Large fluctuations in these
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values would indicate that the electrostatic contribution to binding may be over
or under-estimated in the aliphatic sub-set, compared with the aromatic ligands.
The total absolute sum of partial atomic charges for the ligand (Fig. 5.4a), shows
that the charges are generally weaker, and so do not form comparatively strong
electrostatic interactions with surrounding residues.
The knowledge that errors in the electrostatic free energy of binding most likely
lead to poor binding affinity predictions, has led to discussion about ways to repair
the electrostatic free energy predictions. The first possible problem is that ES-
MACS is using an implicit water model that does not take into account key solvent
interactions between the ligand and the surrounding residues. Inclusion of explicit
water molecules at the back of the ligand pocket would potentially result in a more
accurate representation of the electrostatic changes in free energy due to binding.
Secondly, the internal dielectric constant values are not clearly defined within the
MMPBSA approach and so errors in free energies could be as a result of incorrect
assignment of internal dielectric constants. Finally, although the aforesaid assess-
ments do not categorically attribute the deviations in electrostatic free energies to
poor selection of ligand parameters (and subsequent partial charge assignment), it
must be noted that force field selection, and the manner in which partial atomic
charges are generated, can play a significant role in final calculated binding free
energies. We then proceed to interrogate two ideas: (a) the inclusion of explicit
water molecules, and (b) the modification of the internal dielectric parameter.
5.3.3 MMPBSA calculations with explicit waters
Binding affinities calculated using the MMPBSA method, with the inclusion of
explicit water molecules, are explained in section 5.2.2. This approach resulted in
marginally improved correlation. The inclusion of 20 explicit water molecules was
the upper limit in performance. Although these results are consistent with the
study done by Maffucci et al. [168], the improvements in ranking, in this case, are
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not as significant. The incorporation of this method seems limited, and we have
seen previously that the inclusion of selective explicit water molecules are most
effective when performed manually [16].
5.3.4 MMPBSA calculations with modified internal dielec-
tric
Investigation of the internal dielectric began by calculating binding affinities of 6
ligands using different dielectric constants (Fig. 5.5). Free energy calculations using
MMPBSA were only performed on the systems containing crystal waters, with int
values of 1, 2 and 4. The GB form has been omitted. This is because int in the
GB equation is the medium from which the complex is being transferred from (i.e.
vacuum), so modifying int to anything other than 1 would mean the solvation
free energy is calculated incorrectly. In the PB form, the internal dielectric is the
dielectric of the solute, and so modification of this is theoretically acceptable.
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Figure 5.5: Correlation plot of 6 PAK4 ligands with different int values using
the 1-trajectory ESMACS approach. Only the MMPBSA free energy
method, without configurational entropy is reported here. As the int
increases from 1 to 4, the correlation and ranking improve signifi-
cantly. rs and rp are the Spearman rank and Pearson correlation
coefficients and int is the internal dielectric constant. Standard er-
ror was no greater than ± 1.0 kcal/mol.
We see that an increase in int is followed by a considerable improvement in corre-
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lation and ranking. These promising improvements suggest that changing the int
will bring better correlations than using default settings. Studies show that the
non-polar environment of the PAK4 binding pocket – no regular polar interactions
occur other than the typical 3 hydrogen bond configuration seen in kinases – would
benefit from increased int values [137], and this is supported here. However, there
is still a lack of a protocol that can systematically assign the correct int for a given
system, based on the polarity of solute. At least for the PAK4 system, a int value
of 4 gives strong correlations.
From this, we hypothesised that int is a major factor in predictive performance of
binding affinities. To strengthen this claim, the remaining ligands, bar L01, were
introduced to the study and binding affinities were computed for int = 1 and 4,
using the MMPBSA approach.
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Figure 5.6: Correlation plot for calculated and experimental ∆G values for 13 lig-
ands complexed to PAK4, using the 1-trajectory ESMACS method:
(a) using the MMPBSA free energy method and (b) MMPBSA in-
cluding the configurational entropy term (T∆S) estimated by normal
mode analysis. The dotted line shows the line of best fit. The red
data points are ligands L03, L04 and L18 that are associated with
int value of 4. The black data points have been assigned an int
value of 1. Error bars are removed for clarity, but standard error
was no greater than ± 1.0 kcal/mol.
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Conversely to our hypothesis, modification of the int parameter saw no ranking
or correlation with experimental values. However, when int was changed to 4, for
the aliphatic group of ligands, and kept at 1 for the aromatic group of ligands,
we report a correlation coefficient above 0.80, and a ranking coefficient above 0.90
for all trajectory approaches (Fig. 5.6). At this stage, the configurational entropy
term was included, but we see a slight decline in correlation and ranking. As a
result, we suggest that the modification of the int is ligand-specific, rather than
system specific. This stays true to the theory that a non-polar environment would
benefit from increased int, and perhaps the less polar environment associated with
the aliphatic sub-set of ligands, requires a different int compared to the remaining
ligands.
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Figure 5.7: Distribution of: (a) the absolute sum of the partial atomic charge,
and (b) the calculated electrostatic free energy associated with the
binding free energy, for 21 BACE1 ligands.
The trends described above were investigated further in the BACE1 system. The
BACE1 ligand data set contains ligands with varying ring types and provides a
good comparison with PAK4. The data set is comprised of 21 ligands which can
be sub-divided into 3 categories: ligands containing 5-, 6- and 7-membered rings.
Within each sub-set, the ligands are distinguished through a number of different
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substitutions at the variable group (Fig. A.7).
The BACE1 system shows an opposing trend to what is seen for PAK4. The ligands
containing a 5-membered ring have, comparatively, a smaller total partial charge
(Fig. 5.7a). Based on the PAK4 observations, we would expect these ligands to
have the most positive ∆Gelec but in fact, relative to the related ligands with 6-,
and 7-membered rings, they have the most negative ∆Gelec (Fig. 5.7b). Increasing
the int to 4, as we did in the PAK4 study effectively dampens the ∆GMMelec and
∆GXsol terms, from which we obtain a better representation of calculated binding
affinities, with respect to experimental results. In the case of BACE1, we amplify
the ∆GMMelec and ∆GXsol terms, by modifying int with varying degrees, to obtain a
∆Gcalc more representative to what was evaluated experimentally (Fig. 5.8).
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Figure 5.8: Correlation plot for calculated and experimental ∆G values for 21 lig-
ands complexed to BACE1, using the 1-trajectory ESMACS method:
(a) using the MMPBSA free energy method with an int value of 1,
and (b) using the MMPBSA method with varying int values. The
black data points are assigned int = 1; the blue data points, int = 0.2;
green data points, int = 3; and red ligands, int = 0.5. The dotted
line shows the line of best fit. Error bars and data labels are removed
for clarity.
It was noticed that modifying the int parameter according to the relative total
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partial charge yields an improved correlation and ranking. For instance, the three
ligands with the lowest sum of the total partial charge were assigned an int value
of 0.2 (L01, L04 and L07), whilst the three ligands with the highest sum (L13, L16
and L19) were assigned an int of 0.5. One ligand that falls in between these two
sets (L10), was assigned a value of 0.3.
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Figure 5.9: Correlation plot for calculated and experimental ∆G values for 32
ligands complexed to ROS1, using the 1-trajectory ESMACS method:
(a) using the MMPBSA free energy method with an int value of 1,
and (b) using the MMPBSA method with varying int values. The
black data points denote int = 1; the red data points, int = 0.9, and
the green data points are int = 4. The dotted line shows the line of
best fit. Error bars and data labels are removed for clarity
The obvious reason for this is that in the PAK4 system, the ∆Gelec term is over-
estimated, and thus requires a dampening effect. Conversely, in the BACE1 system,
the said energy terms require an amplifying effect. However, on both occasions,
the atomic partial charges are relatively small compared to other ligands in the
study, so this, in effect, rules out the possibility that the total atomic partial
charges is an important component when deciding the int value. Thus, in turn,
it is unlikely that the over-arching issue is the parameterisation of ligands, and
subsequent partial atomic charge assignment, rather, the way in which MMPBSA
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calculates the long-range interactions has inconsistencies.
The ROS1 system also sees an improvement in ranking when bespoke int values are
assigned to ligands (Fig. 5.9). After assessing the distribution of the electrostatic
free energy of ligands, we assigned a threshold (denoted by a horizontal dotted line
in Fig. 5.10). Ligands that posses a more negative ∆Gelec value than the threshold,
were assigned a int value of 0.90 to amplify the electrostatic contribution. The
remaining ligands, bar L27 and L28, were kept at the default int parameter.
This selection of int values yields a rs value of 0.64, and an rp value of 0.80 –
considerably better than the default int parameter. The trends observed in the
ROS1 system are analogous to the BACE1 system, where an amplification of the
∆Gelec results in more accurate binding free energies.
Unlike the PAK4 and BACE1 systems, we see no obvious trends in ROS1 ligands,
with regards to the ligand structures to which we can attribute the differences in
∆Gelec value. Further, there are no consistencies between the ∆Gelec value and the
absolute sum of the partial atomic charges (Fig. 5.10), which suggests that there are
factors outside the assignment of partial charges, that deliver inconsistent ∆Gelec
values. Selecting int = 4 for ligands L27 and L28 generated a binding free energy
that aligned well with the regression line, however it is not known why these two
ligands require this selection. Similarly to PAK4 and BACE1, ROS1 reports a loss
of correlation when T∆S is included in the binding free energy.
5.3.5 Assessing a solvent accessible surface area-based en-
tropy method
We proceed to take a closer look at the configurational entropy term in Eq. 2.62.
Fig. 5.1 shows that the inclusion of configurational entropy, estimated using NMA
(SNMA) results in a less correlated data set. The WSASA method( SWSASA) is
introduced here, and compared to the NMA approach. A recent preliminary study
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Figure 5.10: Distribution of: (a) the absolute sum of the partial atomic charge,
and (b) the calculated electrostatic free energy associated with the
binding free energy, for 32 ROS1 ligands.
involving WSASA has shown to be able distinguish ligands with different chemical
groups. We apply this method in the systems of study in this chapter, to replicate
this trend.
A comparison of PAK4 binding affinities in conjunction with the two different en-
tropy estimation methods shows no change in correlation. However, when only
ligands containing the aromatic variable moiety are assessed, a significant improve-
ment in ranking and linear correlation are witnessed (Fig. 5.11). Although there
is not a global improvement in statistical metrics, we show that WSASA improves
the predictive performance when considered with the MMPBSA method. It could
be that the calculated binding affinities for this groups of ligands are assigned
correctly, and WSASA is correctly estimating entropy values.
The same comparison was performed for the the ROS1 system, and no significant
improvement in correlation was witnessed when the WSASA method was incor-
porated, in fact there was a slight degradation in correlation. The data set was
subdivided, and ligands that reported the most negative electrostatic values (red
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Figure 5.11: Correlation plots for 13 PAK4 ligands using the 1-trajectory ES-
MACS approach, and including configurational entropy estimates
using: (a) the NMA method and (b) the WSASA method. Data
points in grey are L03, L04 and L18 are included to gain a better
understanding of the performance of the correlation. Black data
points, and consequent regression line are from the remaining lig-
ands in the series. Error bars are removed for clarity.
data points in Fig. 5.10) were assessed. Here we see a slight improvement in corre-
lation, but not considerable to claim that WSASA improves for the correlation for
that particular subset.
With regard to the BACE1 system, it was not possible to obtained configurational
entropy estimates using NMA. This is because due to the large system size, an
excessive amount of minimising iterations were required to give converged results.
Convergence was not achieved for a majority of the analysed frames within the wall
clock time of 48 hours. This is indicative of the problem with entropy calculations
using NMA. If a system is too large, or far from an energy minima, convergence
may not be achievable for some trajectory frames. We were able to obtain config-
urational entropy using the WSASA method and this reported a degradation in
correlation, as seen in the ROS1 example.
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Figure 5.12: Correlation plots for 32 ROS1 ligands using the 1-trajectory ES-
MACS approach, and including configurational entropy estimates
using: (a) the NMA method and (b) the WSASA method. Data
point are coloured respective to the int selections described previ-
ously, however ∆G values used in this plot are obtained using the
default int value. Error bars and data labels are removed for clar-
ity.
5.4 Discussion
We have shown that, in the PAK4 case study, changing the int value to 4 for
a sub-set of ligands which are relatively less polar, and maintaining default int
values for the remaining ligands, result in vastly improved ranking and correlation
in the PAK4 system. This supports previous studies [136, 137, 138] that see large
changes in predictive performance when int is modified. The non-polar residues
of the PAK4 binding pocket best describes the improvement in correlation metrics
when int is increased. Maintaining the int across all ligands results in a lack of
correlation or ranking.
A similar trend was seen in the case of BACE1. The most negative electrostatic
terms correspond to a subset of ligands which are chemically related. Here, ampli-
fying the electrostatic energy was required. As a result, decreasing the int in the
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range of 0.2 and 0.5 for those ligands, saw a vast improvement in ranking. ROS1
behaves analogously to BACE1 where ligands that fall below a ∆Gelec threshold
are subjected to an amplification in electrostatic charge, to obtain better rankings.
Therefore, we suggest that modification of int could ligand-specific, rather than
system-specific.
Inclusion of explicit water molecules to MMPBSA and MMGBSA calculations re-
sult in a slight improvement in ranking, but these are not significant enough for
implementation into the ESMACS protocol. Inclusion of more than 20 explicit
water molecules, results in no further improvement in ranking coefficients. The
purpose of including this approach is that it is easy to implement, and would gen-
erate some improvement in rankings. It is indeed easy to implement, however the
small improvement in ranking metrics does not qualify this as a method that should
be incorporated into all systems of study, where explicit waters are important. In-
clusion of explicit waters should be done after gaining a complete understanding of
the binding mode of the ligand-receptor complex, and then selecting specific water
molecules, as seen in other studies [100]. With this said, there is always a trade-off
and the amount gained by including explicit waters is more than off-set by the very
system-specific requirements that render the approach must less automatable.
When combining the inclusion of explicit water molecules and a variable dielectric
constant we see no improvement in correlation and ranking. It is therefore not
suggested to perform the two methods in tandem. Attempting to adjust the int
parameter initially, will be easier and, in this case, generates better improvements in
results. Ultimately, valid departures from default settings need to be qualified and
at this moment, there is no definitive criterion that can be implemented. On the
other hand, one may study the partial atomic charges (similarly to what is seen in
Fig. 5.4, 5.7 and 5.10) and distinguish the ligands qualitatively. Further, obtaining
binding free energies by changing the MMPBSA int parameter is negligible in time
and effort. In fact, a good estimate can be obtained by dividing the electrostatic
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contribution to the binding free energy (∆GMMelec ) and the free energy of solvation
(∆GXsol) by the int value.
We also highlight the importance of including crystal water molecules prior to sim-
ulation. Ligand L01 demonstrates large changes in conformation, and subsequently
calculated binding affinity, when crystal waters are removed. This observation is
well known, and widespread resulting in several software applications [169, 170]
that automate the inclusion of important water molecules.
Using the WSASA method to estimate configurational entropies led to a consid-
erable improvement in ranking in the PAK4 system containing the aromatic series
of ligands. No change in ranking was observed for the aliphatic series. WSASA
performed equally to NMA when all ligands were taken into account. WSASA
was inferior to NMA in the ROS1 data set. Although WSASA has not reported
consistently improved results, the ability to improve rankings for aromatic ligands
in PAK4 is noteworthy. The ease of completing WSASA calculations on a desktop
computer at a fraction of a time, compared to NMA, means that it is a viable tool
for quick entropy calculations based on actual trajectory frames. The BACE1 sys-
tem demonstrated the difficulties associated with NMA, and WSASA circumvents
this issue.
To conclude, we have shown that varying int values make a significant difference in
the quality binding affinity predictions when the ESMACS protocol is employed.
Although a quantitative ‘rule’ for int selection has not been formally outlined
in this chapter, it is evident that appropriate treatment of this term is critical
to achieve correct binding affinity values. The selection of int will most certainly
depend on the polarity of the binding pocket of the recepter and ligand in question,
and so cannot be generically defined.
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Chapter 6
Application of ensemble-based
binding affinity protocols in a
clinical setting
6.1 Introduction
Much of this thesis so far has described the need for rapid and reliable binding
affinity predictions in a drug discovery setting, however, ensemble-based binding
affinity protocols can also be applied in the medical domain. Today, genotypic
assaying (or genome sequencing) is common practice. Genome sequencing tech-
nology uncovers the genetic information of a patient or cohort of patients that are
suffering from a genetic disease. From this genetic profile, clinicians can deduce the
genetic nature of the disease and prescribe the appropriate therapy [171]. Although
significant advances have been made in genome sequencing capabilities, obtaining
a genetic profile of a patient and subsequently choosing the correct diagnosis, is a
non-trivial approach meaning that clinicians have often turned to decision-support
tools. These tools are aimed for the early diagnosis of patients, allowing the cor-
rect therapy selection. Unfortunately, decision-support tools have also been found
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wanting, and there is a demand for an accurate and reliable tool that can efficiently
diagnose patients. Such methods must gain regulatory approval and so these must
be reliable methods. With this said, there is currently no truly clinical applications
for disease prediction, or early diagnosis. In its infancy, the ESMACS approach
has been successfully employed to determine binding affinity of HIV-1 protease in-
hibitors that are currently used in the clinic, based on different protein sequences
[43, 87].
Half a century after the discovery of the double helical structure of DNA, the
completion of the Human Genome Project (HGP) paved the way for a new era in
genomic research. Relatively crude, first-generation methods were used to sequence
the human genome during the early stages of the HGP, of which Sanger sequenc-
ing [172] was the most prominent. Following the inception of Sanger sequencing,
a number of improvements were made in the following years. Flourometric-based
detection and capillary electrophoresis allowed for reactions to occur in a single
vessel (previously performed in 4 vessels), and improved the capability to detect
nucleotides more accurately. These advances resulted in the development of com-
mercial DNA sequencing machines [173], and eventually simulataneous sequencing
machines thare are able to process hundreds of samples [174, 175].
The rate at which nucleotide sequencing technologies are developing resulted in a
‘genomic revolution’ that is growing at a faster rate than the ‘computing revolution’
[171]. This can be compared using Moore’s law, which states that the complexity
of microchips (measured by the number of transistors per unit cost) doubles every
18 months. The capabilities of genome sequencers has grown at a faster rate than
Moore’s law, doubling every five months between 2004 and 2010. Today next
generation sequencing (NGS) methods [176, 177, 178] give researchers a plethora
of diverse tools from which sequencing can be conducted efficiently. Arguably the
most popular approach is the Solexa method of sequencing developed by Illumina
[179]. The implications of this are faster and cheaper methods for gene sequencing.
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In 2006, Illumina’s first sequencer could sequence a genome for $300,000. A decade
later, this has dropped to $1,000 [180]. Illumina claim that their new machines
are 70% faster and within 3 to 10 years, they will be able to sequence a genome
for $100. Oxford Nanopore is an emerging method that can read longer lengths of
genetic code, making it very efficient [180]. The cost of the Nanopore machine is
considerably cheaper ($75,000) than some of Illumina’s products, which can cost
close to $1,000,000.
NGS techniques are not limited to the mutations in the human genome; nucleotide
sequencing can also be applied to pathogens – any infectious agent that can cause
disease such as a virus, bacteria, fungi [181] etc. – which has a genetic basis. In
2015 the Ebola virus epidemic was a result of a mutation in the genetic code of
Ebolavirus Zaire evolavirus. Within two days of collecting the sample, researchers
were able to sequence the viral genome [182]. As such, genomic research in terms
of pathogenesis can be exploited in two ways: understanding the human genetic
variation related to health and disease, and uncovering the genetic profile of the
pathogen itself.
We are now in an era where we are able to obtain complete DNA sequences of vari-
ous cancer genomes, and with that comes the discovery of ever more mutations that
result in oncogenesis, and resistance to cancer therapies [183, 184]. Our growing un-
derstanding of the cancer genome also demands reliable and rapid decision-support
software to determine the correct therapy based on a patient-specific genetic profile.
Thus, an imperative goal in the medical domain is the development of a reliable
and high-throughput computational tool that is able to rank the potency of cur-
rent therapies across a range of mutated receptors, on clinically relevant timescales.
The “INtegrated and Scalable PredictIon of REsistance” (INSPIRE) project, a US
Department of Energy (DOE) funded ‘INCITE’ award addresses the challenges
represented by drug resistance, through the use of large scale atomistic molecular
simulation [185]. This initiative aims to guide precision cancer therapy in which
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anti-cancer treatments are tailored specifically to patients based on the genome of
their particular cancer.
The work described in this chapter is a collaborative effort between researchers at
University College London (UCL), Carnegie Mellon University in Qatar (CMU-Q)
and Hamad Medical Corporation (HMC), funded by the Qatar National Research
Fund (QNRF). In the state of Qatar breast cancer consitutes 39% of all cancers in
females [186]. Consequently it is pertinent to research how breast cancer develops
in this population to design an appropriate method of treatment. To develop such
a treatment, it is critical to have a comprehensive understanding of the genetic mu-
tations that cause breast cancer. Gene sequences of the estrogen receptor (ER) will
be completed by scientists from HMC and CMU-Q, and will be used in molecular
modelling studies at UCL. Specific mutations, if any, in the Qatari populations will
be investigated for their effects on the drug binding affinities.
We begin by aiming to understand how the ensemble-based protocols employed
throughout this thesis perform for the wildtype (WT) ER and 2 mutated variants,
Y537S and D538G, which are the most common in breast cancer patients [187].
Absolute binding affinities, using ESMACS, will be computed for 5 current cancer
therapies, and the hormone estradiol which is an endogenous agonist of the ER.
ESMACS binding affinities will be generated for the 6 ligands bound to the three
respective ER variants. The TIES protocol is implemented for 3 transformations,
of which all are inhibitors of ER. Similarly to ESMACS, TIES relative binding
affinities will be generated for the WT and ER mutants.
6.2 Hypothesis
In the following sections we will see that the ER undergoes large conformational
changes, dependent on ligand binding and the presence of mutations on the recep-
tor. Hence, the decision to investigate ER is on the basis of the receptor flexibility.
The conformational variation seen in the ER can be difficult to model, particularly
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in short simulations that are implemented in ESMACS and TIES. The ESMACS
method comes with different settings, namely 1-, 2- and 3-trajectory ESMACS ap-
proaches, described in section 2.6.2.3. The 3-trajectory approach calculates free
energies of the three entities (complex, receptor and ligand) from individual sim-
ulations and then takes the difference (Eqn. 2.64c) to achieve the binding affinity
of the ligand to the receptor. The benefit of this approach is that in the free
simulations of each entity, additional conformations are sampled compared to the
1-trajectory approach, where the ligand and protein are both restricted in move-
ment due to being in the bound state. The 3-trajectory ESMACS approach, then,
would be suited to receptors that undergo large conformational changes upon lig-
and binding. We therefore hypothesise that the 3-trajectory ESMACS approach
will provide us with a better estimate of the binding free energy of ER and its
mutant variants, using the six ligands shown in Fig. 6.3, due to the conforma-
tional flexibility of the ER receptor upon ligand binding. We will use TIES relative
binding affinities to support this hypothesis.
6.2.1 Role of the ER in breast cancer
ERs are ligand-activated nuclear transcription factors which bind estrogens to in-
duce physiological effects [188]. Estrogens are hormones that bind to the (ER) and
induce transcriptional regulation, which could either be activation of a particular
target gene or repression, in conjunction with interacting transcription machinery
[189, 190]. The ER regulates the differentiation and maintenance of various differ-
ent tissues [191, 192]. In breast cancers, ER is a major contributor to cell growth,
survival and metastasis [187]. There are two types of ER, ER-α and ER-β, however
ER-α plays the prominent role in ER-positive breast cancer.
ER ligands (Fig. 6.3) bind to the ligand binding domain (LBD) located on the
C-terminal. Due to the flexibility and spaciousness of the cavity, a diverse range of
small molecules are able to bind in the LBD, triggering many different physiolog-
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ical effects. The endogenous estrogen hormone, estradiol, interacts as an agonist
(binds to ER to induce a biological response), whereas synthetic compounds such
as tamoxifen exhibit antagonistic behaviour (binds to ER and inhibits a biological
response). The latter belongs to a class of drugs called “selective estrogen receptor
modulators” (SERMs) which have been used extensively to treat estrogen receptor-
positive breast cancer. Estradiol is sometimes written as 17β-estradiol. Here, we
will simply use estradiol for convenience and clarity.
6.2.2 Effects of mutations on ER function and drug efficacy
Targeted hormone therapy represents a major advance in the treatment of human
cancers which specifically inhibit selected molecular targets. About 2 out of 3
breast cancers are hormone receptor-positive (that is estrogen- or progesterone-
receptor positive), in which high hormone levels induce carcinogenesis. Hormone
therapy can reduce the onset of cancer by either lowering hormone levels or blocking
hormones from binding to their receptor targets and thus preventing a biological
response. Tamoxifen is such a drug that blocks ERs in breast cancer cells and
has been used clinically for more than 30 years to treat hormone receptor-positive
breast cancer.
Although tamoxifen has been used successfully for 3 decades, ER drug resistance
to tamoxifen has resulted in a less efficacious therapy. Drug resistance comes in
two forms: de novo resistance and acquired resistance. The former is found in
ER-positive patients who are unresponsive to hormone therapy from the beginning
of treatment, while the latter is developed in those ER-positive patients who are
initially responsive to hormonal treatment but then acquire resistance. De novo
resistance, although rare, is a result of a genetic disposition of the patient to mu-
tations in the ER [193]. Considering the clinical value of tamoxifen in treatment
of breast cancer, it is clear that preventing and overcoming tamoxifen resistance
remains an important clinical goal.
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At this point it is essential to mention that tamoxifen is not an active, therapeutic
compound, rather, once tamoxifen is passed through the liver, it is metabolise
into afimoxifene which is responsible for the therapeutic effect. Tamoxifen is
metabolised into afimoxifene, which is the main active metabolite and endoxifen,
a minor metabolite. This distinction is important because in this chapter binding
affinities calculations are performed for all three molecules.
6.2.3 Agonist and antagonist binding to ER
Binding of ligands to the ER is facilitated by heat shock protein 90 (HSP90, [194])
which, in the absence of a ligand, opens up the steroid binding cleft to allow entry
of a ligand [195]. HSP90 act as a chaperone, which also expedites the formation of
ER dimers (two ERs covalently bound together), and recruitment of coactivators,
to produce an active complex primed for a physiological response. The agonist and
antagonist binding [188] within the LBD is described below and visually presented
in Fig 6.1.
Estradiol contains a polar moiety forming a small polar sub-pocket within the
LBD, which is defined by the phenol group forming hydrogen bonds with glycine
(G353), arginine (R394) and a water molecule. This is additionally stabilised by
another hydrogen bond with histidine (H524) and an oxygen, on the opposite end
of the ligand. The non-polar nature of the main body lends itself to submerging
into the pocket and is surrounded by hydrophobic residues. Access to the pocket
is restricted by alanine (A350), leucine (L387) and phenylalanine (F404), forming
a rigid architecture. Consequently, the structural pre-requisite for ligand entry
into the binding cavity is a planar ring which is able to slide past the ‘gatekeeper’
residues.
When the LBD is occupied by the agonist estradiol, the C-terminal chain, also
known as the H12 helix, sits over the ligand binding cavity and forms a ‘lid’,
without directly interacting with estradiol. The charged H12 helix is positioned as
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EST AFI
D351
R394
G353
H524 H524
G353
R394
L387 L387
A350 A350F404 F404
WAT WAT
Figure 6.1: A representation of agonist and antagonist binding in a wildtype ER
receptor, using the example of estrogen (left) and afimoxifene (right),
respectively. Only key residues that play a role in ligand binding
are displayed, and all hydrogen atoms have been removed for bet-
ter clarity. Hydrogen bonds are shown as black dotted lines. The
dashed orange lines indicate residues (A350, L387 and F404) that
act like ‘gatekeepers’ by restricting access to the LBD. ‘WAT’ is a
water molecule.
such that the highly conserved hydrophobic residues face inwards, toward the LBD,
and the hydrophilic residues interact with the solvent. The position of H12, when
bound to an agonist, is a pre-requisite for transcriptional activation by generating
a AF-2 cleft that is required for interaction with steroid receptor coactivator 1
(SRC-1, [188, 196]) and (SRC-3, [197]).
In the case of antagonists, such as afimoxifene, the binding mechanism is similar.
Hydrogen bonds are formed between the alcohol groups on either end of the ligand.
However, the long side chain in afimoxifene causes a non-allosteric displacement of
the H12 helix. This is supported by hydrogen bonding between aspartic acid, D351,
and the piperidene group located at the terminus of the ligand side chain. As a
138
6.2. HYPOTHESIS
result, the H12 helix occupies the AF-2 cleft preventing the SRC-1 coactivator to
interact with the ER and trigger transcription activity. Fig. 6.2 summaries the
mechanism of agonist and antagonist binding in ER.
6.2.4 The effects of ER mutant receptors on the binding
mechanism
The mutations of the tyrosine residue at position 537 to serine (Y537S), and aspar-
tic acid at position 538 to glycine (D538G) are the most common cause of acquired
resistance to hormonal therapy in ER-positive breast cancer. The mechanisms of
action are described below [187].
coactivator
H12
Y537
EST
Active
H12
coactivator
Y537
AFI
EST
Inactive
LBD
AF-2 AF-2
LBD
Figure 6.2: A representation of agonist and antagonist binding in a wildtype ER
receptor with estradiol (EST) and afimoxifene (AFI) as examples.
During the process of agonist binding, the modular non-polar estra-
diol settles in the binding pocket allowing the H12 helix to fold over
and act as a ‘lid’ for the LBD. As a result, the ER is available to
interact with coactivators SRC-1 and SRC-3 at the AF-2 cleft and
induce transcriptional activity. The binding of an antagonist such as
AFI, however, means that H12 is displaced and obstructs the AF-2
cleft. Coactivator SRC-1 cannot interact with the AF-2 cleft and is
thus inactive.
In the D538G mutant receptor bound to estradiol, the H12 helix is displaced ac-
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companied by a conformational change in Y537. The Y537 residue in the (WT)
ER-estradiol complex forms a hydrogen bond with N348 forcing the hydrophobic
side chains in the H12 helix to bury inside the LBD. In the ER-estradiol complex
that exhibits the D538G mutation, the Y537-N348 hydrogen bond is not formed
and the hydrophobic side chains face outwards [187].
The D538G mutant even shows activity when in the apo (unbound) form. Here, the
mutant adopts a similar structure to WT ER-estradiol complex, with the H12 helix
twisting inwards towards the LDB. In fact, the H12 helix in the unbound D538G
receptor is stabilised further due to the hydrophobic residues burying themselves
even deeper into the protein surface [187].
The Y537S also becomes active in its unbound state by forming a hydrogen bond
with residue D351. This forms a stable agonist state in the absence of estradiol,
and is subsequently ready for interaction with SRC-1 or SRC-3 [188, 196, 187].
6.3 Methods
ESMACS and TIES binding affinity calculations were performed using the standard
protocol described in Chapter 2.7. Binding affinities were obtained for 6 ER ligands
(Fig. 6.3). Experimental binding affinities were completed using a radiometric
ligand-binding assay by Fanning et al. [187, 198] achieving IC50 values, which
were converted to Ki values using the Cheng-Prusoff equation (2.20). The full and
abbreviated names are shown in Table 6.1.
Two ER structures were used for this study, which represent the open and closed
forms with the respect to the position of the H12 helix. The PDB code of the open
conformation crystal structure is 3ERT [199], and the closed conformation is 1QKU
[200]. The ER structure of the former PDB model is complexed to afimoxifene,
whereas the latter is bound to the native estradiol. The remaining inhibitors were
generated by modifying the AFI inhibitor in 3ERT.
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(a) Tamoxifen (b) Afimoxifene (c) Endoxifen
(d) Raloxifene (e) Toremifene (f) Estradiol
Figure 6.3: Chemical structures of 6 ER ligands. Experimental binding affinities
are not available.
Table 6.1: The full name of the 6 ligands that have been investigated, along with
the associated abbreviations employed in this chapter.
Abbreviation Full Ligand Name
EST Estrogen
TOR Torimefene
EDO Endoxifen 1
RAL Raloxifen
AFI Afimoxifene 2
TAM Tamoxifen
1 Endoxifen is a minor metabolite of tamoxifen. That is, after tamoxifen passes through the liver it is a small
percentage is transformed into endoxifen which imposes a therapeutic effect, not tamoxifen.
2 Afimoxifene is the major metabolite of tamoxifen, and primarily responsible for its therapeutic effect.
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The same crystal structures were used to complete regular TIES calculations. Of
the 6 ligands in the study, only 4 qualified for TIES calculations, as they were
structurally related. Note from section 2.6.1 that TIES calculations involve an
alchemical mutation between two ligands. Excessively large structural differences
and/or changes in the charge between two ligands are likely to cause large con-
formational changes as the ligand mutates, and thus TIES is likely to generate
inaccurate relative binding affinities. There is no definitive process for selecting
the right TIES pair. Chemical changes to a chemical group within a ligand pair
is usually acceptable, for example the removal of a hydrogen atom and the sub-
sequent inclusion of a methyl group is tolerated, like that between endoxifen and
afimoxifene. Other considerations are force field parameterisations, with respect to
charge variation in TIES ligands. We have seen in other studies pertaining to the
CDK2 and TYK2 system that certain chemical groups or structures are not well
tolerated in this respect (sulphonamide group and ring structures, respectively).
Raloxifene and, in particular estradiol, are structurally too different for this ap-
proach, although there is no charge difference between any of the ligands.
The TIES transformations are defined as follows: T01 is an alchemical change
from TAM to AFI, T02 is a transformation from AFI to EDO and lastly, T03
mutates from TAM to TOR. TIES relative binding affinities were completed for
these transformations bound to the each ER receptor, totaling 9 TIES calculations.
To be able to assess the performance of the binding affinity predictions, it is useful
to have experimental binding affinities. Moreover, to perform an accurate assess-
ment against experimental binding affinities, the values need to be obtained using
the same method, and in replicates to obtain error bars. There is no account in
the literature of experimental binding affinities for the full set of ligands. However,
Fanning et al. [187] report experimental binding affinities for EST and AFI bound
to WT, Y537S and D538G ERs, respectively. We will use these values to perform a
partial assessment of computationally derived binding free energies. Caution must
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be taken however, as the reported error bars suggest large uncertainty – results
may deviate up to 50% of the binding affinity value with respect to the Ki metric.
ESMACS binding affinities calculations were all performed on the LRZ SuperMUC
Phase 1 and Phase 2 machines [105] during a project which utilised the entire HPC
facility (approximately 250,000 cores) for a duration of 36 hours (see section 3.4.1).
The TIES calculations were performed under normal operational procedures on
SuperMUC, and required a total of 610,000 core hours.
6.4 Results
We first assess the binding affinities that have been obtained from ESMACS –
namely 1-, 2- and 3-trajectory approaches – against the experimental values re-
ported in Fanning et al. [187]. The results are reported in Table 6.2.
In this analysis, the 3-trajectory ESMACS results show the strongest correlation
with experimental values, particularly the PB and PBNM free energy methods
(rp = 0.92, rs = 0.96). Conversely, the 1-trajectory approach reports a negative
correlation for all free energy methods, since the conformational changes are not
sampled in the single trajectory of the complex. Additionally, the inclusion of
configurational entropy does not degrade the ranking and correlation like it has
done in systems described in previous chapters. The correlation plots of the best
performing ESMACS approaches are shown in Fig. 6.4.
The 3-trajectory approach generates binding affinities from separate, but ensemble-
based, trajectories of the complex, receptor and ligand. We have learned that
upon ligand binding, the ER undergoes large conformational changes, thus, the
3-trajectory ESMACS approach should theoretically capture this resultant free
energy change in the receptor. The binding mode of ER ligands to ER, is described
by the induced-fit model, which the 3-trajectory approach is able to detect. The
1-trajectory method, for instance, does not take into account the conformational
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Table 6.2: Computational and experimental (∆Gexp) binding affinities of estra-
diol, EST, and afimoxifene, AFI, to three ER receptors: WT, Y537S
and D538G. The computational binding affinities are achieved using
the 1-, 2- and 3-trajectory ESMACS approaches. The Generalised
Born (GB), and Poisson-Boltzmann (PB) free energy methods were
used, in addition to configuration entropy obtained from normal mode
analysis (NMA). The Spearman (rs) and Pearson (rp) correlations
are presented for all methods. All values are in kcal/mol.
1-trajectory
Ligand Receptor GB PB GBNM PBNM ∆Gexp
EST WT -28.51 -26.37 -6.86 -4.72 -12.85
EST Y537S -28.37 -27.06 -6.64 -5.33 -11.86
AFI WT -43.27 -34.58 -20.32 -11.63 -12.70
AFI Y537S -42.64 -34.27 -19.99 -11.62 -11.51
AFI D538G -42.63 -33.81 -20.16 -11.34 -11.35
Spearman, rs 0.14 0.15 0.15 0.17
Pearson, rp -0.37 -0.39 -0.39 -0.42
2-trajectory
Ligand Receptor GB PB GBNM PBNM ∆Gexp
EST WT -57.82 -56.91 -17.29 -16.38 -12.85
EST Y537S -58.50 -57.59 -17.46 -16.55 -11.86
AFI WT -38.21 -31.17 -17.51 -10.47 -12.70
AFI Y537S -34.04 -26.87 -14.87 -7.70 -11.51
AFI D538G -31.73 -23.58 -11.98 -3.83 -11.35
Spearman, rs 0.27 0.25 0.61 0.41
Pearson, rp 0.52 0.50 0.78 0.64
3-trajectory
Ligand Receptor GB PB GBNM PBNM ∆Gexp
EST WT -29.93 -40.65 -8.87 -20.23 -12.85
EST Y537S -24.16 -30.20 -3.24 -9.29 -11.86
AFI WT -43.95 -35.39 -22.07 -13.51 -12.70
AFI Y537S -28.86 -18.88 -11.06 -1.08 -11.51
AFI D538G -27.84 -16.49 -7.84 3.50 -11.35
Spearman, rs 0.35 0.92 0.23 0.91
Pearson, rp 0.59 0.96 0.48 0.95
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change of the receptor upon binding. All the energy terms cancel out and what
is left is the free energy of the direct ligand contacts with the protein. For this
reason 1-trajectory ESMACS generates worse rankings and correlations for this
ligand set. The promising correlations observed show that ESMACS, using the
3-trajectory approach, is able to correctly determine binding affinities of systems
that undergo large structural changes.
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Figure 6.4: A correlation plot between 3-trajectory ESMACS absolute bind-
ing affinities and experimental binding affinities using: (a) the
MMPBSA free energy method, and (b) the MMPBSA method with
the inclusion of configurational entropy obtained using normal mode
analysis (T∆SNMA). Error bars are removed for clarity but are no
greater than ± 2 kcal/mol.
Since the 3-trajectory approach has been implemented, this raises the question of
which ER model should initially be used to generate simulation trajectories – the
open or closed conformation. As we know the receptor simulation is independent
of ligand binding, and sampling is solely of the receptor in solvent. We assess the
3-trajectory ESMACS binding affinities varying in the starting ER conformation.
Binding affinity values are shown in Table 6.3.
When selecting either the open or closed conformation as the starting point for
MD simulations, we see that the GB method, with the inclusion of configurational
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Table 6.3: Computational and experimental (∆Gexp) binding affinities of estra-
diol, EST, and afimoxifene, AFI, to three ER receptors: WT, Y537S
and D538G. The computational binding affinities are achieved using
the 3-trajectory ESMACS approaches, differentiated by the starting
conformation of the ER receptor prior to simulation (open and closed).
The Generalised Born (GB), and Poisson-Boltzmann (PB) free en-
ergy methods were used, in addition to configuration entropy obtained
from normal mode analysis (NMA). The Spearman (rs) and Pear-
son (p) correlations are presented for all methods. All values are in
kcal/mol.
3-trajectory closed conformation
Ligand Receptor GB PB GBNM PBNM ∆Gexp
EST WT -29.93 -40.65 -8.87 -19.60 -12.85
EST Y537S -29.17 -30.20 -3.24 -9.29 -11.86
AFI WT -8.92 -14.12 -7.66 -12.86 -12.70
AFI Y537S -3.19 1.38 0.88 0.44 -11.51
AFI D538G 4.05 -0.85 3.73 -1.18 -11.35
Spearman, rs 0.35 0.51 0.96 0.89
Pearson, rp 0.59 0.71 0.98 0.94
3-trajectory open conformation
Ligand Receptor GB PB GBNM PBNM ∆Gexp
EST WT -64.96 -61.92 -23.28 -20.25 -12.85
EST Y537S -54.84 -50.46 -15.18 -10.81 -11.86
AFI WT -43.95 -35.39 -22.07 -13.51 -12.70
AFI Y537S -28.86 -18.88 -11.06 -1.08 -11.51
AFI D538G -27.84 -16.49 -7.84 3.50 -11.35
Spearman, rs 0.59 0.56 0.98 0.88
Pearson, rp 0.77 0.75 0.99 0.94
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entropy (GBNM ), generates better correlation and ranking coefficients. When the
open conformation is selected, the GB and GBNM approaches show superior per-
formance compare to the PB variant. With regard to the closed conformation,
we initially see that the GB method is worse than PB, but including the config-
urational entropy, GBNM improves significantly and outperforms PBNM . These
results show us that either the open or closed conformation can be chosen as the ini-
tial starting point for MD simulations, from which binding affinities are computed.
Normal mode analysis, in this case, accurately calculates the entropic changes due
to conformational change in the receptor, yielding strong correlations for the full
binding affinity with experimental values. Fig. 6.5 shows correlation plots for the
GB variants.
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Figure 6.5: A correlation plot between 3-trajectory ESMACS absolute binding
affinities (initial receptor conformation is closed) and experimental
binding affinities using: (a) the MMGBSA free energy method, and
(b) the MMGBSA method with the inclusion of configurational en-
tropy obtained using normal mode analysis (T∆SNMA). Error bars
are removed for clarity but are no greater than ± 2 kcal/mol.
We have shown here that 3-trajectory ESMACS approach yields superior results
compared to the single trajectory and averaged receptor approaches. This is due
to the conformational changes observed upon ligand binding, and thus individual
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trajectories are required to gain a more representative sampling of phase space.
Normal mode analysis correctly calculates the configurational entropy as a result
of the conformational change upon binding. Including the configurational entropy
significantly improves the correlation and rankings. Either the open or closed
receptor conformation can be selected subject to the inclusion of configurational
entropy values.
6.4.1 ESMACS versus TIES relative binding affinities re-
port a strong correlation
It is not realistic to have experimental values available each time ESMACS or TIES
calculations are being performed. Clearly, if such protocols are ever to become
predictive tools which clinicians can turn to with confidence, then accurate and
reliable theoretical binding affinities are essential. TIES relative binding affinities
were generated for the transformations described in section 6.3. By comparing
TIES binding affinities with relative ESMACS binding free energy values, we are
able to assess the two protocols which, as a result, gives us further confidence that
ESMACS and TIES generate accurate and reliable binding affinities. Table 6.4
shows the values, correlation and ranking coefficient values.
TIES relative binding affinities show a very good agreement with the 1-trajectory
ESMACS approach, exploiting the MMPBSA free energy method. This is contrary
to what is seen when absolute ESMACS binding affinities are correlated against
experimental values, where the 3-trajectory method shows superior correlation and
ranking metrics. A similar agreement is witnessed when configurational entropy is
included, albeit with a slight degradation. There is a lack of correlation between
TIES and any 3-trajectory ESMACS approach. This includes when the open or
closed conformation trajectories are selected.
Although the 3-trajectory ESMACS approach correctly predicts the induced-fit
model that is represented by ER ligand binding, the 1-trajectory approach gener-
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Table 6.4: Relative ESMACS and TIES binding affinities for three TIES transfor-
mations, bound to three ER receptors: WT, Y537S and D538G. The
relative ESMACS binding affinities are determined by finding the dif-
ference between the difference between the absolute ESMACS binding
affinities, appropriate for each transform. With regard to ESMACS,
the Generalised Born (GB), and Poisson-Boltzmann (PB) free en-
ergy methods were used, in addition to configuration entropy obtained
from normal mode analysis (NM). The Spearman (rs) and Pearson
(rp) correlations are presented for all end-point free energy methods,
with respect to TIES binding affinities. All values are in kcal/mol.
1-trajectory 3-trajectory
Receptor Transform GB PB GBNM PBNM GB PB GBNM PBNM TIES
WT
T01 2.88 1.57 1.22 -0.09 7.56 6.56 3.16 2.17 2.32
T02 -2.77 -2.22 -2.72 -2.16 -2.71 -4.58 -3.06 -4.93 -0.61
T03 1.24 0.04 0.28 -0.91 4.69 1.14 4.33 0.19 0.52
Y537S
T01 2.37 1.06 0.67 -0.64 0.90 2.24 -2.04 -0.70 2.25
T02 -2.77 -2.22 -2.72 -2.16 -2.71 -4.58 -3.06 -4.93 -0.82
T03 7.50 0.12 0.32 -1.06 -0.04 -0.79 -1.28 -2.62 0.71
D538G
T01 2.48 0.81 1.04 -0.63 3.76 4.93 0.26 1.44 2.42
T02 -2.23 -1.88 -2.30 -1.95 7.42 8.41 7.71 8.70 -0.43
T03 -1.63 0.46 0.89 -0.27 3.34 3.6 3.71 3.47 0.65
Spearman, rs 0.41 0.87 0.77 0.73 0.17 0.26 0.00 0.04
Pearson, rp 0.64 0.93 0.88 0.85 0.42 0.51 0.02 0.19
ated better correlations with TIES because this approach takes into account only
the ligand interactions that play a direct role in binding (receptor energies are
cancelled out). As a result, the 1-trajectory yields a more ‘accurate’ result that
corresponds well with TIES. With regard to the reproducibility of the binding
affinities, both approaches yield highly reproducible values. Error bars for both
approaches have been removed in Fig. 6.6, for clarity. The error is no greater than
± 0.04 kcal/mol for TIES, ± 0.23 kcal/mol for ESMACS with MMPBSA, and ±
0.28 kcal/mol for ESMACS with MMPBSA−T∆SNMA.
The outlier in Fig. 6.6b (T03-D538G) is as a result of an incorrect estimation of the
relative binding affinity obtained from the 1-trajectory ESMACS method with the
inclusion of T∆SNMA. The likely reason is that the change in T∆SNMA between
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TAM and TOR is considerably larger than the change in ∆G between the same
ligand pair, resulting in a significant shift in binding affinity when T∆SNMA is
included.
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Figure 6.6: A correlation plot between TIES relative binding affinities and
1-trajectory ESMACS relative binding affinities using: (a) the
MMPBSA free energy method, and (b) the MMPBSA method with
the inclusion of configurational entropy obtained using normal mode
analysis (T∆SNMA). Error bars for both approaches have been re-
moved for clarity.
6.5 Discussion
There is a need for an automated, predictive tool that can generate accurate and re-
liable binding affinities which clinicians can use to make rapid treatment decisions.
A decision-support tool that can estimate binding affinities accurately, rapidly and
reliably would help clinicians make the correct therapy choices in an efficient man-
ner. Further, such a method would complement the rapidly improving capabilities
of genome sequencing methods. Here we show that ESMACS and TIES are able
to correctly estimate binding affinities for ER ligands bound to WT ER and two
of the most common mutations reported in ER-positive breast cancer, Y537S and
D538G.
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ESMACS is a versatile protocol which has been demonstrated to work well in
the ER system, and can be exploited in different ways. The 3-trajectory ES-
MACS approach, correctly estimates binding affinities for 5 ligands compared with
experimental values. The relative ESMACS binding affinities obtained from the
1-trajectory approach show strong agreement with TIES binding affinities. This
strongly validates ESMACS and TIES approaches as accurate. In scenarios where
experimental values are not available, such methods would be suitable to provide
reliable binding affinities. Although strong correlations and rankings have been re-
ported in ESMACS and TIES, to further strengthen the results, additional binding
affinities should be obtained.
The 3-trajectory ESMACS results correlate well with experimental binding affini-
ties because it is able to predict binding affinities based on the induced-fit model.
This is because free energy differences are obtained from individual, but ensemble-
based, trajectories, where more conformations are sampled. The 1-trajectory ap-
proach on the other hand generates free energy values from only a ligand-receptor
trajectory (completed as an ensemble also). As a result, most of the receptor en-
ergies are cancelled out leaving only the energy change that is directly implicated
in ligand binding. This represents the lock-and-key method of binding which is
not attributed to ER ligand binding. Therefore we obtain worse correlations and
rankings with respect to experimental binding affinities when the 1-trajectory ES-
MACS approach is used. However, this is also the reason why the 1-trajectory
ESMACS approach correlates well with TIES relative binding affinities. We gain
a more ’accurate’ binding affinity because of the fact that only key interactions in
connection to ligand binding are captured.
The 3-trajectory method is limited by larger error bars. Since we obtain free
energies from the complex, receptor and ligand independently, this increases the
variation in free energy values. For example, the receptor free energies may vary
by several kcal/mol which, when included in the bootstrapping process from which
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standard errors are calculated, can contribute considerably. The 1-trajectory ES-
MACS approach does not have this issue for the reason that we obtain standard
errors from just the ligand-receptor complex.
The open and closed receptor conformations were used to calculate the 3-trajectory
binding affinities. Interestingly, we see that when selecting either conformation
across all ligands, the MMGBSA method with the addition of configurational en-
tropy report very good correlations. This example provides a further example of
the fact that normal mode analysis can accurately estimate the entropic cost, in
systems that have large conformational changes upon ligand binding. In previous
chapters, normal mode analysis has generally shown mixed results in correlation
and ranking coefficient, however this is an example where this estimation works
well.
In conclusion, we have shown that the 3-trajectory ESMACS approach, with the in-
clusion of configurational entropy obtained by NMA, successfully predicts binding
affinities for ligands bound to ER. The large conformational changes that take place
upon ligand binding to ER are captured using the 3-trajectory approach, which the
1-trajectory method fails to do. This is also the first instance that we see config-
urational entropy significantly improving the correlation compared to MMGBSA
alone, suggesting that NMA best predicts configurational entropy when systems
with large conformational changes are studied. A strong correlation was reported
when the relative binding affinities using 1-trajectory ESMACS was compared with
TIES binding affinities. This further supports the correct calculation of absolute
and relative binding affinities of ligands bound to ER.
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Chapter 7
Conclusion
The question that is often raised about predictions based on computer simula-
tion, irrespective of the scientific discipline, is if the modelling is correct. On one
hand, computational models are sometimes met with skepticism by experimental
scientists, and on the other, molecular modelling results have been accepted with-
out sufficient validation. Both opinions are attributed to a lack of confidence in
computational techniques that do not take into account the requirement of replica
simulations to generate reproducible results. With the continuous progression of
high performance computing hardware and computational techniques alike, it is
now time to drive forward the development of computational tools for predictive
purposes. The drug discovery domain, within the pharmaceutical industry, is an
area where predictive tools are an obvious, and possibly near term, solution to
stagnating productivity and rising costs. In this industry, quantifying the bind-
ing affinity of a small molecule drug to its target protein is of high interest. Two
ensemble based methods, “Enhanced Sampling of Molecular dynamics with Ap-
proximation of Continuum Solvent” (ESMACS), and “Thermodynamic Integration
with Enhanced Sampling” (TIES) have been described in this thesis, which have
the capacity to compute accurate and reproducible binding affinities, rapidly, on
an industrially relevant scale.
7.1. SUMMARY OF FINDINGS AND LIMITATIONS
7.1 Summary of findings and limitations
We began with a critical analysis of ESMACS and TIES, and also compared these
ensemble approaches to FEP+ (or FEP/REST), developed by Schro¨dinger [46, 45].
With regard to ESMACS, we generate good binding affinities for 100 ligands across
all 5 systems, which vary in size and flexibility. The systems are cyclin-dependent
kinase 2 (CDK2), tyrosine kinase 2 (TYK2), induced myeloid leukemia cell dif-
ferentiation protein (MCL1), tyrosine-protein phosphatase non-receptor type 1
(PTP1B) and thrombin. The 1-trajectory Molecular Mechanics and the Poisson-
Boltzmann Surface Area approximation (MMPBSA) yields the best correlation and
ranking coefficients and also demonstrates highly reproducible results that are, in
most cases, characterised by small error bars.
There are several limitations to using ESMACS. The approach is not able to sample
ligand conformations that are separated by large energy barriers, which was wit-
nessed in the bromodomain receptor [201]. This has also been identified in CDK2,
where some ligands have rotamers where completely independent ESMACS calcu-
lations are required to generate binding affinities. As a result, it is not known if
the starting structure, prior to molecular dynamics (MD) simulation, is correct, re-
sulting in binding affinities that are based possibly on an incorrect ligand-receptor
conformation. Enhanced sampling techniques, like metadynamics, are required to
obtain a clearer understanding of ligand-receptor dynamics prior to ESMACS cal-
culations. There were challenges in generating acceptable parameters for ligands
containing a sulphonamide group. The initial parameters, give rise to incorrect par-
tial charges on the sulphur and nitrogen atoms. These parameters were manually
improved by ‘dampening’ the charges on these atoms. This resulted in improved
binding affinity rankings and correlations for the CDK2 system. ESMACS gener-
ated binding affinities with larger error bars for charged ligands.
TIES binding affinities for the same systems that have been used in the ESMACS
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study, show very good reproducibility (very small error bars), and a very high
root mean square error (RMSE) and mean absolute error (MAE) coefficient, which
indicates accurate and reliable relative binding affinity predictions.
The improved ligand parameters that were generated for the CDK2 system, were
also employed for TIES, but resulted in very poor binding affinity values. There
are several reasons why the ligand parameters seemed to work reasonably well for
ESMACS, but failed to produce respectable binding affinities when TIES was em-
ployed. Firstly, and the more likely possibility, is it could be due to an anomalously
high charge variations accruing in the alchemical transformation region in TIES. A
less likely possibility, is that it could be a case of simply increasing the λ windows,
because not enough intermediate states are sampled.
Comparing to FEP+, ESMACS correlations and rankings are significantly bet-
ter than what has been published [45]. For instance, it was reported that when
the Molecular Mechanics and the Generalised Born Surface Area approximation
(MMGBSA) method is used to obtain binding affinities, it yields a negative corre-
lation with experimental values. We have shown that this is not the case, and in fact
we produce a reasonably good correlation. TIES results are an improvement on the
FEP+ protocol, with respect to MAE and RMSE metrics. FEP+ does not take
into account reproducibility; TIES demonstrates reproducibilty within carefully
controlled stochastic uncertainties [42]. The FEP+ is a part of the Schro¨dinger
suite, which is a proprietary application, includes the Optimised Potentials for
Liquid Simulations (OPLS 2.1 [45]) force field, where TIES is open access. FEP+
utilises enhanced sampling in the form of the replica exchange solute tempering
(REST) technique, to sample phase space that is not reachable in conventional
unbiased MD. Researchers have recently implemented enhanced sampling features
in TIES [73].
The objective of the study related to the PAK4 system was to improve upon bind-
ing affinities that did not produce any correlation with experimental values. As a
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result we considered the effect of solvent models within our protocol, investigat-
ing the inclusion of explicit water molecules and modifying the internal dielectric
parameter (int) within the MMPBSA free energy method. We also assessed a
method that estimates configurational entropy based on a weighted average of the
solvent accessible surface area of each atom (WSASA). WSASA is an alternative
to normal mode analysis (NMA) which consumes a large amounts of core hours
when performing entropy calculations, within the ESMACS workflow.
Modifying the int for specific ligands, in the PAK4 system shows a vast improve-
ment in ranking and correlation. In particular, when increasing the int to 4, for
ligands that are comparatively less polar, we see a good correlation and ranking
metric. To test this, we extended this idea to two other systems, β-site amyloid pre-
cursor protein cleaving enzyme 1 (BACE1) and reactive oxygen species 1 (ROS1),
and we see a similar trend. We witness the importance of maintaining key crystal
waters that are captured within the PDB crystal structure. There is a very large
change in binding affinity in independent ESMACS binding affinities when crystal
waters were included and excluded, respectively. The WSASA method for estimat-
ing the configurational entropy due to the binding processes has shown promising
results when used for the PAK4 system. It is noteworthy that WSASA yields good
correlation and rankings when ligands with aromatic variable chemical groups, in
the PAK4 system, were assessed. WSASA has the benefit that it is computational
undemanding (it can be completed on a regular commercial desktop) and assesses
actual trajectory snapshots without the removal of explicit water molecules, as
opposed to energetically minimised trajectory snapshots without solvent contribu-
tions, which required by NMA.
The inclusion of some explicit water molecules that are directly involved in ligand
binding did not improve the rankings significantly. In a bid to develop a highly
automated workflow to generate binding affinities, it raises the question whether
manual input to include explicit water molecules is counter productive. Although
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improvement in rankings have been seen when modifying int, there still lacks clear
and systematic criteria in the selection of int. There are still issues remaining
about the possible ligand parameters for the saturated and/or unsaturated rings
in PAK4, and indeed, ring structures in BACE1 and ROS1. Repeating ESMACS
calculations with different parameters would be beneficial in assessing this, and such
a study is currently in progress with AM1-BCC [202] parameterisation method.
Binding affinity predictions are a useful asset in the clinical setting, where clini-
cians can be supported by accurate and reliable decision-support tools. Binding
affinities using the TIES and ESMACS approach were applied to the estrogen re-
ceptor (ER) system to understand how these protocols perform for receptors that
exhibit mutations – these mutations are the most common in ER-positive breast
cancer. Thus, we studied the wild type (WT) ER and two mutant ERs, Y537S
and D538G. Six ligands were selected of which one was the endogenous hormone
estradiol, and 5 current therapies for ER-positive breast cancer.
We obtained very good results using 3-trajectory MMPBSA and MMGBSA, with
the inclusion of configurational entropy obtained from NMA. This is the only in-
stance in this dissertation that the 3-trajectory approach yields better results than
1-trajectory, but two studies have been published that report superior 3-trajectory
results [100, 203]. The 3-trajectory ESMACS method is preferred in ligand-receptor
systems that represent the induced-fit model, where significant conformational
changes occur when the ligand is bound. This is witnessed in the ER system
and is the reason for the superior binding affinity rankings when the 3-trajectory
method is applied. The 1-trajectory method is better suited for the lock-and-key
model that describes ligand binding. In this model, there are no large conforma-
tion changes upon ligand binding and so the majority of the free energy differences
can be attributed to the interactions of the ligand with residues that comprise the
binding pocket. This is also the reason why the 1-trajectory ESMACS approach
yields better correlations with TIES relative binding affinities.
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The inclusion of configurational entropy estimates significantly improve the correla-
tion and ranking in the ER system, a result that has been previously reported [43].
The likely reason for this is that the conformational changes that are experienced
due to ligand binding are quite large, and so NMA can more accurately estimate
the entropic contribution, compared to smaller configurational changes. We also
witness that selecting the open conformation of the ER gives superior results for
the MMGBSA free energy method. This also requires the inclusion of an con-
figurational entropy estimate. Relative ESMACS binding affinities (1-trajectory,
MMPBSA) correlate very well with TIES binding affinities. This is a good indi-
cation that the binding affinities are correctly calculated. These methods, at least
for the ER system, can be used to corroborate one another. Thus we gain even
more confidence in the results which is a key characteristic for a clinical decision
support tool.
7.2 Implications for future research
Ligand parameterisation is a key issue that needs to be addressed. A number of
systems in this thesis have been linked with inaccurate ligand parameters, leading
to poor binding affinity values. The inability to successfully generate these on a
regular basis, even though the problem is an isolated issue in force fields and not
directly an error in the ESMACS/TIES workflow, renders all free energy approaches
unreliable. Currently, significant effort is spent on assigning correct atomic charges.
With this said, considerable improvement has been made on CDK2 ligands that
contain sulphonamide groups. The partial charges that were used were adopted
from the CHARMM force field, so a possibility is to assess the performance of
ESMACS/TIES binding affinities across widely used open-source force fields like
CHARMM, GROMOS and AM1-BCC, to name three. Although this would give
an indication of the performance of different force fields for particular biological
system, an individual assessment of the performance of a force field needs to be
made on a case-by-case basis.
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FEP+ employs the REST enhanced sampling method which allows the simulation
to access conformations that conventional molecular dynamics would not other-
wise. This has the benefit of sampling ligand-receptor conformations that occur
in reality and thus give us more accurate ligand binding affinities. TIES now has
this capability by including replica exchange, and λ exchange enhanced sampling
approaches [73].
ESMACS has shown good results in some cases, and modest in others. ESMACS
calculations need to move away from the ‘default’ settings that are currently em-
ployed. This has been proved by investigating the effects of int on binding affinities
in PAK4, and manual manipulation of ligand partial charges in CDK2. There needs
to be systematic and clear criteria when selecting important parameters when gen-
erating binding affinities. This may be specific to the polarity of the ligand, or
a receptor target. However, currently there is no defined ’rule’ for the selection
of int. Further work is required to understand when changes in int should be
made. These efforts should be focused on understanding the binding interfaces of
the ligand and the receptor. We see that a universal int value is not applicable,
and so a more granular approach needs to be taken with respect to each ligand.
A possible approach is to develop a model that connects the ion-ion interactions
between ligands and neighbouring protein residues, and the int parameter. This
model would be used to select the most appropriate int for the ligand-receptor
simulation.
Configurational entropy is currently a limitation in the ESMACS approach. NMA
requires the same amount of CPU usage, and 3 to 4 times the wall clock time
to complete calculations. Compounding this, the entropy estimates are based on
an energetically minimised set of trajectory snapshots that excludes solvent effects
(calculations are in vacuum). The WSASA shows signs of positive results in the
PAK4 system but did not improve upon the NMA results in other systems. Faster,
more realistic and efficient codes such as WSASA are being implemented to speed
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up this part.
It has, however, been shown that chaotic dynamics of ligand-receptor systems
result in Gaussian random processes from which probabilistic binding affinities
can be achieved. As such, we have high confidence in the values obtained using
TIES/ESMACS supported but a tight control over errors. Both TIES and ES-
MACS show a high level of reproducibility that is currently not available in others
methods. Coveney et al. have also developed an ensemble based method that
generates absolute binding affinities from alchemical free energy techniques [73].
This follows a similar approach TIES, but with the introduction of other alchemi-
cal transformations to achieve absolute values. The approach also employs replica
simulations.
7.3 Concluding remarks
ESMACS and TIES have shown promise as tools to expedite the hit-to-lead and
lead optimisation stages of drug discovery programmes and can also impact the
clinical setting as decision-support tools. The protocols are distinguishable by the
reproducible nature of determining binding affinities through the use of replica
simulations, and a high level of automation facilitated by high-performance com-
puters. We have seen that ESMACS and TIES are robust protocols which have
been applied to a spectrum of systems containing a diverse set of ligands. The
outcomes were reproducible binding affinity predictions characterised by a tight
control of errors. ESMACS in particular has shown promise as a tool in the clinical
setting by correctly predicting binding affinities of six ligands bound to a wild-type
estrogen receptor and two mutated variants which are most commonly found in
ER-positive breast cancer. With that said, both ESMACS and TIES are highly
sensitive protocols which require careful manipulation of settings depending on the
system of study. This was most evident when we investigated the optimal selec-
tion of int in the PAK4, BACE1 and ROS1 systems. Other factors outside the
160
7.3. CONCLUDING REMARKS
development of ESMACS and TIES include the quality of the crystal structure
that is available, the reliability of the experimental binding affinity values to which
a comparison is made, and the accuracy of the force field model that has been
selected (particularly in the case of uncommon ligands). At this current stage,
only a highly technical user is able to successfully navigate the protocol to achieve
correct binding affinities. The Binding Affinity Calculator (BAC) facilitates the
employment of ESMACS and TIES through an automated workflow. BAC version
2.0 now exists and a user-friendly BAC (uf-BAC) is under development, allowing
non-technical users to compute binding affinities.
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Appendix A
Ligand Chemical Structures
(a) L1Q -8.18 (b) L1S -11.25 (c) LIR -7.67 (d) LI9 -9.74
(e) LIU -9.08 (f) LIY -9.79 (g) L17 -7.04 (h) L20 -8.72
(i) L21 -7.83 (j) L22 -7.86 (k) L26 -8.43 (l) L28 -11.11
(m) L29 -9.88 (n) L30 -9.81 (o) L31 -9.54 (p) L32 -9.75
Figure A.1: Chemical structures and experimental binding affinities of 16 CDK2
inhibitors. The ligands with a meta substitution on the benzene ring
exhibit rotomerism (labelled red) and thus an additional model was
built. All values are reported in kcal/mol
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(a) L01 -9.54 (b) L02 -10.94 (c) L03 -8.98 (d) L04
-11.31
(e) L05 -9.21 (f) L06 -8.26 (g) L07 -10.98 (h) L08 -7.75
(i) L09 -9.56 (j) L10 -7.42 (k) L11 -11.28 (l) L12 -9.00
(m) L13 -9.70 (n) L14 -11.70 (o) L15 -9.78 (p) L16 -10.53
Figure A.2: Chemical structures and associated experimental binding affinities
for TY2 ligands. All values are reported in kcal/mol.
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(a) L23 -8.83 (b) L26 -8.24 (c) L27 -6.12 (d) L28 -6.62
(e) L29 -6.94 (f) L30 -7.85 (g) L31 -7.92 (h) L32 -6.58
(i) L33 -6.88 (j) L34 -6.87 (k) L35 -8.81 (l) L36 -8.18
(m) L37 -8.95 (n) L38 -7.02 (o) L39 -7.03
Figure A.3: Chemical structures of MCL1 binding affinities and associated ex-
perimental binding affinities. All values are reported in kcal/mol.
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(p) L40 -7.25 (q) L41 -7.13 (r) L42 -8.90 (s) L43 -7.03
(t) L44 -8.67 (u) L45 -8.95 (v) L46 -7.60 (w) L47 -5.78
(x) L48 -6.66 (y) L49 -8.36 (z) L50 -9.33 (aa) L51 -8.45
(ab) L52 -9.23 (ac) L53 -9.96 (ad) L54 -9.78
Figure A.3: Chemical structures of MCL1 binding affinities and associated ex-
perimental binding affinities. All values are reported in kcal/mol.
167
(ae) L56 -9.26 (af) L57 -9.04 (ag) L58 -9.41 (ah) L60 -8.92
(ai) L61 -8.08 (aj) L62 -7.96 (ak) L63 -9.06 (al) L64 -9.50
(am) L65 -8.41 (an) L66 -8.43 (ao) L67 -7.58 (ap) L68 -7.69
Figure A.3: Chemical structures of MCL1 binding affinities and associated ex-
perimental binding affinities. All values are reported in kcal/mol.
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(a) L66 -7.84 (b) L67 -7.34 (c) L68 -7.74 (d) L69 -7.72
(e) L70 -7.72 (f) L71 -7.74 (g) L72 -8.60 (h) L73 -8.38
(i) L74 -9.10 (j) L75 -8.71 (k) L76 -9.41 (l) L77 -10.11
(m) L78 -9.08 (n) L79 -9.13 (o) L80 -8.71
Figure A.4: Chemical structures of PTP1B ligands and associated experimental
binding affinities. All values are reported in kcal/mol.
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(a) L1A -7.48 (b) L1B -8.46 (c) L1C -8.56 (d) L1D -8.25
(e) L3A -8.32 (f) L5A -7.58 (g) L6A -9.18 (h) L6B -8.89
(i) L6E -8.91 (j) L7A -8.22
Figure A.5: Chemical structures of thrombin ligands and associated experimental
binding affinities. All values are reported in kcal/mol.
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L1 -10.48 kcal/mol L2 -9.26 kcal/mol L3 -10.19 kcal/mol
L4 -8.51 kcal/mol L5 -7.44 kcal/mol L6 -10.40 kcal/mol
L7 -10.44 kcal/mol L8 -6.86 kcal/mol L9 -10.93 kcal/mol
L10 -9.20 kcal/mol L11 -8.12 kcal/mol L12 -10.48 kcal/mol
L13 -7.60 kcal/mol L14 -8.26 kcal/mol L15 -10.96 kcal/mol
L16 -10.12 kcal/mol
Figure A.6: Chemical Structures and binding affinities of ROS1 Ligands
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L17 -10.97 kcal/mol L18 -8.57 kcal/mol L19 -10.93 kcal/mol
L20 -9.49 kcal/mol L21 -10.80 kcal/mol L22 -11.21 kcal/mol
L23 -9.60 kcal/mol L24 -11.48 kcal/mol L25 -9.58 kcal/mol
L26 -9.95 kcal/mol L27 -6.86 kcal/mol L28 -6.86 kcal/mol
L29 -11.13 kcal/mol L30 -11.29 kcal/mol L31 -10.62 kcal/mol
L32 -8.40 kcal/mol
Figure A.6: Cont... Chemical Structures and binding affinities of ROS1 Ligands
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L01 -7.86 L04 -7.60 L07 -5.08 L10 -10.01
L13 -9.50 L16 -7.14 L19 -8.92 L02 -9.19
L05 -6.89 L08 -9.57 L11 -9.16 L14 -7.05
L17 -7.09 L21 -7.20 L03 -2.93 L06 -10.47
L09 -10.41 L12 -6.84 L15 -7,65 L18 -5.49
L20 -9.61
Figure A.7: Chemical structures of BACE1 ligands and associated experimental
binding affinities. All values are reported in kcal/mol.
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Appendix B
ESMACS and TIES Binding
Affinity Tables
Table B.1: Binding free energies using the 1-trajectory ESMACS approach for
CDK2 ligands bound to the CDK2 receptor. GB/PB is the free en-
ergy method using the Generalised Born or Poisson Boltzmann ap-
proximation. GB/PBNM is the above method with the inclusion of
configurational entropy term. All values are in kcal/mol.
1-trajectory
Ligand GB PB GBNM PBNM ∆Gexp
L1Q -35.50 -29.61 -15.82 -9.92 -8.18
L1S -39.24 -36.50 -16.48 -13.73 -11.25
L1R -41.97 -35.96 -22.48 -16.47 -7.67
L1R-R -41.98 -35.30 -22.48 -15.81 -7.67
LI9 -37.27 -32.88 -17.72 -13.34 -9.74
LIU -40.32 -36.86 -16.36 -12.91 -9.08
LIU-R -41.50 -38.27 -17.88 -14.65 -9.08
LIY -42.32 -39.35 -21.28 -18.31 -9.79
L17 -36.57 -31.83 -17.25 -12.53 -7.04
L17-R -37.28 -31.96 -17.29 -11.97 -7.04
L20 -36.67 -31.41 -14.49 -9.23 -8.72
L20-R -42.67 -36.97 -19.71 -14.01 -8.72
L21 -34.85 -30.81 -14.30 -10.25 -7.83
L21-R -35.95 -30.30 -15.21 -9.57 -7.83
L22 -39.60 -35.36 -19.16 -14.92 -7.86
L22-R -41.99 -36.54 -21.69 -16.23 -7.86
L26 -38.01 -32.55 -16.92 -11.46 -8.43
L28 -44.36 -38.76 -22.91 -17.32 -11.11
L29 -38.11 -33.95 -15.49 -11.39 -9.88
L30 -40.58 -37.27 -20.01 -16.69 -9.81
L31 -40.97 -36.10 -20.49 -15.62 -9.54
L32 -38.41 -37.52 -15.93 -15.04 -9.75
L32-R -40.47 -35.83 -18.38 -13.72 -9.75
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Table B.2: Binding free energies using the 2-trajectory ESMACS approach for
CDK2 ligands bound to the CDK2 receptor. GB/PB is the free en-
ergy method using the Generalised Born or Poisson Boltzmann ap-
proximation. GB/PBNM is the above method with the inclusion of
configurational entropy term. All values are in kcal/mol.
2-trajectory
Ligand GB PB GBNM PBNM ∆Gexp
L1Q -335.94 -359.52 -322.49 -346.06 -8.18
L1S 1717.47 1727.46 1715.21 1725.21 -11.25
L1R 85.03 111.26 112.69 138.92 -7.67
L1R-R 81.00 105.31 108.93 133.24 -7.67
LI9 -337.18 -363.76 -325.59 -352.18 -9.74
LIU 7.17 45.54 39.86 78.22 -9.08
LIU-R 10.11 49.73 41.12 80.75 -9.08
LIY 78.43 100.30 107.33 129.20 -9.79
L17 -328.83 -354.13 -315.90 -341.21 -7.04
L17-R -333.98 -362.02 -320.37 -348.41 -7.04
L20 -332.05 -356.67 -317.76 -342.38 -8.72
L20-R -337.75 -362.39 -321.53 -346.17 -8.72
L21 -325.94 -354.28 -313.21 -341.54 -7.83
L21-R -333.93 -354.34 -320.56 -340.98 -7.83
L22 85.86 111.07 113.99 139.20 -7.86
L22-R 80.29 103.75 109.63 133.09 -7.86
L26 -330.17 -354.74 -314.96 -339.53 -8.43
L28 78.66 101.47 108.08 130.89 -11.11
L29 -332.62 -360.82 -317.44 -345.70 -9.88
L30 83.32 105.11 111.11 132.90 -9.81
L31 85.41 108.40 114.02 137.01 -9.54
L32 14.81 55.07 44.47 84.72 -9.75
L32-R 14.19 56.25 43.64 85.71 -9.75
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Table B.3: Binding free energies using the 3-trajectory ESMACS approach for
CDK2 ligands bound to the CDK2 receptor. GB/PB is the free en-
ergy method using the Generalised Born or Poisson Boltzmann ap-
proximation. GB/PBNM is the above method with the inclusion of
configurational entropy term. All values are in kcal/mol.
3-trajectory
Ligand GB PB GBNM PBNM ∆Gexp
L1Q -335.69 -359.19 -322.33 -345.83 -8.18
L1S 1718.22 1728.13 1715.80 1725.71 -11.25
L1R 88.49 114.01 115.94 141.46 -7.67
L1R-R 85.47 109.00 113.14 136.68 -7.67
LI9 -336.63 -363.17 -325.11 -351.66 -9.74
LIU 7.64 45.94 40.19 78.49 -9.08
LIU-R 11.54 51.59 42.59 82.64 -9.08
LIY 82.22 103.27 111.06 132.11 -9.79
L17 -327.53 -352.75 -314.86 -340.09 -7.04
L17-R -332.94 -360.94 -319.56 -347.56 -7.04
L20 -331.52 -356.06 -317.48 -342.02 -8.72
L20-R -336.69 -361.50 -320.68 -345.49 -8.72
L21 -325.81 -354.01 -313.11 -341.30 -7.83
L21-R -332.87 -353.17 -319.72 -340.03 -7.83
L22 59.25 83.80 87.16 111.71 -7.86
L22-R 54.52 77.32 83.52 106.31 -7.86
L26 -330.13 -354.58 -314.98 -339.42 -8.43
L28 83.27 105.21 112.57 134.51 -11.11
L29 -355.17 -379.11 -340.72 -364.72 -9.88
L30 86.80 107.74 114.50 135.44 -9.81
L31 89.74 111.86 118.29 140.41 -9.54
L32 15.54 55.85 45.29 85.59 -9.75
L32-R 16.22 58.16 45.51 87.46 -9.75
178
Table B.4: TIES relative binding free energies for CDK2 ligand pairs. ‘Initial’
and ‘Final’ indicate the starting end end ligands of the respective
TIES transformations. ∆Gcomalch is the free energy of the alchemical
transformation bound to the receptor, and ∆Gaqalch is the free energy
of the alchemical transformation in aqueous solution. ∆∆Gcalc and
∆∆Gexp are the calculated and experimental relative binding affini-
ties, respectively. All values are in kcal/mol.
Name Initial Final ∆Gcomalch ∆G
aq
alch ∆∆Gcalc ∆∆Gexp
T00 L28 L29 76.60 76.73 0.13 -1.23
T01 L1S L28 2.47 2.41 -0.07 -0.14
T02 L1S L30 4.65 4.31 -0.33 -1.44
T03 LI9 L26 4.97 4.21 -0.75 -1.31
T04 L20 L21 -9.33 -11.69 -2.35 -0.89
T05 LIY L31 -8.37 -8.45 -0.07 -0.25
T06 LIY L30 -13.89 -13.53 0.36 0.02
T07 L1Q L1R 1.36 0.01 -1.35 -0.51
T08 L1Q L1S -2.59 -1.96 0.63 3.07
T09 L1Q LIU -45.38 -40.51 4.87 0.90
T10 L1Q LIY -47.52 -45.50 2.01 1.61
T11 L1Q L22 -4.32 -2.97 1.35 -0.32
T12 L1Q L28 -57.11 -55.13 1.98 2.93
T13 L1Q L30 -62.01 -59.62 2.38 1.63
T14 L1Q L31 -52.80 -51.50 1.30 1.36
T15 L1Q L32 -76.95 -75.97 0.98 1.57
T16 L1Q LI9 14.08 15.86 1.78 1.56
T17 L1Q L20 -20.33 -18.48 1.85 0.54
T18 L1Q L21 -29.50 -30.11 -0.61 -0.35
T19 L1Q L26 18.72 19.51 0.79 0.25
T20 L1Q L29 -55.91 -54.06 1.85 1.70
T21 L1Q L17 -14.85 -15.33 -0.48 -1.14
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Table B.5: Binding free energies using the 1-trajectory ESMACS approach for
TYK2 ligands bound to the TYK2 receptor. GB/PB is the free en-
ergy method using the Generalised Born or Poisson Boltzmann ap-
proximation. GB/PBNM is the above method with the inclusion of
configurational entropy term. All values are in kcal/mol.
1-trajectory
Ligand GB PB GBNM PBNM ∆Gexp
L01 -30.77 -12.80 -30.07 -12.09 -9.54
L02 -36.25 -16.93 -35.18 -15.86 -10.94
L03 -29.42 -10.46 -29.19 -10.23 -8.98
L04 -33.48 -16.95 -31.98 -15.45 -11.31
L05 -32.72 -15.34 -30.33 -12.95 -9.21
L06 -29.47 -11.23 -29.44 -11.19 -8.26
L07 -34.33 -16.13 -32.65 -14.45 -10.98
L08 -33.76 -13.10 -31.41 -10.75 -7.75
L09 -32.72 -14.04 -31.26 -12.58 -9.56
L10 -26.67 -7.01 -29.37 -9.71 -7.42
L11 -35.23 -17.96 -33.81 -16.54 -11.28
L12 -32.47 -13.19 -31.66 -12.38 -9
L13 -31.47 -12.82 -30.96 -12.30 -9.7
L14 -33.85 -15.84 -32.49 -14.48 -11.7
L15 -31.25 -13.64 -30.60 -12.99 -9.78
L16 -37.39 -19.84 -33.81 -16.26 -10.53
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Table B.6: Binding free energies using the 2-trajectory ESMACS approach for
TYK2 ligands bound to the TYK2 receptor. GB/PB is the free en-
ergy method using the Generalised Born or Poisson Boltzmann ap-
proximation. GB/PBNM is the above method with the inclusion of
configurational entropy term. All values are in kcal/mol.
2-trajectory
Ligand GB PB GBNM PBNM ∆Gexp
L01 -26.94 -10.20 -29.08 -12.33 -9.54
L02 -35.93 -17.22 -36.30 -17.59 -10.94
L03 -34.61 -15.67 -32.09 -13.14 -8.98
L04 -35.85 -18.08 -34.26 -16.49 -11.31
L05 -27.77 -11.02 -25.38 -8.62 -9.21
L06 -31.50 -12.84 -31.48 -12.82 -8.26
L07 -33.53 -18.29 -31.41 -16.17 -10.98
L08 -27.68 -7.05 -26.22 -5.58 -7.75
L09 -36.66 -15.76 -31.95 -11.05 -9.56
L10 -28.86 -11.02 -31.52 -13.67 -7.42
L11 -34.63 -17.65 -35.33 -18.34 -11.28
L12 -32.40 -12.69 -31.04 -11.33 -9
L13 -30.17 -12.13 -29.09 -11.05 -9.7
L14 -31.77 -13.25 -31.28 -12.76 -11.7
L15 -34.87 -15.46 -33.81 -14.39 -9.78
L16 -38.07 -18.96 -33.98 -14.87 -10.53
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Table B.7: Binding free energies using the 3-trajectory ESMACS approach for
TYK2 ligands bound to the TYK2 receptor. GB/PB is the free en-
ergy method using the Generalised Born or Poisson Boltzmann ap-
proximation. GB/PBNM is the above method with the inclusion of
configurational entropy term. All values are in kcal/mol.
3-trajectory
Ligand GB PB GBNM PBNM ∆Gexp
L01 -24.44 -53.93 -545.97 -574.73 -9.54
L02 -31.96 -66.00 -422.00 -454.28 -10.94
L03 -32.20 -61.68 -430.07 -458.77 -8.98
L04 -32.40 -63.84 -407.34 -437.75 -11.31
L05 -25.32 -55.81 -518.26 -548.35 -9.21
L06 -28.87 -61.28 -406.14 -437.45 -8.26
L07 -28.56 -64.58 -475.81 -510.79 -10.98
L08 -24.96 -55.74 -418.91 -449.08 -7.75
L09 -34.64 -65.30 -492.75 -522.62 -9.56
L10 -26.03 -60.61 -392.02 -425.40 -7.42
L11 -30.81 -65.37 -440.01 -473.55 -11.28
L12 -30.19 -63.68 -384.17 -416.93 -9
L13 -27.89 -59.75 -394.81 -426.01 -9.7
L14 -27.77 -59.64 -459.19 -490.21 -11.7
L15 -32.29 -61.93 -443.81 -472.55 -9.78
L16 -36.01 -65.76 -631.39 -661.59 -10.53
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Table B.8: Binding free energies using the 1- 2- and 3-trajectory ESMACS ap-
proach for MCL1 ligands bound to the MCL1 receptor. GB/PB is the
free energy method using the Generalised Born or Poisson Boltzmann
approximation. The configurational entropy term was not estimated
for this system. All values are in kcal/mol.
1-trajectory 2-trajectory 3-trajectory
Ligand GB PB GB PB GB PB ∆Gexp
L23 -53.29 -45.17 -52.90 -44.49 -52.05 -43.61 -8.83
L26 -50.63 -43.00 -51.87 -42.99 -50.71 -41.74 -8.24
L27 -42.74 -36.54 -46.67 -42.04 -45.99 -41.27 -6.12
L28 -43.24 -37.31 -43.62 -38.95 -41.73 -36.83 -6.62
L29 -45.36 -39.00 -44.99 -37.99 -42.56 -35.61 -6.94
L30 -44.84 -38.78 -46.90 -40.98 -46.13 -40.18 -7.85
L31 -43.71 -38.28 -39.44 -34.10 -38.58 -33.21 -7.92
L32 -43.32 -37.66 -38.93 -32.79 -37.68 -31.55 -6.58
L33 -42.81 -36.74 -47.26 -42.72 -46.25 -41.68 -6.88
L34 -42.48 -36.81 -44.50 -38.20 -43.18 -36.81 -6.87
L35 -47.36 -41.63 -45.82 -39.49 -44.83 -38.47 -8.81
L36 -49.66 -43.74 -45.08 -39.49 -43.79 -38.13 -8.18
L37 -47.68 -43.42 -46.00 -43.71 -45.15 -42.77 -8.95
L38 -51.11 -43.42 -53.40 -44.95 -50.72 -42.23 -7.02
L39 -38.17 -33.81 -38.48 -34.55 -36.42 -32.40 -7.03
L40 -46.83 -40.51 -48.32 -43.05 -45.82 -40.49 -7.25
L41 -44.53 -39.48 -46.62 -41.01 -45.04 -39.48 -7.13
L42 -51.96 -44.11 -52.87 -45.89 -51.66 -44.69 -8.9
L43 -47.32 -40.36 -47.06 -39.15 -45.92 -37.99 -7.03
L44 -51.97 -44.72 -52.14 -44.25 -50.98 -43.09 -8.67
L45 -54.06 -48.01 -55.09 -50.75 -54.23 -49.85 -8.95
L46 -50.47 -43.52 -49.30 -41.10 -48.70 -40.46 -7.6
L47 -43.04 -37.12 -44.98 -38.49 -43.67 -37.11 -5.78
L48 -43.31 -36.02 -44.61 -36.63 -42.52 -34.52 -6.66
L49 -42.32 -38.39 -44.98 -40.46 -42.50 -37.89 -8.36
L50 -46.55 -43.25 -49.45 -44.83 -46.83 -42.12 -9.33
L51 -48.77 -41.59 -50.24 -43.30 -47.66 -40.51 -8.45
L52 -51.12 -45.25 -49.48 -42.77 -49.04 -42.27 -9.23
L53 -54.03 -49.28 -51.40 -45.47 -50.74 -44.86 -9.96
L54 -55.17 -47.28 -53.87 -46.55 -53.01 -45.73 -9.78
L56 -52.67 -47.03 -52.71 -47.67 -52.11 -47.10 -9.26
L57 -54.01 -44.87 -52.42 -44.56 -51.29 -43.46 -9.04
L58 -56.22 -50.33 -58.17 -53.20 -57.47 -52.66 -9.41
L60 -51.66 -47.02 -53.98 -48.91 -53.61 -48.55 -8.92
L61 -48.03 -44.29 -46.05 -41.54 -44.38 -39.79 -8.08
L62 -49.73 -42.71 -48.29 -40.78 -46.79 -39.09 -7.96
L63 -53.78 -49.26 -51.19 -46.01 -50.96 -45.87 -9.06
L64 -54.24 -46.27 -51.62 -43.51 -50.87 -42.82 -9.5
L65 -54.10 -49.11 -53.31 -48.91 -52.81 -48.52 -8.41
L66 -55.67 -47.53 -54.92 -47.89 -54.21 -47.17 -8.43
L67 -50.84 -46.65 -50.45 -45.59 -49.02 -44.24 -7.58
L68 -51.38 -43.71 -50.82 -43.24 -48.75 -41.18 -7.69
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Table B.9: Binding free energies using the 1- 2- and 3-trajectory ESMACS ap-
proach for PTP1B ligands bound to the PTP1B receptor. GB/PB is
the free energy method using the Generalised Born or Poisson Boltz-
mann approximation. The configurational entropy term was not esti-
mated for this system. All values are in kcal/mol.
1-trajectory 2-trajectory 3-trajectory
Ligand GB PB GB PB GB PB ∆Gexp
L66 -55.65 -45.83 -52.30 -40.60 -51.64 -40.17 -7.84
L67 -58.52 -48.17 -60.42 -49.13 -59.79 -48.70 -7.34
L68 -58.13 -48.64 -58.75 -51.68 -57.97 -51.15 -7.74
L69 -57.64 -47.06 -59.99 -50.35 -59.27 -49.82 -7.72
L70 -59.31 -49.28 -54.96 -44.11 -53.94 -43.22 -7.72
L71 -58.16 -48.25 -57.30 -47.56 -56.50 -47.00 -7.74
L72 -57.54 -44.63 -56.05 -40.36 -55.19 -39.69 -8.60
L73 -54.55 -43.03 -54.69 -41.18 -54.11 -40.80 -8.38
L74 -59.73 -47.84 -62.09 -50.79 -61.29 -50.21 -9.10
L75 -57.39 -46.94 -61.76 -52.31 -61.10 -51.82 -8.71
L76 -58.05 -46.88 -58.91 -49.33 -57.48 -48.12 -9.41
L77 -48.53 -46.17 -50.23 -48.57 -49.01 -47.37 -10.12
L78 -57.50 -45.88 -51.48 -39.18 -49.71 -37.66 -9.08
L79 -59.78 -45.11 -59.30 -46.28 -57.82 -44.97 -9.13
L80 -59.97 -46.30 -62.22 -48.56 -60.90 -47.44 -8.71
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Table B.10: Binding free energies using the 1- 2- and 3-trajectory ESMACS ap-
proach for thrombin ligands bound to thethrombin receptor. GB/PB
is the free energy method using the Generalised Born or Poisson
Boltzmann approximation. The configurational entropy term was
not estimated for this system. All values are in kcal/mol.
1-trajectory 2-trajectory 3-trajectory
Ligand GB PB GB PB GB PB ∆Gexp
L1A -37.24 -32.48 -40.06 -34.41 -38.08 -32.16 -7.48
L1B -41.58 -35.39 -41.10 -35.25 -39.20 -33.00 -8.46
L1C -43.38 -36.88 -45.63 -38.85 -43.83 -36.63 -8.56
L1D -40.28 -35.97 -43.98 -41.03 -41.35 -38.25 -8.25
L3A -39.57 -35.56 -37.72 -35.04 -35.18 -31.97 -8.32
L3B -43.52 -38.43 -41.68 -37.34 -38.92 -34.67 -7.86
L5A -37.11 -32.50 -37.42 -33.76 -34.94 -31.35 -7.58
L6A -42.35 -38.65 -42.77 -35.91 -39.99 -32.88 -9.18
L6B -43.37 -37.92 -42.25 -36.13 -38.39 -32.67 -8.89
L6E -40.45 -35.76 -36.89 -31.83 -34.38 -29.08 -8.91
L7A -40.37 -36.16 -39.71 -36.14 -35.58 -32.55 -8.22
Table B.11: Spearman rank (rs) and Pearson rank (rp) correlation for all tra-
jectory ESMACS approaches, with the inclusion of crystal waters.
Metrics are report with and without ligand L01 to highlight the re-
liance of this ligand to the initial correlation that is observed.
1-traj 2-traj 3-traj
rs rp rs rp rs rp
All
GB 0.16 0.40 0.23 0.48 0.24 0.49
PB 0.23 0.48 0.09 0.30 0.08 0.29
GB−T∆S 0.25 0.50 0.37 0.61 0.41 0.64
PB−T∆S 0.37 0.61 0.18 0.42 0.19 0.43
no L01
GB 0.02 -0.14 0.04 0.20 0.04 0.21
PB 0.03 0.17 0.01 0.08 0.01 0.07
GB−T∆S 0.06 0.24 0.21 0.46 0.26 0.51
PB−T∆S 0.22 0.47 0.06 0.25 0.08 0.28
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Table B.12: Binding free energies obtained using the 1-trajectory ESMACS ap-
proach for PAK4 ligands with varying internal dielectric values
int. Values are shown for the Poisson-Boltzmann free energy
method (MMPBSA) and the same method with the inclusion
of configurational entropy, estimated using normal mode analysis
MMPBSANM . All values are in kcal/mol.
MMPBSA MMPBSANM
Ligand int = 1 int = 4 int = 10 int = 1 int = 4 int = 10 ∆Gexp
L01 -39.53 -57.96 -61.64 -16.53 -34.96 -38.64 -11.70
L03 -31.95 -41.42 -43.32 -9.99 -19.46 -21.36 -11.66
L04 -32.26 -42.11 -44.08 -9.63 -19.48 -21.45 -10.62
L18 -30.43 -39.78 -41.64 -8.53 -17.88 -19.74 -11.26
L19 -29.99 -39.39 -41.27 -7.30 -16.70 -18.58 -8.38
L20 -31.58 -40.01 -41.70 -7.37 -15.80 -17.49 -8.33
L22 -32.21 -39.88 -41.42 -9.83 -17.50 -19.04 -9.17
L23 -33.31 -41.13 -42.70 -12.36 -20.18 -21.75 -9.89
L24 -31.39 -39.68 -41.34 -9.45 -17.74 -19.40 -8.07
L25 -32.35 -41.37 -43.17 -11.45 -20.47 -22.27 -7.75
L27 -33.56 -40.18 -41.51 -14.27 -20.89 -22.22 -9.35
L29 -32.81 -40.68 -42.25 -12.53 -20.40 -21.97 -8.50
L30 -32.28 -40.78 -42.49 -11.48 -19.98 -21.69 -8.80
L31 -33.71 -41.86 -43.49 -13.28 -21.43 -23.06 -8.39
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Table B.13: Binding free energies obtained using the 1-trajectory ESMACS ap-
proach for PAK4 ligands with a varying number of explicit water
molecules included in the free energy calculation. Values are shown
for the Poisson-Boltzmann (MMPBSA) and Generalised Born free
energy method (MMGBSA) without configurational entropy. All
values are in kcal/mol.
1-trajectory MMPBSA
Ligand 10 20 30 40 50 60 70 0
L01 -40.13 -40.08 -39.36 -39.53 -39.77 -39.88 -39.94 -39.17
L03 -29.33 -29.36 -28.77 -28.92 -29.14 -29.25 -29.30 -31.89
L04 -31.70 -31.97 -31.37 -31.58 -31.80 -31.95 -31.98 -32.18
L18 -30.48 -29.94 -30.02 -30.26 -30.38 -30.45 -30.47 -30.37
L19 -27.71 -26.15 -25.41 -25.31 -25.46 -25.58 -25.65 -29.91
L20 -28.16 -25.68 -24.97 -24.99 -25.16 -25.26 -25.28 -31.53
L22 -27.82 -25.21 -24.61 -24.68 -24.86 -24.95 -24.98 -32.15
L23 -29.00 -29.62 -29.48 -29.78 -30.03 -30.14 -30.22 -33.22
1-trajectory MMGBSA
Ligand 10 20 30 40 50 60 70 0
L01 -47.93 -45.49 -43.83 -42.23 -40.87 -39.87 -39.17 -52.59
L03 -33.90 -29.56 -26.17 -23.21 -20.86 -19.22 -17.94 -39.97
L04 -35.74 -33.59 -31.56 -29.67 -28.16 -27.16 -26.36 -40.19
L19 -35.88 -33.14 -31.12 -29.41 -28.24 -27.39 -26.71 -39.43
L20 -32.53 -28.46 -25.72 -23.46 -21.69 -20.39 -19.40 -40.00
L22 -32.14 -26.81 -24.11 -21.86 -20.09 -18.85 -17.90 -40.82
L23 -32.60 -27.57 -25.25 -23.31 -21.78 -20.76 -19.96 -36.84
L18 -34.43 -34.02 -32.90 -31.71 -30.75 -30.14 -29.64 -41.18
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Table B.14: Binding free energies using the 1-trajectory ESMACS approach for
ROS1 ligands bound to the ROS1 receptor. MMPBSA is the
free energy method using the Poisson Boltzmann approximation.
MMPBSANM is the above method with the inclusion of configu-
rational entropy term. All values are in kcal/mol.
1-trajectory
Ligand MMPBSA MMPBSANM ∆Gexp
L01 -41.04 -41.04 -10.48
L02 -38.13 -38.13 -9.26
L03 -39.75 -39.75 -10.19
L04 -41.17 -41.17 -8.51
L05 -38.43 -38.43 -7.44
L06 -41.60 -41.60 -10.40
L07 -43.05 -45.65 -10.44
L08 -33.15 -33.15 -6.86
L09 -43.09 -43.09 -10.93
L10 -39.03 -39.03 -9.20
L11 -37.97 -37.97 -8.12
L12 -44.43 -47.09 -10.48
L13 -34.50 -34.50 -7.60
L14 -39.51 -39.51 -8.26
L15 -42.22 -42.22 -10.96
L16 -44.30 -44.30 -10.12
L17 -45.57 -48.46 -10.97
L18 -41.20 -41.20 -8.57
L19 -42.03 -45.00 -10.93
L20 -48.97 -48.97 -9.49
L21 -41.99 -41.99 -10.80
L22 -44.13 -44.13 -11.21
L23 -44.02 -44.02 -9.56
L24 -47.76 -50.77 -11.48
L25 -46.25 -49.28 -9.58
L26 -42.16 -42.16 -9.95
L27 -43.06 -29.53 -6.86
L28 -45.74 -29.49 -6.86
L29 -45.29 -48.96 -11.13
L30 -43.12 -46.35 -11.29
L31 -43.60 -46.95 -10.62
L32 -42.79 -42.79 -8.40
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Table B.15: Binding free energies using the 1-trajectory ESMACS approach for
BACE1 ligands bound to the BACE1 receptor. MMPBSA is the
free energy method using the Poisson Boltzmann approximation.
MMPBSANM is the above method with the inclusion of configu-
rational entropy term. All values are in kcal/mol.
1-trajectory
Ligand MMPBSA MMPBSANM ∆Gexp
L01 -39.81 -32.82 -3.38
L02 -40.00 -40.00 -4.75
L03 -37.55 -37.55 -3.97
L04 -43.45 -39.46 -3.69
L05 -43.57 -43.57 -5.02
L06 -41.34 -41.34 -4.33
L07 -42.01 -30.82 -3.60
L08 -42.49 -42.49 -5.10
L09 -40.87 -40.87 -4.34
L10 -43.10 -30.30 -3.62
L11 -42.79 -42.79 -4.94
L12 -41.40 -41.40 -4.02
L13 -44.17 -37.13 -3.65
L14 -45.07 -45.07 -5.18
L15 -40.83 -40.83 -4.06
L16 -47.06 -39.79 -3.24
L17 -47.52 -47.52 -5.05
L18 -44.45 -44.45 -3.95
L19 -44.29 -33.20 -4.49
L20 -42.87 -42.87 -4.82
L21 -46.55 -46.55 -5.31
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